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Introduction
Hematopoiesis
Functional mature blood cells like granu-
locytes, monocytes, platelets and red blood 
cells have a limited life span and therefore 
they need to be continuously generated by 
the human body 1. All blood cells are derived 
during life from a small population of cells. 
These hematopoietic stem cells (HSC) 
reside in the bone marrow. Hematopoiesis 
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Figure 1, Hematopoiesis
Blood cell development progresses from a hematopoietic stem cell (HSC), which resides in the bone 
marrow. These HSCs can undergo either self-renewal or differentiation into a multilineage committed 
progenitor cell: a common lymphoid progenitor (CLP) or a common myeloid progenitor (CMP). These 
cells then give rise to more-differentiated progenitors, comprising those committed to two or more 
lineages that include granulocytes and macrophages (GMP), and megakaryocytes and erythroid cells 
(MEP). Lymphoid progenitors can differentiate into mature B and T-cells, while the myeloid progenitors 
differentiate into monocytes, granulocytes, erythrocytes and platelets. Recently, it was shown that 
murine stem cells can also differentiate directly into the megakaryocyte/erythrocyte progenitors (dotted 
line).
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or blood cell development is the continuous 
process during which HSC differentiate into 
mature functional blood cells 2;3. The HSC is 
capable of self-renewal to maintain a pool of 
immature cells in the bone marrow. The HSC 
is furthermore characterized by its capabil-
ity to repopulate lethally irradiated mice in 
serial bone marrow transplantations 4. The 
generation of mature functional blood cells 
from HSCs is a tightly regulated process 
(Figure 1). The long term (LT) HSC dif-
ferentiates via the short term (ST) HSC into 
either common lymphoid or myeloid pro-
genitors (CLP and CMP). The CLP develops 
into mature lymphoid cells; B and T-cells 5. 
The CMP differentiates towards a common 
granulocyte/macrophage progenitor cell 
(GMP) or to a common megakaryocytic/
erythrocytic progenitor cell (MEP) 6. Recent 
work suggest that in mice the MEP may also 
directly descent from the HSC 7. The GMP 
cells differentiate into mature neutrophils 
or in monocytes/macrophages, while MEP 
differentiation results in functional erythro-
cytes/megakaryocytes. The progenitor cells 
are characterized by a high proliferation rate, 
while the mature cells divide at much lower 
rate.
Different regulatory mechanisms are 
responsible for maintaining steady state 
levels of the mature blood cells and make it 
possible that the human body can react on 
extracellular stimuli. This is executed by 
hematopoietic growth factors and cytokines, 
which are produced by various cells (e.g. 
fibroblasts, liver, stroma, and kidney cells) 
in both a constitutive and inducible fashion. 
This system allows the human body to react 
to events like bleeding or infection, when 
specific subsets of mature hematopoietic cells 
are needed 8. For example, erythropoietin is 
the crucial cytokine regulator for red blood-
cell production 9, while thrombopoietin is 
capable of stimulating platelet differentia-
tion 10. GM-CSF, G-CSF and M-CSF control 
the myeloid differentiation of monocytes 
and granulocytes 11. Via a complex network 
of signal transduction pathways 12;13, these 
lineage determining factors stimulate or 
suppress specific transcription factors that are 
crucial for myeloid differtiation. In response 
to these growth factors the progenitor cells 
are directed towards a specific cell type. 
To date, several transcriptional regulators 
have been found to play an essential role in 
the differentiation of myeloid cells. Mouse 
models have shown the function of several 
essential transcriptional regulators during 
myelopoiesis such as PU.1 14;15, C/EBPα 16, 
C/EBPβ 17 ,C/EBPε 18 and Gfi1 19-23. PU.1 is 
expressed in myeloid cells and its expression 
is induced during both monocytic and granu-
locytic differentiation 24;25. Two different 
studies with knock-out mice showed that 
PU.1 is an essential transcription factor for 
myeloid differentiation 14;15. The CCAAT/
enhancer binding proteins (C/EBP) α, β and ε 
are all expressed in granulocytes. C/EBPα is 
mainly expressed in immature granulocytes 
26;27, while C/EBPε is expressed in more 
mature granulocytes 28. Both C/EBPα and ε 
are necessary for the normal generation of 
functional granulocytes. C/EBPα -/- mice 
lack neutrophils and eosinophils but retain 
monocytes and immature monoblasts 16. 
Mice deficient for C/EBPε retain neutro-
phils, however they lack secondary granules 
18;29. Recently, it was found that C/EBPβ is 
essential for the generation of granulocytes 
during emergency situations such as infec-
tions when host defence requires rapid 
mobilization of bone marrow granulocyte 
progenitors 17. The transcriptional repressor 
Gfi1 was recently discovered as an essential 
transcription factor for granulocytic dif-
ferentiation. Gfi1 mRNA was expressed 
at a high level in granulocytes and at low 
levels in monocytes 30-32. However, at protein 
13
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level the highest expression was observed 
in monocytes (this thesis, chapter 5). Gfi1 
-/- mice feature a block in neutrophil differ-
entiation, resulting in the accumulation of an 
immature myelomonocytic cell population 
which result in the lack of functional granu-
locytes 32;33. 
Leukemia
During their life span HSCs may accumulate 
DNA damage, which can result in the onset 
of leukemia. Acute leukemia is a form of 
hematological cancer and is characterized 
by a differentiation block resulting in the 
expansion of immature, clonal hematopoietic 
cells (blasts). These blasts fail to differenti-
ate into mature functional blood cells and 
this results in the accumulation of a large 
number of these cells in the bone marrow. 
Leukemia is defined by the presence of more 
than 20% blasts in the bone marrow. This 
malignant cell population competes with the 
non-malignant HSC for available space in 
the bone marrow (Figure 2). This results in 
reduced numbers of healthy progenitor cells 
and decreased normal hematopoieis, which 
finally results in the symptoms of which 
patients with leukemia are suffering from 
bleeding disorders, fatigue and/or recurrent 
infections. 
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Figure 2, Leukemic transformation
DNA damage may contribute to leukemogenesis which results by blocking differentiation. Leukemic 
cells accumulate in the bone marrow, and finally may also be found in the peripheral blood. In the bone 
marrow these immature leukemic blasts displace the normal hematopoietic stem cells and progenitor 
cells, which results in decreased numbers of normal functional blood cells. 
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Leukemia can be classified in chronic or 
acute leukemia. Acute leukemia is character-
ized by rapid developing disease character-
ized by a complete block in differentiation. 
In contrast chronic leukemia develops 
more slowly in line with the malignant cell 
population which has the ability to partly dif-
ferentiate. Leukemia can be further divided 
in different types, according to which lineage 
is involved; lymphoid or myeloid cells. 
By considering whether they are acute or 
chronic, and whether they are myelogenous 
or lymphocytic, leukemias can be divided 
into 4 main types: acute myeloid leukemia 
(AML), chronic myeloid leukemia (CML), 
acute lymphocytic leukemia (ALL) or 
chronic lymphocytic leukemia (CLL) 34. 
Acute Myeloid Leukemia (AML)
This thesis focuses on the normal and 
leukemic myeloid development. AML can 
be subdivided according to the French-
American-British (FAB) classification 
in 8 types (AML-M0 to AML-M7) 35-42. 
This classification is defined by the degree 
of differentiation based on morphologi-
cal and cytochemical analysis. The more 
recent defined World Health Organization 
(WHO) classification also includes specific 
cytogenetic abnormalities, which  allows a 
better classification into different prognostic 
subgroups 43.
The insight of the molecular pathogenesis 
of acute myeloid leukemias (AML) has seen 
dramatic progress over the last years. Two 
major types of genetic events have been 
described that are crucial for leukemic 
transformation: alterations in myeloid tran-
scription factors governing hematopoietic 
differentiation 44 and activating mutations of 
signal transduction proteins 45. It is assumed 
that mutations in transcription factors result 
in a block in differentiation and mutations 
in signal transduction result in enhanced 
proliferation and cell survival. Mutations in 
transcription factors can also affect signal 
transduction pathways and vice versa 12 as is 
depicted in Figure 3. Several types of these 
mutations are directly linked with the type 
of leukaemia and with clinical outcome 43;46. 
Furthermore, several recurrent abnormalities 
can be used to monitor the disease in time 
using molecular diagnostic tools 47. In table 1 
a number of recurrent mutations in AML and 
the prognosis they confer are depicted. 
In the last couple of years a large number 
of recurrent mutations in AML have been 
found. Also proteins that are currently not 
known to be mutated in leukemia have been 
identified to play an important role during 
Inappropriate
signalling
Alterations in 
signalling
Alterations in 
transcription
Inappropriate
transcription
increased
proliferation
reduced
apoptosis
blocked 
differentiation
Figure 3, Mutations in both transcription factor 
as well as in signal transduction pathways
The interplay of different molecular alterations 
in the development of AML. Inappropriate 
signal transduction can result in alterations in 
gene expression. Vice versa, changes in gene 
expression can affect the signal transduction. 
These alterations may result in one or more of 
the hallmarks of the onset of AML: increase in 
proliferation, reduction of apoptosis and/or a 
block in differentiation. Figure adapted from 12.   
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Table 1, Recurrent mutations in acute myeloid leukemia
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hematopoiesis. In addition, proteins that 
control the activity of the above described 
proteins, for example by post-transcriptional 
regulation, can play an essential role during 
normal and malignant hematopoiesis. 
Different forms of post-translational modi-
fications are known like phosphorylation, 
acetylation or methylation. The major focus 
of this thesis is the modification of proteins 
with ubiquitin during normal and malignant 
hematopoiesis.   
Protein modification with ubiquitin 
Since the discovery of ubiquitination more 
than 20 years ago it has become clear that 
protein modification with ubiquitin is a 
very important post-translational regulation 
mechanism. Different types of protein modi-
fications by ubiquitin exist and can regulate 
protein activity in different ways. Some types 
of ubiquitination may result in altering the 
biological function of proteins, while other 
forms of ubiquitin modifications result in the 
specific degradation of proteins by the 26S 
proteasome. In this manner, the ubiquitin 
proteasome system (UPS) regulates several 
important biological processes like cell 
division, apoptosis and differentiation 48. In 
this review the different forms of ubiquitina-
tion and their role during hematopoiesis will 
be discussed. In addition, novel therapies 
targeting the UPS in hematopoietic malig-
nancies will be highlighted. 
Ubiquitination 
Ubiquitin is a conserved, small peptide (76 
amino acids) that can be coupled to substrate 
proteins in a three-step enzymatic cascade. 
This cascade starts with the activation of free 
ubiquitin by the ubiquitin-activating enzyme 
(E1) through an ATP-dependent reaction 
(Figure 4A). During the second step, the 
activated ubiquitin is transferred to ubiquitin 
Figure 4, Protein ubiquitination; a three-step 
process
A, The ubiqutination of proteins is mediated in a 
three-step process. The ubiquitin peptide is bound 
and activated by an E1 activating enzyme. The 
activated enzyme is subsequently bound to an E2 
conjugating  enzyme. These E2 enzymes interact 
with ubiquitin E3 ligases. The latter specifically 
recognize substrate proteins and mediate the 
covalent linkage of ubiquitin to substrate protein. 
B, The human genome encodes for only one E1 
enzyme and a small number of E2 enzymes. The 
large number of and variety of proteins regulated 
by ubiquitination demands high specificity and 
account for the growing number of E3 ligases. 
Genomic analysis predicts the presence of over 
00 proteins with motifs implicated in ubiquitin 
processes. 
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conjugating enzymes (E2). Finally, through 
a functional interaction with E2 enzymes, 
ubiquitin ligases (E3) recognize specifically 
substrates and facilitate the conjugation of 
ubiquitin to a lysine residue of the target 
proteins. Therefore, the specificity of the 
UPS is determined by the E3 ligases 49. 
The large number and variety of proteins 
regulated by ubiquitination demands high 
specificity and accounts for the number 
of different E3 ligases encoded by our 
genome as is depicted in Figure 4B. The 
more general steps of the UPS are carried 
out by a smaller number of proteins. At this 
moment only one E1 and approximately 30 
E2 enzymes are known 50;51. E3 ligases can 
be subdivided into different classes based on 
activity and structural domains. One group of 
E3 enzymes has ubiquitin ligase activity by 
itself like proteins that contain RING finger, 
HECT or U-box domains. The other group 
of E3 proteins feature only E3 ligase activity 
when complexed with other proteins. These 
proteins like the SOCS-box, F-box and 
cullin proteins play a role in the recognition 
of substrates 48. 
Different kinds of ubiquitin modifications: 
different functions
During protein ubiquitination, the C-terminal 
glycin residue of ubiquitin is conjugated to 
lysine residues within substrate proteins. 
Proteins can be modified with ubiquitin 
in various ways (Figure 5). If only one 
ubiquitin moiety is coupled to a protein this 
is called mono-ubiquitination. Different 
types of growth factor receptors are mono-
Figure 5, Different types of ubiquitin modifications; different functions
The covalent linkage of the C-terminus of ubiquitin (C) takes usually place at a lysine residue (K) of the 
substrate protein. Ubiquitination occurs in different ways. Substrates can be mono-ubiquitinated, which 
can result in a change in subcellular localization. Poly-ubiquitination can take place in different ways. 
In poly-ubiquitination, ubiquitin peptides are coupled to a lysine residue of the preceding ubiquitin. 
Ubiquitin contains  lysines (6,11,2,29,33,48,63) that can all be used to form poly-ubiquitin chains. 
The most common forms of poly-ubiquitin are linked via lysine 48 or 63. Poly-ubiquitination linked via 
K63 results in altered protein function, while proteins modified via K48 linked poly-ubiquitin chains are 
recognized by the 26S proteasome. 
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ubiquitinated. This results in receptor 
internalization followed by recycling of the 
receptor to the cell membrane or by transport 
to lysosomes where these receptors are 
degraded by proteases 52. Many proteins can 
also be modified with poly-ubiquitin chains. 
The covalent coupling of one ubiquitin to a 
preceding ubiquitin takes place on one of the 
7 lysines (at position 6, 11, 27, 29, 33, 48, 63) 
of ubiquitin (Figure 5). Poly-ubiquitin chains 
linked via different lysines of ubiquitin 
take on different structures resulting in a 
different fate of the ubiquitinated proteins. 
Poly-ubiquitination of proteins linked via 
lysine 63 (K63) results in functional modula-
tion of the substrate as has been shown for 
several proteins involved in DNA-repair 
53-56, transcriptional regulation 57 or signal 
transduction 58;59. The most common type 
of poly-ubiquitination is characterized by 
chains linked through lysine 48 (K48) of 
the preceding ubiquitin. Proteins supplied 
with a K48 or K29-linked ubiquitin chain 
are specifically recognized by the 26S 
proteasome. The function of poly-ubiquitin 
chains linked via K6, K11 or K33 remains 
poorly understood. Despite the potential 
for enormous complexity of poly-ubiquitin 
chains due to the use of different lysines in 
one poly-ubiquitin chain (mixed chains), it is 
assumed that within one chain the ubiquitin 
moieties are linked through the same lysine 
60. However, recent in vitro ubiquitination 
studies of cyclin B1 showed that also mixed 
ubiquitin chains can be formed 61. 
Protein degradation by the 26S protea-
some
When a substrate protein is marked with 4 
or more ubiquitin peptides linked via K48, 
this complex can be recognized by the 26S 
proteasome resulting in active degradation 
of the marked protein. The 26S proteasome 
consists of a 19S and 20S component 62;63 
and is localized both in the nucleus and 
cytoplasm. The 20S core of the proteasome 
has the shape of a barrel consisting of 4 
rings each containing 7 proteins (Figure 
6A) that harbour different protease activities 
(caspase-like, trypsin-like and chymotryp-
sine-like). The different proteolytic activities 
cleave proteins into small peptides. As the 
proteolytic activity is localized inside this 
barrel like structure, proteins outside the pro-
teasome are protected against its proteolytic 
activity. The 20S core has a 19S regulatory 
cap on both ends, which are responsible for 
recognition, de-ubiquitination, unfolding and 
internalization of poly-ubiquitinated proteins 
64. Mammals also have another regulatory 
complex that, instead of the 19S complex, 
can associate with the 20S proteasome: 11S 
(PA28). This complex contains the PA28α 
and PA28β subunits whose expression is 
induced by IFNα. Accumulating evidence 
suggests that the 11S regulatory complex 
plays a role in the production of antigenic 
peptides for presentation by MHC class 1 
molecules 65;66.  
De-ubiquitination
The ubiquitination of proteins is a reversible 
process. De-ubiquitinating proteins (DUBs) 
can remove covalently attached ubiquitin 
from substrate proteins, through cleavage 
of single ubiquitin moieties or chains from 
the substrate or from a preceding ubiquitin 
molecule. The human genome encodes for 
approximately 80 DUBs 67. These DUBs 
abolish the effect of E3 ligases by removing 
the ubiquitin from substrate proteins, which 
may prevent their degradation (Figure 6B). 
Another essential role for DUBs is the 
removal of ubiquitin from ubiquitinated 
proteins in the 19S part of the proteasome 
(Figure 6A), resulting in re-usable free 
ubiquitin 51;67. Recently, specific DUBs have 
been implicated in hematopoiesis. For 
19
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example, a murine DUB family was found 
to be induced after cytokine exposure in 
hematopoietic cells. Of this family, DUB-1 
is rapidly induced after stimulation with IL-3 
or GM-CSF, while DUB-3 is induced with 
IL-4 and 6 in different hematopoietic cells. 
DUB-2 is regulated specifically by IL-2 in 
T-cells. The expression of DUB-2 can inhibit 
apoptosis due to cytokine redrawal 68. DUB-
3 blocks the proliferation of murine Ba/F3 
and NIH3T3 cells 69. Recently, the DUB 
USP42 was identified in a translocation with 
RUNX1 in acute myeloid leukemia (AML) 70. 
Its involvement in this translocation suggests 
that deregulation of ubiquitin-associated 
pathways may be important in leukemogen-
esis.  
NF-κB signaling; an example of an UPS 
regulated pathway
An example in which the UPS regulates the 
activity of a biological pathway at several 
levels by (de-) ubiquitination and pro-
teasomal degradation is the NF-κB pathway. 
NF-κB is a transcription factor that regulates 
the expression of several genes involved 
in proliferation, apoptosis and immunity. 
In the inactive form NF-κB is localized in 
the cytoplasm. In order to regulate genes 
in the nucleus NF-κB needs to be released 
from its interactor IκB. This inhibitor keeps 
NF-κB inactive in the cytoplasm. Upon 
activation of for example the IL-1 receptor, 
signal transduction proteins are recruited to 
the intracellular part of the receptor (Figure 
Ub
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Figure 6, The 26S Proteasome
A, The 26S proteasome is responsible for the 
degradation of ubiquitinated  proteins which 
are cleaved in small inactive peptides. The 26S 
proteasome consist of a 20S core and 19S lid 
component. The 20S part contains the catalytic 
domain which harbours protease activities. The 
19S component recognizes poly-ubiquitinated proteins and subsequently unfolds and removes ubiquitin 
from substrates. B, De-ubiquitination enzymes can remove both mono as well as poly-ubiquitin chains 
from substrate proteins, resulting in free ubiquitin and non-ubiquitinated substrates. In this way the 
altered function or degradation is inhibited due to the DUB activity.
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7A). One of these proteins, TRAF6, is sub-
sequently auto-ubiquitinated upon receptor 
binding with ubiquitin chains linked via 
K63. The ubiquitination of TRAF6 is con-
trolled by the DUBs CYLD and A20, that 
can remove the ubiquitin of TRAF6 and as 
a consequence inhibit the NF-κB route 71-73. 
The K63 ubiquitin chain on TRAF6 does not 
target this protein for proteasomal degrada-
tion, but is essential for the recruitment of 
proteins that phosphorylate downstream 
kinases. These downstream kinases (the IKK 
complex) are responsible for the phosphory-
lation of IκB. The phosphorylated form of 
IκB is specifically recognized by an E3 ligase 
complex (SCF-βTrCP) that ubiquitinates IκB 
via K48 (Figure 7B). This results in the 26S 
proteasomal degradation of IκB, resulting in 
the release of NF-κB from its inhibitor and 
the translocation to the nucleus were NF-κB 
can be active to regulate genes 58. In B-cells 
NF-κB can be activated upon activation of the 
TNF receptor family by the 26S proteasome 
in a different manner. In this case, the IKKα 
complex phosphorylates p100, a precursor of 
the p52 sub-unit of NF-κB. The precursor is 
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Figure 7, Regulation of NF-κB by the UPS
A, Activation of the IL-1 receptor (IL-1R) results in recruitment of several proteins to the intracellular 
part of the receptor. Binding of one of these proteins (TRAF6) results in autoubiquitination with ubiquitin 
chains coupled via K63. This process is inhibited by the DUBs A20 and CYLD. The ubiquitination 
of TRAF6 results in the recruitment of adapter proteins, which subsequently results in the auto-
phosphorylation of TAK1. B, After activation by phosphorylation of TAK1, the IKK complex is activated 
which results in the phosphorylation of IκB. This is the signal for the E3 ligase complex (SCF-βTrCP) 
to ubiquitinate IκB with chains linked via K48 resulting in the proteasomal degradation of the inhibitor 
of NF-κβ. Unbound NF-κB is translocated to the nucleus where it functions as transcription factor to 
activate genes. Another route in which NF-κB can be activated is by partial protein degradation. After 
phosphorylation by IKKα, the p100 precursor is poly-ubiquitated. The 26S proteasome mediates the 
maturation of the p100 into the active, mature p52 NF-κB subunit, which translocates to the nucleus. 
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normally inactive since it is retained in the 
cytoplasm. Upon phosphorylation the p100 
protein is poly-ubiquitinated and processed, 
but not completely degraded, by the 26S 
proteasome. The p100 protein is partially 
degraded resulting in an active mature p52 
subunit, which translocates to the nucleus 
were it can be active 74;75. 
Ubiquitination and protein degradation in 
normal hematopoiesis
Ubiquitination and proteasomal degradation 
play a crucial role during various important 
biological processes during hematopoi-
esis like proliferation, differentiation and 
apoptosis. Several proteins involved in blood 
cell development are known to be regulated 
by the UPS 76. Examples are the growth factor 
receptor c-kit , cyclin D 77, the anti-apoptotic 
protein Bcl-2 78 and the transcription factors 
AML1 79, GATA-2 80, C/EBPα 81 and Gfi1 
82. Although it is known that these proteins 
are degraded via the UPS for the majority 
the responsible ubiquitin E3 ligase are not 
known. 
So far, some E3 ligases were shown to play a 
role in hematopoietic cells. For example the 
ubiquitin ligase Triad1. The Triad1 mRNA and 
protein levels are induced specifically during 
myeloid cell differentiation. Overexpression 
of Triad1 resulted in an inhibition of clono-
genic growth of murine bone marrow cells 
(CFU-GM). As the ubiquitin ligase activity of 
Triad1 was essential to these processes, this 
showed that the UPS can play an important 
role during myelopoiesis 83. Another member 
of the TRIAD family of E3 ligases, Triad3, 
was shown to catalyze the ubiquitination 
of the Toll like receptors TLR4 and 9. This 
results in the proteasomal degradation of 
these receptors. In this way Triad3 controls 
the intensity and duration of TLR signaling, 
thereby playing an important role during 
innate immunity 84. Cullin 4A (Cul4A) is an 
example of an essential subunit in a specific 
RING finger E3 ligase complex. Cul4A was 
found to directly interact with HoxA9 and 
together with the complete E3 complex to 
ubiquitinate this homeodomain transcription 
factor. HoxA9 is a key regulator of hemato-
poiesis and is expressed in primitive cells 
and downregulated upon granulocytic differ-
entiation. The Cul4A mediated degradation 
of HoxA9 may play an important role during 
the differentiation of granulocytes, influenc-
ing Cul4A expression has direct effect on 
granulocytic differentiation 85;86. 
The UPS also plays an essential role in the 
attenuation of receptor signaling after their 
activation in hematopoietic cells. An example 
are the suppressor of cytokine signaling 
(SOCS) proteins. By binding specifically 
to activated growth factor receptors SOCS 
proteins recruit E3 ligase complexes to these 
receptors. These complexes ubiquitinate the 
activated receptor which results in the pro-
teasomal degradation or internalisation of the 
receptor. Together with the E3 complexes the 
SOCS proteins are responsible for the attenu-
ation of the signal after receptor stimulation 
87;88. Another protein regulating the activity of 
receptors is CBL. This protein is a negative 
regulator of a number of activated tyrosine 
kinase receptors like the colony-stimulation 
factor receptor (CFS1R), the platelet-derived 
growth factor (PDGF) receptor and the stem 
cell factor (SCF) receptor (c-Kit). After 
receptor activation, Cbl catalyses the ubiqui-
tination of these receptors. This ubiquitina-
tion results in receptor internalisation and 
lysosomal targeting where these receptors 
are degraded by proteases 89. In this way, 
Cbl prevents the receptors from remaining 
constitutively active, which can result in 
oncogenic transformation 89;90.
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Altered ubiquitination and malignant 
hematopoiesis
Alterations in ubiquitination may contribute 
to the onset of malignant transformation 
91. Due to mutations or misexpression the 
UPS can be disturbed. Three common 
types of alterations in the UPS will be 
discussed that may occur in hematopoietic 
malignancies. Discussed alterations are: (I) 
Mutations in ubiquitin E3 ligases resulting 
in impaired ubiquitination of their substrate, 
(II) Misexpression of E3 ligases, resulting 
in altered ubiquitination of substrates (III) 
Mutations in substrates which makes them 
insensitive for the activity of the UPS.
When ubiquitin ligases are inactivated by 
genetic defects this results in diminished 
ubiquitination of their respective substrate 
proteins which subsequently can result in ma-
lignancies. This is illustrated by inactivating 
mutations in the Von Hippel Lindau (VHL) 
E3 ubiquitin ligase which can be detected in 
patients with congenital polycythemia. These 
mutations result in defective ubiquitination 
and subsequent stabilization of its substrate 
Hif1α (Figure 8A). Hif1α is a transcription 
factor and its stabilization results in an 
increased expression of erythropoietin. It is 
assumed that increased erythropoietin ex-
pression levels contribute to the onset of this 
form of polycythemia 92. Another example in 
which the E3 ligase is inactivated is Fanconi 
anemia (FA). FA is characterized by chro-
mosomal instability and a correlated predis-
position to malignancies like acute myeloid 
leukemia (AML). Normally, after DNA-
damage, Fanconi anemia D2 (FANCD2) 
is mono-ubiquitinated, which results in the 
relocalization of FANCD2 to damaged DNA 
for repair. A complex of multiple FA proteins 
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Figure 8, Alterations in the UPS in 
hematological malignancies
A, Inactivating mutation in the E3 ligase 
VHL found in congenital polycythemia 
results in the inhibition of ubiquitination 
and subsequent accumulation of the 
transcription factor HIF1α. B, Mutations in 
FA proteins reduce the mono-ubiquitination 
of FANCD2 resulting in the inhibition of 
DNA repair functions. Usp1 is a DUB that 
can remove mono-ubiquitin from FANCD2. 
C, Overexpression of the E3 ligase MDM2 
leads to constitutive degradation of the 
tumor suppressor p53. D, Mutations in 
c-myc found in lymphoma prevent the 
interaction with its SCF E3 ligase complex, 
resulting in the stabilization of c-myc. 
A
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is responsible for the mono-ubiquitination of 
FANCD2 (Figure 8B). In patients suffering 
from FA, mutations are found in one of 
these FA proteins. The mutations prevent the 
proper mono-ubiquitination of FANCD2 and 
thereby inhibit the FANCD2 initiated DNA 
repair 93. Recently also a DUB for FANCD2 
was identified, which deubiquitinates 
FANCD2 after the DNA damage is repaired 94.
 
Mutations resulting in mis-expression of 
E3 ligases have also been described. If the 
substrate proteins are tumor suppressors 
or pro-apoptotic proteins this can result in 
oncogenic transformation. One example is 
the ubiquitin ligase MDM2 which ubiqui-
tinates and targets the tumor suppressor p53 
for proteasomal degradation. In about 70% 
of all leukemias MDM2 is overexpressed 
when compared to non-malignant cells 95, 
for example due to gene amplifications 96. 
Overexpression of MDM2 results in the 
constitutive ubiquitination and subsequent 
degradation and inactivation of p53 (Figure 
8C). Inactivation of p53 is often a hallmark 
of oncogenic transformation. A comparable 
mechanism in which p53 is inhibited is found 
leukemias characterized by the AML1-ETO 
fusion protein. AML1-ETO specifically 
represses the p14arf protein 97. p14arf normally 
interacts with MDM2 thereby neutralizing 
the interaction of MDM2 with p53 98. The 
downregulation of p14arf in AML1-ETO 
positive leukemias may result in increased 
MDM2 activity and increased degradation 
of p53. 
Finally, mutations in substrate proteins may 
result in inhibition of their ubiquitination 
when they are no longer recognized by E3 
ligases. An example are point mutations in 
the c-myc oncogene, which are found in 
lymphoma’s. The c-myc oncogene encodes 
a short-lived transcription factor that plays 
an important role in cell cycle regulation, 
differentiation and apoptosis. Mutations in c-
myc results in diminished phophorylation of 
c-myc. The SCF E3 ligase complex of c-myc 
recognizes only the phosphorylated form 
of c-myc (Figure 8D). As a consequence 
mutated c-myc is no longer ubiquitinated by 
SCF resulting in the stabilization and accu-
mulation of the oncoprotein c-myc 99 which 
might be one of the steps necessary for the 
onset of lymphoma’s. 
The UPS as novel therapeutic target
Since changes in ubiquitination and subse-
quent alterations in function or turnover of 
substrate proteins have been implicated in 
the onset of hematological malignancies, 
the UPS is a new potential therapeutic 
target. One of the targets is the 26S protea-
some itself. Proteasome inhibition results in 
growth inhibition and apoptosis of multiple 
myeloma (MM) cells while wild type cells 
are less sensitive 100. A recently published 
phase III study showed that treatment with 
the proteasome inhibitor Velcade is more suc-
cessful for treatment of refractory multiple 
myeloma than the standard treatment with 
dexamethasone 101. Proteasome inhibition 
results in stabilization of substrate proteins 
which normally would have been degraded 
by the proteasome (Figure 9A). Recently, 
other proteasome inhibitors than Velcade 
were shown to induce apoptosis also in 
Velcade resistant MM cells 102. It is assumed 
that the apoptotic effect of Velcade is caused 
by the stabilization of pro-apoptotic proteins, 
for example by abrogating the degradation of 
IκB thereby inhibiting the activation of the 
transcription factor NF-κB (Figure 9A) 103. 
However, recent studies showed that MM 
cells are far more sensitive to proteasome 
inhibitors than to IκB kinase inhibitors, sug-
gesting that NF-κB is not solely responsible 
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for the observed increase of apoptosis. MM 
cells produce large amounts of antibodies, 
also resulting in large amounts of misfolded 
proteins. When misfolded proteins cannot 
be correctly refolded they are targeted for 
endoplasmatic reticulum-associated protein 
degradation (ERAD), which involves the 
activity of the 26S proteasome 104. After 
proteasome inhibition these unfolded protein 
accumulate and induce an unfolded-protein 
response that may result in subsequent cell 
cycle arrest and apoptosis 105. Another theory 
is that during the late phase of plasma cell 
differentiation the proteasome activity is 
decreased due to the  massive amount of Ig 
production, thereby making these cells more 
sensitive for proteasome inhibition 106. Both 
hypotheses could explain why MM cells 
are especially sensitive for treatment with 
proteasome inhibitors. 
While clinical outcomes with proteasome 
inhibitors are promising 107;108, this type of 
therapy does not target specific proteins and 
therefore may affect all proteins which are 
normally degraded. The recent identifica-
tion of specific alterations in ubiquitin E3 
ligases provide very specific targets for 
novel inhibitors instead of reducing the 
activity of the complete 26S proteasome 109. 
A well characterized example is the MDM2 
mediated ubiquitination and subsequent 
degradation of the tumor suppressor p53. As 
described above, several tumors are charac-
terized by MDM2 amplification resulting in 
constitutive degradation and inactivation of 
p53. Recently, small molecule antagonists 
of MDM2 (Nutlins) were identified, which 
specifically disrupt the interaction with p53 
by binding to the p53 binding domain of 
MDM2 (Figure 9B). The treatment of MDM2 
overexpressing cell lines and in vivo tumor 
models with nutlins resulted in the activation 
of p53 and subsequent inhibition of prolif-
eration and induction of apoptosis 110. This 
therapy can only be effective when p53 is not 
mutated as stabilization of mutated p53 is not 
beneficial. In contrast to other tumors, the 
majority of patients suffering from leukemia 
have wild type p53. In vitro tests showed that 
treatment of both AML 111 as well as B-CLL 
112 cells with nutlins resulted in p53 mediated 
apoptosis. Thus, nutlins may be promising 
new drugs, especially for the treatment of 
hematological cancers. 
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Figure 9, The UPS as novel therapeutic 
target in cancer treatment
A, Inhibition of the 26S proteasome 
results in diminished degradation of 
ubiquitinated proteins and result in 
the accumulation of proteins which 
would normally be degraded. B, 
Overexpression of MDM2 results in 
p53 inactivation through constitutive 
26S proteasomal degradation. Nutlins 
specifically inhibit the interaction 
between MDM2 and p53. This results 
in accumulation of p53 protein levels 
and apoptosis. 
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The last years several aberrancies in the UPS 
were identified which play an important role 
in cancer development including hematopoi-
etic malignancies. Besides the use of a general 
intervention of the UPS by proteasome 
inhibitors, novel therapies which specifi-
cally disrupt E3 ligase-substrate interactions 
are being tested. This shows that inhibition 
of ubiquitination is a very powerful tool to 
modify the activity of proteins and makes the 
UPS a very interesting therapeutic target. 
Outline of this thesis
Various proteins known to play an important 
role during hematopoiesis are subject to ubiq-
uitination. However, most of the ubiquitin 
E3 ligases responsible for their ubiquitina-
tion  are still unknown. The human genome 
encodes for approximately 700 proteins 
with domains implicated in the UPS. It is 
important to broaden our knowledge of these 
genes during normal and malignant hemato-
poiesis to identify novel specific, drugable 
targets. This thesis is an example of such a 
study. It studies the function and role of a 
novel ubiquitin E3 ligase; Triad1. 
Figure 10, The TRIAD domain
A novel subclass of  RING finger containing E3 ligases was identified. These protein contain the TRIAD 
domain, which consists of 2 RING fingers flanking a DRIL domain. 
Triad1 belongs to the family of RING 
finger proteins. More precisely, Triad1 is 
the founding member of a novel RING 
finger protein subclass (TRIADs). In 
contrast to most RING finger containing 
proteins that contain only one RING finger, 
TRIAD proteins contain two RING fingers. 
Furthermore, these RING fingers flank 
a novel domain which is only found in 
between two RING fingers (Figure 10). This 
Double RING finger Linked (DRIL) domain 
is a cysteine rich domain like a RING finger. 
The Two RING fingers and DRIL (TRIAD) 
domain was found in several other proteins 
113;114. 
Triad1 is induced during the differentiation 
of hematopoietic stem cells towards mature 
monocytes and granulocytes. Using retro-
viral expression the biological relevance of 
the Triad1 expression was studied in chapter 
2. In chapter 3 the function of the different 
domains of Triad1 were studied by both 
functional as well as biochemical assays. In 
chapter 4 two novel RING finger proteins 
were identified to interact with Triad1. We 
have found that Triad1 also interacts with the 
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transcriptional repressor Growth factor inde-
pendence 1 (Gfi1) in chapter 5. Gfi1 is an 
essential transcription factor for granulocytic 
differentiation 19;21;23. Finally, in chapter 6 we 
studied the regulation of Gfi1 protein levels 
by the ubiquitin proteasome system during 
myeloid differentiation. 
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The E3 ubiquitin-protein ligase Triad1 inhibits clonogenic 
growth of primary myeloid progenitor cells
Abstract 
Protein ubiquitination plays important roles in a variety of basic cellular processes. 
Proteins are ubiquitinated by E2-E3 ubiquitin ligase complexes. Depending on the 
type of ubiquitin chain conjugated, proteins are either targeted for degradation by 
the proteasome or their activity is specifically altered. We describe a novel conserved 
nuclear protein, Triad1, which is strongly induced during myeloid differentiation. Triad1 
contains a TRIAD motif that harbours 2 RING finger structures. Triad1 binds the E2 
ubiquitin conjugating enzyme UbcH7 as well as ubiquitinated proteins and supports 
the formation of ubiquitin chains that are recognized by the proteasome. The biological 
function of Triad1 in myelopoiesis was studied by performing CFU-GM assays using 
retrovirally transduced primary murine bone marrow cells. Triad1 severely inhibited 
myeloid colony formation. In contrast, two Triad1 RING finger point mutants that 
failed to bind UbcH7 did not affect colony formation. Moreover, proteasome inhibition 
counteracted the inhibition of colony formation exerted by wild type Triad1. In liquid 
cultures, Triad1 did not influence differentiation but strongly inhibited proliferation 
resulting in a G0/G1 accumulation. We conclude that proteasomal degradation of 
proteins that are ubiquitinated by Triad1 affects the clonogenic growth of primary 
myeloid progenitor cells.
Introduction
Granulocytes and monocytes develop 
from common myeloid progenitor cells 
through a complex network of cell growth, 
differentiation and apoptosis regulating 
factors. Alterations in these processes may 
cause acute myeloid leukemia, which is 
characterized by uncontrolled proliferation 
of immature myeloid cells that fail to 
differentiate towards mature functional 
cells1,2. In leukemia mutations occur in 
genes encoding tyrosine kinases like Flt3, 
c-kit, N-ras and transcription factors like 
AML1, CBFB, GATA1, PU.1, C/EBPα 
and RARα1,2.  While the transcription 
factors predominantly play a role in lineage 
commitment, activation of tyrosine kinases 
is thought to result in proliferative and/or 
survival signals1,2. Recent studies have 
shown that several proteins involved in 
myelopoiesis (including proteins mutated in 
leukemia) are inactivated through ubiquitin 
(Ub)-proteasomal degradation pathways3-7. 
This form of targeted protein degradation is 
accomplished by the covalent conjugation 
of Ub to substrate proteins, usually in the 
form of a multi-Ub chain, which marks these 
proteins for progressive degradation by the 
26S proteasome8,9. Protein ubiquitination is 
catalyzed through a cascade of reactions. 
Ub is first activated by the ATP-dependent 
Ub-activating E1 enzyme and subsequently 
transferred to one of a set of E2 Ub-
conjugating enzymes. The E2 enzymes 
act in conjunction with accessory E3 Ub 
protein ligases. In the E2-E3 complex, the 
E3 component binds to protein substrates, 
allowing the E2 to form a multi-Ub chain 
linked to a lysine of the substrate protein8,9. 
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Thus, the E3 Ub ligases play a crucial role in 
this process as these proteins recognize the 
cellular proteins destined for ubiquitination10. 
To date, several types of E3 Ub ligases 
have been described. These include HECT, 
RING finger, U-box, SOCS-box, F-box 
and cullin ligases11-20. While the first three 
types of proteins are actively involved in 
substrate ubiquitination the last three do not 
ubiquitinate substrate proteins themselves 
but are part of larger protein complexes that 
exhibit Ub ligase activity15-19. Despite the fact 
that several proteins that play an important 
role in myelopoiesis are known to be targeted 
by the Ub-proteasome pathway, only a few 
E3 Ub ligases involved in myelopoiesis have 
been described. These include the cullin Ub 
ligase Cul-4A implicated in myelopoiesis4,21. 
Cul-4a heterozygous mice have diminished 
multipotent progenitors and enforced 
Cul-4A expression inhibits granulocytic 
differentiation of myeloid PLB-985 cells21. 
An important target of Cul-4A in myelopoiesis 
may be the transcription factor HoxA9 that 
is targeted by Cul-4A for ubiquitination 
resulting in its proteasomal degradation4. 
Another group of Ub ligases involved in 
myelopoiesis are the SOCS proteins. All 
of these proteins contain a suppressor of 
cytokine signaling (SOCS) box that provides 
in the scaffold for interaction with Ub ligase 
complexes15,16. One of the main functions of 
the SOCS box proteins is to recruit substrate 
proteins to ligase complexes resulting in 
their ubiquitination. SOCS3 is induced upon 
G-CSF treatment, binds to the activated G-
CSF receptor and negatively regulates G-
CSF receptor-mediated STAT activation22. In 
addition, mice with loss of SOCS3 function 
in the hematopoietic compartment develop 
neutrophilia23. Although it is not exactly 
clear how SOCS proteins inhibit cytokine 
signaling, it has been suggested that the 
ubiquitination and subsequent degradation 
of signaling molecules may be involved in 
this process24. Finally, another important E3 
Ub ligase involved in myelopoiesis is the 
RING finger protein Cbl. Cbl catalyzes the 
ubiquitination of several activated receptor 
tyrosine kinases including the colony-
stimulating factor 1 (CSF-1) receptor25. The 
ligand binding stimulated ubiquitination of 
these receptors results in their internalization 
and targeting to lysosomes where they are 
degraded. As this inhibits these receptors to 
recycle through early endosomes to the cell 
surface, Cbl negatively regulates receptor 
signaling25. Here, we identify a novel E3 Ub 
ligase, Triad1, to be strongly induced during 
granulocytic and monocytic differentiation 
and show that the Ub ligase activity of 
Triad1 inhibits the proliferation of committed 
myeloid progenitor cells.
Methods
Subtractive PCR, 5’ and 3 ’RACE and 
classical and real-time RT-PCR
Subtractive PCR was performed using 
polyA+ mRNA isolated from 0 and 18 
hours ATRA treated NB4 cells (PCR-select 
cDNA subtraction kit, Clontech). Subtracted 
radiolabeled PCR fragments were isolated 
from polyacrylamide gel, re-amplified, 
cloned in pCR2.1 and sequenced. Methods 
for cDNA synthesis and classical and real-
time RT-PCR were as described26. 5’RACE 
was performed using the Marathon cDNA 
amplification kit (Clontech) on 1.0 µg of 
human spleen mRNA. Relevant primers are 
indicated in supplementary Table 1.
Plasmid constructs
Triad1 coding sequences were PCR amplified 
using cDNA derived from NB4 cells and 
cloned in pCR2.1. A 10 aa human myc epitope 
was introduced at the 3’ end of the coding 
sequence of Triad1 by PCR and cloned into 
pSG5 and non-tagged Triad1 was cloned into 
pcDNA3.1. Triad1 coding sequences were 
41
The E3 ligase Triad1 regulates myelopoiesis
generated by PCR and cloned in pEGFP-
C1 to generate GFP-Triad1, pFastBacHT to 
generate His-Triad1 in Hi5 cells (Baculovirus 
expression system, Invitrogen) and in pGEX-
2TK to generate GST-Triad1. For retroviral 
transduction Triad1 coding sequences were 
inserted into the retroviral pLRZS vector. For 
yeast-two-hybrid assays sequences coding 
for Triad1 aa 1-119 and 109-493 were cloned 
in pGAD-C. All primers used for cloning 
purposes and for generating the Triad1 point 
mutants H158A and C161A by site-directed 
mutagenesis are indicated in supplementary 
Table 1. The integrity of all Triad1 sequences 
was checked by sequence analysis. 
Immunofluorescence, Northern blotting, GST- 
and His-captures and immunoprecipitations
In these studies antibodies against CD34, 
CD3, CD14, CD15, CD45 (Beckman 
Coulter), Mac1 (BD Biosciences), GFP 
(7.1/13.1 Roche), myc (9E10, Santa 
Cruz), UbcH7 and UbcH9 (Transduction 
laboratories), Ub (6C1,Sigma), Flag 
(M2, Sigma), annexinV (AlexaFluor 647, 
Molecular Probes) and Triad1 were used. 
Triad1 antibodies were generated by 
immunizing rabbits with a KLH-coupled 
peptide corresponding to Triad1 aa 473-
486, followed by affinity purification using 
peptides immobilized on Affigel 10 columns 
(Biorad). Human hematopoietic subsets were 
isolated by FACS with appropriate antibodies. 
Granulocytes were selected based on CD45 
positivity and scatter plot. Cell purity was 
confirmed to be more than 95% by flow 
cytometric analysis. For immunofluorescence 
experiments cells were stained with indicated 
primary antibodies followed by staining 
with a secondary antibody. For detection 
of endogenous Triad1 by multicolor 
flowcytometry (Cytomics FC500, Becton 
Dickinson), cells were stained with a Triad1 
antibody using fix-and-perm approaches as 
described27 followed by blocking of cells 
Table 1. Sequences of Triad1 oligonucleotides
Name  Sequence (5’-3’)
AO     GTCGCGAATTCGTCGACGCG(T)15AP1    GTCGCGAATTCGTCGACGCG
AP2    ACTCACTATAGGGCTCGAGCGGC
T1B    TGCCTGGTTCCAGCTGTCAGA  
T1D    TGCTCTGAGGCTGAGGTGTG
T1K    GCAGACAGCTATGACAGAGG
T1O    AAAGGTGAGCCACAGACATG
T1P    TGCCAGTGTCTCTCAGGAGT
T1V    TTTGATCCCGAGGAGTACCA
T1W    GTTCACTTGCTTGACCTACA
T1X    TGTAGGTCAAGCAAGTGAAC
T1Y    TGGTACTCCTCGGGATCAAA
T1Z    TGATCTGCAACTTGGCTGGA
T1AB   GATGGGATGTGGGAACATGT
T1exp1 GATCGGATCCATGTCAGTGGACATGAATAGCCAG
T1exp2 TCGCGAATTCTTAGGTGTCATGGAAATCTTTCAGC
T1G1   GGATCCTTAGGATGGGATGTGGGAACATGT
T1G2   GGATCCTACAAGTCCAATTCTGCTCA
T1M4   TCGCGGATCCTTACAGGTCCTCCTCGCTGATCAG
       CTTCTGCTCGGTGTCATGGAAATCTTTCAGC
T1M5   GATCGAATTCATGCTAAGATGTCAGTGG
T1qF   TGGTCCTTTCTTTTGTGCCAGTA
T1qR   GCAGCAAGACAGTGTCAGGTTT
T1qP   CCAAATGTGACCCTGCTCAGAGCTATACCAC
H158AF TCTCTGGCCTGTCAGGCCCAGTTTTGCCGCAGC
H158AR GCTGCGGCAAAACTGGGCCTGACAGGCCAGAGA
C161AF TGTCAGCACCAGTTTGCCCGCAGCTGCTGGGAG
C161AR CTCCCAGCAGCTGCGGGCAAACTGGTGCTGACA
For amplification of overlapping Triad1 RT-PCR 
fragments 2, 3, 4 (Figure 1) primer combinations 
T1V-T1AB, T1Z-T1P and T1K-T1O were used, 
respectively. For 3’ RACE primers AO was 
used for cDNA synthesis followed by PCR using 
primers AP1 and T1D, followed by hemi-nested 
PCR using primers AP1 and T1B. For 5’ RACE 
primers AP2 and T1X were used in PCR followed 
by hemi-nested PCR using primers AP2 and T1Y. 
T1M4 and T1M5 were used to for the construction 
of a C-terminally myc tagged Triad1 PCR 
construct. The 30 bp myc-tag encoding sequence 
is underlined. Primers H158AF, H158AR, C161AF 
en C161AR were used to construct Triad1 H158A 
and Triad1 C161, respectively. For generation 
of GST-Triad1 and GFP-Triad1 primer pairs 
T1exp1 and T1exp2 were used. For cloning full 
length Triad1 in pCDNA3.1 and retroviral vectors 
primers T1M4 and T1exp2 were used. For cloning 
Triad1-119 and Triad1109-493 in pGAD vector primer 
combinations T1exp1-T1G1 and T1G2-T1exp2 
were used, respectively. For Triad1 qPCR primers 
T1qF and T1qR and probe (TET-label) T1qP were 
used. BamHI and EcoRI sites introduced by PCR 
for cloning purposes are indicated (bold italics).
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   1 TAGAATACTTGGGTGACATCTGCCTGAGAGATCTCCAAGAATTACAGAAGACAAAAATAC  hTriad1 MSVDMNSQGSDSNEEDYDPNCEEEEEEEEDDPGDIEDYYV
  61 TAATGCATTTGAGAAAGCGGTAGTTTTGGGGGGAGGGGGAAAAAGCAACTGCTTTCCTGA  mTriad1 MSVDMNSQGSDSNEEDYDPNCEEEEEEEED-PGDIEDYYV
 121 TCTGCAACTTGGCTGGATGCTAAGATG TCA GTG GAC ATG AAT AGC CAG GGG   dTriad1 ------------MDSDIEMDMESDNDGEYD--DDYDYYNT
                              M   S   V D   M   N   S   Q   G  9  eTriad1 -------------MDDEDMSCTSGDDYAGY--GDEDYYNE
 172 TCT GAC AGC AAT GAA GAG GAC TAT GAC CCA AAT TGT GAG GAA GAG   motif      *************************************
 S   D   S   N   E   E   D   Y   D   P   N   C   E   E   E  24  
 217 GAA GAA GAA GAA GAA GAC GAC CCT GGG GAC ATA GAG GAC TAT TAC   hTriad1 GVASDVEQQGADAFDPEEYQFTCLTYKESEGALNEHMTSL
 E   E   E   E   E   D   D   P   G   D   I   E   D   Y   Y  39  mTriad1 GVASDVEQQGADAFDPEEYQFTCLTYKESEGALHEHMTSL
 262 GTG GGA GTA GCC AGC GAT GTG GAG CAG CAG GGG GCT GAT GCC TTT  dTriad1 GEDCDVERLDPKRADPEYFEYECLTVEDIEKLLNERVEKL
 V   G   V   A   S   D   V   E   Q   Q   G   A   D   A   F  54  eTriad1 ADVDAADDVAVTPTHSEEADYECLSVNQVERVFIDGVNSL
 307 GAT CCC GAG GAG TAC CAG TTC ACT TGC TTG ACC TAC AAG GAA TCT   motif   ********************
 D   P   E   E   Y   Q   F   T   C   L   T   Y   K   E   S  69  
 352 GAG GGT GCC CTC AAT GAG CAC ATG ACC AGC TTA GCT TCT GTC CTA   hTriad1 ASVLKVSHSVAKLILVNFHWQVSEILDRYKSNSAQLLVEA
      E   G   A   L   N   E   H   M   T   S   L   A   S   V   L  84  mTriad1 ASVLKVSHSVAKLILVNFHWQVSEILDRYRSNSAQLLVEA
 397 AAG GTA TCT CAT TCA GTT GCT AAA CTT ATA TTA GTT AAT TTC CAC   dTriad1 NTILQITPSLAKVLLLEHQWNNVAVVEKYRQDANALLVTA
      K n V   S   H   S   V   A   K   L   I   L   V   N   F   H  99  eTriad1 VSRISINEKFARILLQANHWDVDKIARLVRNDRNDFLRKC
 442 TGG CAA GTT TCA GAG ATA TTG GAC AGA TAC AAG TCC AAT TCT GCT
      W   Q   V   S   E   I   L   D   R   Y   K   S   N   S   A  114  hTriad1 RVQPNPSKHVPTS---------------------------
 487 CAA CTG CTT GTT GAG GCT CGA GTT CAG CCT AAT CCA TCA AAA CAT   mTriad1 RVQPNPSKHVPTA---------------------------
      Q   L   L   V   E   A   R   V   Q   P   N   P   S   K   H  129  dTriad1 RIKPPSVAVTDTASTSAAAASAQLLRLGSSGYKTTASATP
 532 GTT CCC ACA TCC CAT CCC CCT CAC CAC TGT GCA GTG TGT ATG CAG   eTriad1 HIDAKPEPKRKLSSTQS-------V---------------
      V   P   T   S   H   P   P   H   H C A   V   C   M   Q 144
 577 TTT GTG CGA AAG GAA AAC CTA CTC TCT CTG GCC TGT CAG CAC CAG   hTriad1 -HPPHHCAVCMQFVRKENLLSLACQHQFCRSCWEQHCSVL
F   V   R   K   E   N   L   L   S   L   A   C   Q   H   Q 159 mTriad1 -HPPHHCAVCMQFVRKENLLSLACQHQFCRSCWEQHCSVL
 622 TTT TGC CGC AGC TGC TGG GAG CAG CAC TGC TCA GTT CTC GTC AAG   dTriad1 QYRSQMCPVCASSQLGDKFYSLACGHSFCKDCWTIYFETQ
F   C   R   S   C   W   E   Q   H   C   S   V   L   V   K 174 eTriad1 -LAKGYCSVCAMDGYTE-LPHLTCGHCFCEHCWKSHVESR
 667 GAC GGC GTG GGC GTG GGA GTC TCT TGC ATG GCT CAG GAC TGT CCA   motif         $  $             $ $  $  $
D   G   V   G   V   G   V   S   C   M   A   Q   D   C   P  189 
 712 CTC CGT ACA CCA GAG GAC TTT GTG TTT CCA TTG CTT CCC AAT GAA   hTriad1 VKDGVGVGVSCMAQDCPLRTPEDFVFPLLPN-EELREKYR
      L   R   T   P   E   D   F   V   F   P   L   L   P   N   E  204  mTriad1 VKDGVGVGISCMAQDCPLRTPEDFVFPLLPN-EELRDKYR
 757 GAA TTG AGA GAG AAA TAC AGG CGC TAC CTC TTC AGG GAC TAT GTG   dTriad1 IFQGISTQIGCMAQMCNVRVPEDLVLTLVTR-PVMRDKYQ
      E   L   R   E   K   Y   R   R   Y   L   F   R   D   Y   V  219  eTriad1 LSEGVASRIECMESECEVYAPSEFVLSIIKNSPVIKLKYE
 804 GAG AGT CAT TAC CAG CTC CAG CTG TGC CCT GGT GCA GAC TGC CCC   motif             $    $
      E   S   H   Y   Q   L   Q   L C   P   G   A   D   C   P 234
 847 ATG GTT ATT CGG GTA CAG GAG CCT AGA GCT CGC CGA GTA CAG TGC   hTriad1 RYLFRDYVESHYQLQLCPGADCPMVIRVQEPRARRVQCNR
M   V   I   R   V   Q   E P   R   A   R   R   V   Q   C 249 mTriad1 RYLFRDYVESHFQLQLCPGADCPMVIRVQEPRARRVQCNR
 892 AAT CGG TGC AAC GAG GTC TTC TGT TTC AAG TGT CGT CAG ATG TAT   dTriad1 QFAFKDYVKSHPELRFCPGPNCQIIVQSSEISAKRAICKA
N   R   C   N   E   V   F   C   F   K   C   R   Q   M   Y 264 eTriad1 RFLLRDMVNSHPHLKFCVGNECPVIIRSTEVKPKRVTCMQ
 937 CAC GCA CCC ACA GAC TGT GCC ACA ATC CGG AAA TGG CTC ACG AAG   motif                   #    #               #
H   A   T   P   D   C   A   T   I   R   K   W   L   T   K  279 
 982 TGT GCA GAC GAC TCT GAA ACA GCC AAC TAC ATT AGT GCT CAC ACT   hTriad1 CNEVFCFKCRQMYHAPTDCATIRKWLTKCADDSETANYIS
      C   A   D   D   S   E   T   A   N   Y   I   S   A   H   T  294  mTriad1 CSEVFCFKCRQMYHAPTDCATIRKWLTKCADDSETANYIS
1027 AAA GAC TGT CCC AAG TGC AAC ATC TGC ATT GAG AAG AAT GGA GGC   dTriad1 CHTGFCFRCGMDYHAPTDCQVIKKWLTKCADDSETANYIS
      K   D C   P   K   C   N   I   C   I   E   K   N   G   G 309 eTriad1 CHTSFCVKCGADYHAPTSCETIKQWMTKCADDSETANYIS
1072 TGC AAT CAC ATG CAA TGC TCC AAA TGT AAA CAC GAC TTC TGC TGG   motif        #  #    #    #
C   N   H   M   Q   C   S   K   C   K   H   D   F   C   W 324
1117 ATG TGT CTA GGA GAT TGG AAG ACT CAT GGC AGT GAA TAC TAT GAG   hTriad1 AHTKDCPKCNICIEKNGGCNHMQCSKCKHDFCWMCLGDWK
M   C   L   G   D   W   K   T   H   G   S   E   Y   Y   E  339  mTriad1 AHTKDCPKCNICIEKNGGCNHMQCSKCKHDFCWMCLGDWK
1162 TGC AGT CGT TAC AAG GAG AAT CCT GAC ATC GTG AAC CAG AGC CAA   dTriad1 AHTKDCPKCHICIEKNGGCNHMQCFNCKHDFCWMCLGDWK
      C   S   R   Y   K   E   N   P   D   I   V   N   Q   S   Q  354  eTriad1 AHTKDCPQCHSCIEKAGGCNHIQCTRCRHHFCWMCFGDWK
1207 CAA GCC CAG GCG AGG GAA GCC CTC AAG AAG TAC TTA TTC TAC TTT   motif        $  $         $ $  $  $    $  $
      Q   A   Q   A   R   E   A   L   K   K   Y   L   F   Y   F  369 
1252 GAG AGG TGG GAA AAC CAC AAT AAA AGC TTG CAG CTA GAG GCA CAG   hTriad1 THGSEYYECSRYKENPDIVNQSQQAQAREALKKYLFYFER
      E   R   W   E   N   H   N   K   S   L   Q   L   E   A   Q  384  mTriad1 THGSEYYECSRYKENPDIVNQSQQAQAREALKKYLFYFER
1297 ACA TAC CAG CGG ATT CAC GAG AAG ATT CAG GAG AGG GTC ATG AAC   dTriad1 THGSEYYECSRYKDNPNIANESVHVQAREALKKYLHYYER
      T   Y   Q   R   I   H   E   K   I   Q   E   R   V   M   N  399  eTriad1 SHGSEYYECSRYKENPSVAAEANHVKARRALEKYLHYFER
1342 AAT CTG GGG ACA TGG ATC GAC TGG CAG TAC CTA CAG AAT GCT GCC    motif                       ^^^^^^^^^^^^^^^^^^^^
      N   L   G   T   W   I   D   W   Q   Y   L   Q   N   A   A  414 
1387 AAG CTC TTG GCC AAG TGT CGA TAC ACC CTG CAA TAC ACC TAC CCA   hTriad1 WENHNKSLQLEAQTYQRIHEKIQERVMNNLGTWIDWQYLQ
      K   L   L   A   K   C   R   Y   T   L   Q   Y   T   Y   P  429  mTriad1 WENHNKSLQLEAQTYERIHEKIQERVMNNLGTWIDWQYLQ
1432 TAT GCA TAT TAC ATG GAG TCC GGA CCC AGG AAG AAG CTG TTT GAA   dTriad1 WENHSKSLKLEQQTIDRLRQRINSKVMNGSGTWIDWQYLF
      Y   A   Y   Y   M   E   S   G P   R   K   K   L   F   E  444  eTriad1 FENHSKSLKMEEELRDKIRKKIDDKVNEHNGTWIDWQYLH
1477 TAC CAG CAG GCT CAG CTG GAG GCT GAG ATC GAA AAC CTC TCA TGG    motif   ^^^^^^^^^^^^^^^^^^^^^^^^^^^^
      Y   Q   Q   A   Q   L   E   A   E   I   E   N   L   S   W  459  
1522 AAA GTG GAG CGT GCA GAC AGC TAT GAC AGA GGG GAC TTG GAG AAC  hTriad1 NAAKLLAKCRYTLQYTYPYAYYMESGPRKKL------FEY
      K   V   E   R   A   D   S   Y   D   R   G   D   L   E   N  474  mTriad1 NAAKLLAKCRYTLQYTYPYAYYMESGPRKKL------FEY
1567 CAG ATG CAT ATA GCG GAG CAG CGG AGG AGA ACC CTG CTG AAA GAT   dTriad1 NAAALLAKCRYTLQYTYPYAYYMEAGSRKNL------FEY
      Q   M   H   I   A   E   Q   R   R   R   T   L   L   K   D  489  eTriad1 KSVSLLTKCRYTLQYTYPFAYFLSATPRKNLVCFLGKFEY
1612 TTC CAT GAC ACC TAAGTTGGGATGTGGATGTGCCGGGGTGAGGAAGATGTGGCTG    motif                                        ^^^
      F   H   D   T   *                                          493 
1667 CAAGGTCTCCCGGCTGCCATACTGCATGCTGCAGGCTCTGCCTTTCATGACCCCAGGCAA     hTriad1 QQAQLEAEIENLSWKVERADSYDRGDLENQMHIAEQRRRT
1727 CAGCCAGGGCCCCACTCCTGAGAGACACTGGCAACACCTCTTAGTTGATTTCTGTTTTCT   mTriad1 QQAQLEAEIENLSWKVERADSYDRGDLENQMHIAEQRRRT
1787 TCTCTTTTCACTTTTTGTTTCTACCAGGGTAGAGGCCATGTTGAACTGGCCTCTTTTCAG   dTriad1 QQAQLEAEIENLSWKIERAETTDLGDLENQMDIAEKRRTT
1847 GACTTTTATTTCCCCCTGGATGGTTGTTGGGAGGGAGGGAAAGTGTTTTCTGAATGGCTA   eTriad1 QQAQLEKEVEELAWAVERADGTARGALEAHMHRAEHKRQT
1907 TTAATAGTATTAGATCATTACAACTTATGTAACTTTCAAAGGTTGTACAATTATACAAAA   motif   ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
1967 AAAAAAAAAAAGGCAAACTATAGGATAACACAGAGCCCTTTTTGAAAATAAATTGGCATT
2027 GGAGTGTTTTACCCTCTAGCTGTTTTACTTAGAATGTAACATATGCTGCCTACCCACCTC   hTriad1 LLKDFHDT--
2087 AAAATGTCTGTACTGCAAGAGGGCCCTGGGCCTCTGCTTTCCATATTCACGTTTGGCCAG   mTriad1 LLKDFHDT--
2147 AGTTGTAGTCCCAAAGAAGAGCATGGGTGGCAGATGGTAGGGAATTGAACTGGCCTGTGC   dTriad1 LLKDFFPVDA
2207 AATGGGCATGGAGCACAAGGGGTCACAGCATGCCTCCTGCCTTACCGTGGCAGTACGGAG   eTriad1 LLHDFFF---
2267 ACAGTCCAGAACATGGTCTTCTTGCCACGGGGTGTTGTTGTCTCTGGTGGTGCTGCATGT
2327 CTGTGGCTCACCTTTATTCTTGAAACTGAGGTTTACCTGGATCTGGCTACTGAGGCTAGA
2387 GCCCACAGCAGAATGGGGTTGGGCCTGTGGCCCCCAAACTAGGGGGTGTGGGTTCATCAC
2447 AGTGTTGCCTTTTGTCTCCTAAAGATAGGGATCTACTTTTGAAGGGAATTGTTCCTCCCA
2507 AATAAATTTGCTTTACCTTGGTCCTTTCTTTTGTGCCAGTATTCAAGTGGTATAGCTCTG
2567 AGCAGGGTCACATTTGGCCAAACCTGACACTGTCTTGCTGCATTCTCCTTTGGCAAACAT
2627 CAGGGTCAGAATTCAGGATAGCCCTTCCTAGGGCACTGGACTTTCTGGCATGGGGGCTGT    
TRIAD domain 
A                   R           D      R2     CC         CC 
A                   R           D      R2     CC         CC 
              Identity 
N-ter                     C-ter
A                   R           D      R2     CC         CC 
30
97
6426
A                   R           D      R2     CC         CC 
80
100
2687 GTTTGCACAAGTTATTTTCATGTTACCTGGAGAGTGTCCAGAGGCTGCTCTGAGGCTGAG
2747 GTGTGTTCCCCCTTGCCTGGTTCCAGCTGTCAGAGGGATACCATCCTAGGGTCTGGGAAT
2807 CCAAGGCCACGAGACTCCTTGGTTTGTGGTCCGAGATCCTGTACTAAGGAGGGTCTGGCC
2867 AGAGGAACAGACCAGCTTTTGCACAATGAAGCGCAAGGGAACAAGTGGTTTGCCTGGTGT
human2927 CCTACCTGTCCTGAACCTGGTCCTGTGGGCCATTGAAAAGTTAGATCTGTGATCTCTGGG2987 GTTTTTGTGGCTTTGTTCAATGCTTCCACTCTAGGGCAGGCAGAGCAGTCTATACTCTCC
3047 CAAGCCTGCTTGACCTCCAAGTAGAGCTGATACAGAGATCTGTGAATATTGTGATAGAAA
3107 TTCTTTGGTATTCATACATTTCAGCTGCAAGTCAGCAATTTCCCAGGTACCATGTAAGCT
3167 ATAAAACAGTCATTCTTAAAGACAGAGGATAGCTGTGACTCATGGGATCATGAGGTCCAT mouse3227 GGCTGGTTGCAGGTTCCCTTTTTCCTTCCTCAGGTTTTGTCTCTTCCTGTGTTGTCCCCA
3287 GCAAGGGAGAGACTGTGGGGTGGATTGGGAGAACAGATTAGGAGTATAGCAAATGAACCC
3347 AGAATGGAACAGTGGGGAGCTAACTGTGAATGAGGAGAGTACCTGCTGCAGGACCTGGAG
3407 GTCAGGTGTGAATGCTGTATTGGCACAGGGAATAAATATCCTGGCGTCTGGAGCCTTCAC
fruitfly 3467 CTCTCCGTCAAGTCCTTCCTGTGATACTGCCATGGCACAGGATCTGAGTTGCAGCTCTGC3527 ACCCTAAATCACACCCTGGGCATTGTCTGGGCTGCAGGGCTGCCAGGTTCTGTACTTGTG
3587 TCCAGCTGTGGCCCTGGATGCTGGAGCTGGAGGGTTTTCTGTGCTCAGACTGTAGCCTGT
3647 AGCTCTTGGCCTGTGTAGAGCCCCCTCCTGTGCCCTCAGTGGCTGTCGTTTGTTAACATC
3707 ATCAGGAAGATGGGAAAGGTCAGGCAGAATTTTTCTGCCCTACAAAGGGTGGAAGAGAAA
elegans3787 GGACACAGTATTTTCATGAATTTACCATATATCTTTGTTTTTCTTCAACGAAAAAGTTAA
3827 TTGAGGCAATGTCATCTGCTCAAAGTTGAGTGGTTTATTCACAATAAACTGTAAGTTTCT
3887 GATTAT 
Supplementary Figure 1, Triad1 transcript, protein and protein conservation. 
A. Human Triad1 cDNA and protein sequence. The translational start site (cDNA position 145) is 
accompanied by a Kozak consensus sequence (underlined) and followed by a 149 bp open reading 
frame. A poly-adenylation signal is present at cDNA position 3869 (bold). Typical Triad1 protein 
domains are a 55 aa N-terminal acidic (aa pos 4-58, underlined), two RING finger (aa positions 139-
188 and 297-326, bold, boxed with cys/his residues essential to the RING finger structure encircled), 
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with rabbit serum and subsequent staining 
for relevant surface markers. For Triad1 
Northern blot hybridization 10 µg total 
RNA isolated from NB4 cells treated with 
ATRA (10-6 M) for various time points or 
1.0 µg mRNA from hematopoietic cells was 
hybrized using Triad1 clone 14-5 as a probe. 
For GST-captures, 10 µg of immobilized 
GST or GST-Triad1 was incubated with 
cell lysates from 107 NB4 cells. For capture 
of His-tagged proteins, lysates from 
transfected 293T cells were incubated with 
His-select beads (Sigma) under denaturing 
conditions (6M guanidiumchloride). 
For immunoprecipitations, lysates from 
transfected COS cells were incubated 
with indicated antibodies. Bound proteins 
were washed, separated by SDS-PAGE, 
immunoblotted and stained with relevant 
antibodies. 
Yeast-two-hybrid analysis
For yeast-two-hybrid analyses UbcH bait28 
and Triad1 prey constructs were transfected 
to the yeast strain AH109 (Clontech). This 
strain contains two selectable markers 
(histidine and adenine) and a lacZ reporter. A 
positive interaction in yeast was defined by 
growth of blue colonies 4 days after plating 
cells on leucine, tryptophane, adenine and 
histidine deficient SD medium containing 
X-α-gal. 
Proteasome activity measurements and in 
vitro ubiquitination assays
Proteasome activity was determined in primary 
murine bone marrow cells after treatment 
with 10-8 M MG132. For measurements, 67.5 
µg protein lysates (concentration determined 
using Bradford assay) were incubated with 
the proteasome substrate Suc-Leu-Leu-Val-
Tyr-AMC (Boston Biochem) for 2 hrs at 
37°C as described29. AMC liberated from 
the substrate by proteasome activity was 
determined by measuring fluorescence 
(Fluorstar, BMG, Isogen Life Sciences)29. 
For in vitro ubiquitination assays His-Triad1 
was isolated from Hi5 cells (Baculovirus 
Bac-to-Bac system, Invitrogen) using His-
select spin columns followed by elution 
using 250 nM imidazole. Imidazole was 
removed from His-Triad1 protein eluates 
using a Microcon YM-10 filter (Amicon) and 
protein concentrations were determined with 
the Bradford assay. Ubiquitination assays 
were performed using 1.6 µg reticulocyte 
fraction IIA (Boston Biochem), bovine 
Ub (Sigma) or recombinant UbK48-only 
(Boston Biochem) with freshly prepared 
His-Triad1 for 60 min at 37°C followed by 
staining of ubiquitinated proteins in Western 
blot analysis using a Ub specific antibody 
(C61, Sigma) as described30.
a cysteine-rich (DRIL, aa positions 228-20, bold, boxed and cys/his residues encircled) and two 
C-terminal coiled coil (aa pos 351-399 and 442-48, shaded) domains. The two putative NLS (aa 
pos 242-248 and 438-444) are in bold and underlined. Alternative splicing occurs at cDNA position 
399 (vertical arrow, see also Figure 1b, lane 2). B. Triad1 amino acid conservation. Indicated are the 
acidic(*), ring finger ($), DRIL (#) and coiled coil (^) regions. Genbank accession numbers of murine, 
D. melanogaster (CG-509A) and C. elegans (4G323) proteins are respectively, XP_484030, NP_
434, and NP_500829. The putative human/mouse NLS PRARRVQ and PRKKLFE are respectively 
present at aa positions 242/241 and 438/43, whereas the C. elegans NLS PEPKRKL and KPKR are 
respectively present at aa positions 111 and 233. C. Extremely high C-terminal conservation (identity 
between human Triad1 and other species is indicated in percentages). Note that despite the overall low 
N-terminal conservation, all cysteine and histidine residues characteristic for the N-terminal RING 
finger structure and DRIL domain are conserved (see also supplemental Figure 1b). A = acidic, R = 
RING finger, D = DRIL domain, R2 = RING2 finger, CC = coiled coil.
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Clonogenic assays (CFU-GM) and myeloid 
cell proliferation
Retroviral vectors (pLZRS) were transfected 
to retroviral producer phoenix cells (kindly 
provided by Dr. G. Nolan). Primary murine 
bone marrow cells isolated from femurs 
from 6 weeks old female CBA/CA mice 
were prestimulated for two days with SCF, 
IL-12, IL-3, Flt-3, TPO and α-TGFβ and 
subsequently infected with retroviruses 
on retronectin coated dishes. After 24 hrs 
GFP positive cells were sorted by FACS 
and seeded in semi-solid medium (5,000 
cells/well) containing pokeweed mitogen 
stimulated mouse spleen conditioned 
medium, horse serum and SCF. Colonies 
were counted 5 days later yielding between 
83 to 125 colonies after CFU-GM of empty 
vector transduced cells and morphologically 
analyzed after May-Grünwald-Giemsa 
staining. To determine proliferation in liquid 
assays, 5,000 cells were seeded in 96-well 
plates using the above-mentioned medium 
without agar. Relative cell numbers were 
determined by FACS using fluorescent 
beads. Apoptosis and DNA histograms 
were determined by flowcytometer using 
AnnexinV and propidium iodide staining, 
respectively. Percentages of cells in various 
phases of cell cycle were determined using 
ModFit software (Verity).
0      24     48     96      hrs
GAPDH
ATRA (10-6) M
Triad1
A                         R1              D       R2         CC CC
1 493
Triad1 protein
TRIAD domain
Triad1 transcript
M      1        2      3       4       5       M Figure 1, Identification of 
Triad1.
A. Northern blot hybridization 
using subtracted clone 14-5 
detecting the ATRA-mediated 
induction of a 4 Kb transcript 
in NB4 cells (time of ATRA 
incubation is given at the top in 
hours). Rehybridization with a 
GAPDH probe indicates equal 
loading. B. Triad1 5’ and 3’ 
RACE and RT-PCR fragments 
as depicted in Figure 1C 
(lane numbers correspond to 
fragment numbers in Figure 
1C). Alternative splicing 
results in the detection of two 
RT-PCR fragments (lane 2). 
RACE and PCR fragments 1-
5 were amplified using primer 
combinations indicated in 
supplementary Table 1. C. 
Schematic representation of the 3.9 Kb ATRA induced Triad1 transcript (see supplementary Fig. 1 
for sequences). Indicated are the 149 ORF (open box) and overlapping cDNA and 5’ and 3’ RACE 
fragments as well as the localization of fragment 14-5 representing the clone identified in the subtractive 
PCR screen. D. Schematic representation of Triad1 protein domains. A = acidic domain; R1 and R2 are 
RING finger structures; D = DRIL domain; CC = coiled coil domain.
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Figure 2, Triad1 is highly 
expressed in granulocytes. 
A. Northern blot hybridization 
using Triad1 clone 14-
5 as a probe detects high 
Triad1 expression in mature 
granulocytes compared to 
complete bone marrow and T-
cells. B. Triad1 quantitative RT-
PCR detects high expression in 
granulocytes and low expression 
in immature CD34+ and T-cells. 
Data are from two samples from 
unrelated healthy volunteers. 
Expression in CD34+ cells 
was set at 1.0 and values 
were normalized for PBGD 
expression as described26. C. 
Triad1 real-time PCR detects 
high expression in peripheral 
blood compared to bone marrow 
(expression in total bone marrow 
was set at 1.0). Amongst non-
hematopoietic tissues highest 
expression was observed in fetal 
brain. 
A
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Results
Identification of genes induced during 
granulocytic differentiation
Acute promyelocytic leukemia cells can be 
forced to differentiate along the granulocytic 
lineage by the vitamine A derivative all-trans 
retinoic acid (ATRA). To identify genes 
involved in granulocytic differentiation we 
performed a subtractive PCR screen using 
RNA isolated from promyelocytic leukemia 
(NB4) cells before and 18 hours after ATRA 
treatment. Northern blotting using one of 
the subtracted clones (clone 14-5) showed 
the induction of a 4 Kb mRNA in NB4 cells 
24 hours after ATRA treatment to reach 
maximum levels at 48 hours (Figure 1A). The 
subtracted clone appeared identical to human 
randomly cloned expressed cDNA sequences 
identified in database searches (not shown). 
By using these sequences in database walks 
a 3.9 Kb cDNA contig was constructed. This 
contig was confirmed by amplification of 
overlapping RT-PCR fragments and 5’- and 
3’-RACE (Figures 1B and C). Sequence 
analysis of the 3.9 Kb transcript identified 
a poly-adenylation signal (ATAAA) 24 bp 
upstream of the 3’ end of the transcript and 
a translational start codon at cDNA position 
145. This start codon is accompanied by a 
consensus Kozak sequence and is followed 
by a 1479 bp open reading frame (ORF, 
supplementary Figure 1). The coding 
sequences were confirmed by sequence 
analysis of 12 independent clones (Genbank 
accession number AF099149). In line with 
multiple bands observed in RT-PCR (see 
Figure 1B), three Triad1 clones contained 
different insertions of extra sequences present 
46
Chapter 2
M
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
0
50
100
150
200
250
300
CD34+ CD3+ Mo1 Mo2 Gr1 Gr2 Gr3
CD14+ CD15+
immature   mature    immature             mature
Figure 3, Triad1 is a predominantly nuclear 
protein and is highly expressed in mature 
granulocytes and monocytes.                                                    
A. IF of Triad1-myc reveals a nuclear diffuse 
localization with exclusion of nucleoli in L88/5 
cells53. In cells with strong nuclear staining some 
cytoplasmic staining is also observed. Phase 
contrast image (phase contrast) indicating cellular 
structures are given at the right. Immunofluorescence of empty vector transduced cells did not reveal 
significant staining (not shown). B. A Triad1 specific affinity purified antibody detects low endogenous 
Triad1 expression in CD34+ and T-cells and high nuclear expression in mature granulocytes and 
monocytes. DNA was stained with DAPI and merged pictures are indicated. Representative results from 
one of three unrelated healthy volunteers are indicated. Triad1 IF detects in granulocytes a ring-shaped 
nuclear sublocalization. Strongest Triad1 expression is observed in the DAPI dull region (arrows) 
within the lobes of the nuclei. As negative control, cells were stained with pre-immune serum taken prior 
to peptide vaccination, revealing no significant signals (not shown). C. Intracellular Triad1 was stained 
on fresh bone marrow (n=1) or leukopheresis material (n=1) and analyzed by flowcytometer yielding 
similar results. The figure shows the mean fluorescence of indicated compartments of the leukopheresis 
sample. Lowest expression was observed in CD3+ and CD34+ cells. Within the CD14+ fraction 
lowest expression was observed in the more immature fraction (Mo1) compared to mature monocytes 
(Mo2). Likewise, in immature myelocytic fractions (Gr1 including promyelocytes and Gr2 including 
myelocytes/metamyelocytes) lower expression was observed compared to mature granulocytes (Gr3). 
Cells were co-stained for Triad1 and CD45 in combination with CD34, CD3, CD14 or CD15. Within 
the CD14+ and CD15+ populations immature and mature compartments were defined based on CD45 
staining and side scatter as described (see also supplementary Figure 2)54. Staining with pre-immune 
serum resulted in 30-100-fold lower signals (not shown).
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CD15+
CD34+ CD45+CD34+
Triad1
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Triad1
2 Supplementary Figure 2, Triad1 
expression in hematopoietic subsets 
measured with flowcytometer. 
A. Representative CD45/side scatter 
plot with CD34+ cells in pink. Triad1 
expression within CD45+CD34+ 
compartment is indicated. B. Identical 
sample as in A with CD3+ cells in pink. 
Triad1 expression within CD45+CD3+ 
compartment is indicated. C. Identical 
sample as in A with CD14+ cells 
indicated in pink. CD14+ compartment 
is divided into two subcompartments 
Z and AD representing respectively, 
fractions with more pro-monocytes 
and mature monocytes based on CD45 
and side scatter plot (Van Lochem et 
al, Cytometry 60B:1-13, 2004). Triad1 
expression in both compartments is 
indicated and the mean Triad1 expression 
in these two fractions (Mo1 and Mo2) 
is indicated in Figure 3c. D. Identical 
sample as in with CD15+ cells indicated 
in pink. The CD15+ compartment is 
divided into three subcompartments 
AB, AD and AE representing 
respectively immature myelocytic 
cells (including promyelocytes), more 
committed myelocytic cells (including 
myelocytes/metamyelocytes) and mature 
granulocytes (neutrophils) (Van Lochem 
et al, Cytometry 60B:1-13, 2004). 
Triad1 expression in these compartments 
is indicated and the mean Triad1 
fluorescence in these three fractions 
(Gr1–3) is indicated in Figure 3c.
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at cDNA position 399 possibly representing 
splice variants (Genbank accession numbers 
AF099150, AF099151, and AF099152).
Identification of Triad1
The 1479 bp ORF in the 3.9 Kb transcript 
predicts the formation of a 493 aa protein 
(Figure 1D). We have called this protein 
Triad1 referring to its cysteine-histidine rich 
TRIAD motif 31. The TRIAD (two RING 
fingers and DRIL) motif consists of two RING 
fingers that flank the DRIL (double RING 
finger linked) domain. The DRIL (a.k.a. 
IBR32) domain resembles other cysteine-rich 
motifs as the LAP/PHD, LIM and RING 
finger domains31. Recent data indicate that 
the C-terminal RING finger (RING2) of the 
TRIAD motif has a distinct topology from 
the classical RING finger structure and that 
it binds only one zinc atom instead of two33. 
Further Triad1 protein analysis identified an 
acidic N-terminal region, two C-terminal 
coiled coil regions and two putative nuclear 
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localization signals. To determine whether 
Triad1 is conserved during evolution we 
performed database searches and identified 
full length murine, D. melanogaster, and C. 
elegans orthologs (supplementary Fig. 1). 
The conservation in the last 231 aa C-terminal 
part of Triad1 between D. melanogaster 
and C. elegans compared to human Triad1 
is very high being 80% and 64% identical, 
respectively. Comparison of complete murine 
and human Triad1 shows that the proteins 
are 98% identical. The strong evolutionary 
conservation of Triad1 suggests that it exerts 
important biological functions.
Triad1 is induced during normal 
granulocytic/monocytic differentiation
Triad1 gene expression is induced during 
forced granulocytic differentiation of 
promyelocytic leukemia (NB4) cells. To 
determine the relevance of this observation 
we analyzed Triad1 expression in normal 
human hematopoiesis. Triad1 Northern blot 
hybridization using RNA isolated from total 
bone marrow, mature granulocytes and T-
cells revealed strongest Triad1 expression 
in granulocytes (Figure 2A). In agreement, 
Triad1 quantitative RT-PCR detected high 
expression in mature granulocytes and low 
expression in T-cells and immature CD34+ 
cells, indicating that Triad1 is induced during 
maturation of immature CD34+ cells towards 
mature granulocytes (Figure 2B). Further 
expression studies showed detectable Triad1 
expression by real-time PCR in a large set 
of human tissues tested indicating that the 
function of Triad1 is probably not limited to 
hematopoiesis (Figure 2C). 
To determine the subcellular localization of 
Triad1 a C-terminally myc epitope-tagged 
Triad1 (Triad1-myc) expression vector 
was transfected to L88/5 stromal cells. 
Indirect immunofluorescence (IF) using the 
myc epitope recognizing antibody 9E10 
revealed a clear nuclear diffuse staining with 
exclusion of the nucleoli (Figure 3A). In cells 
with highest IF levels, some cytoplasmic 
staining was also observed. To determine the 
endogenous Triad1 expression in primary 
hematopoietic cells an affinity purified Triad1 
antibody was used in indirect IF. Analysis of 
immature CD34+ and T-cells revealed a weak 
nuclear staining (Figure 3B). In contrast, a 
strong nuclear localization was observed in 
both granulocytes and monocytes. While 
the localization in monocytes was nuclear 
diffuse, a ring-shaped nuclear organization 
was observed in granulocytes (Figure 3B). To 
determine at what stage Triad1 was induced 
during myelopoiesis we stained fresh bone 
marrow and leukopheresis samples with 
a Triad1 antibody and analyzed the cells 
by flowcytometry. Co-staining with CD34 
(immature progenitors), CD3 (T-cells), CD14 
(monocytes) or CD15 (granulocytes) showed 
that Triad1 is lowly expressed in immature 
CD34+ and T-cells, and that the expression 
gradually increases upon maturation towards 
committed myelo-monocytic progenitors to 
reach highest levels in mature monocytes and 
granulocytes (Figure 3C and supplementary 
Figure 2). Together, these data indicate that 
Triad1 is induced at the mRNA and protein 
level during differentiation of immature 
blood cells towards both monocytes 
and granulocytes and that it localizes 
predominantly to the nucleus in primary 
human hematopoietic cells. 
Triad1 is an E3 Ub ligase
The RING finger structure provides in an 
interface for interaction with E2 Ubcs and 
all RING finger proteins that bind Ubcs 
exhibit Ub ligase activity20. Since Triad1 
harbors two RING fingers we tested whether 
it binds to Ubcs using yeast-two-hybrid 
assays. For these experiments two Triad1 
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prey-fragments were used, one coding for 
amino acids 1-119, Triad1[1-119], lacking the 
TRIAD structure and one for amino acids 
109-493, Triad1[109-493], including the TRIAD 
structure. No interaction was observed 
between Triad1[1-119] and a panel of Ubcs28 
tested including cdc34, UbcH5, -6, -7, -8, 
-9, -10 and 13 (not shown). In contrast, a 
clear interaction between Triad1[109-493] and 
UbcH7 was observed as indicated by growth 
of yeast cells on medium lacking both 
histidine and adenine (Figure 4A). When 
less stringent yeast-two-hybrid conditions 
were used (histidine selection only) an 
interaction between Triad1[109-493] and UbcH6 
and UbcH13 (a.k.a. Bendless) was also 
found (data not shown). Since endogenous 
UbcH7 is readily detectable in NB4 cells we 
incubated cell lysates from these cells with 
GST-Triad1 to confirm the UbcH7 interaction 
as observed in yeast-two-hybrid assays. 
Bound proteins were stained with an UbcH7 
antibody in Western blot analysis, showing 
that Triad1 efficiently binds endogenous 
UbcH7 from NB4 cells (Figure 4B). Staining 
for UbcH9 in these experiments was negative 
while UbcH9 is also easily detectable in NB4 
cells by Western blotting (not shown). To test 
whether the N-terminal RING finger was 
involved in UbcH7 binding we constructed 
two independent Triad1 RING finger point 
mutants in which one of the predicted zinc 
coordinating amino acids were changed 
into alanine (H158A, C161A). Mutations 
were introduced in the Triad1 prey-construct 
(Triad1[109-493]) and used in yeast-two-hybrid 
assays. While normal Triad1[109-493] interacts 
with UbcH7 in yeast-two-hybrid assays, both 
point mutants did not interact with UbcH7 
indicating that the N-terminal RING finger 
of Triad1 is essential for UbcH7 binding 
(Figure 4A). To further test whether Triad1 
might function as Ub ligase we determined 
whether Triad1 binds ubiquitinated proteins. 
To this end, Triad1-myc and Flag-tagged 
Ub (Flag-Ub) were co-expressed in the 
presence or absence of proteasome inhibitors 
followed by myc immunoprecipitation (IP). 
Triad1 staining of myc-immunoprecipitated 
proteins in Western blot analysis revealed 
that proteasome inhibition resulted in 
stabilization of Triad1. Flag staining of 
proteins bound to Triad1 detected a smear 
of ubiquitinated proteins that appeared more 
intense when transfected cells were treated 
with a proteasome inhibitor, suggesting that 
Triad1 binds ubiquitinated proteins (Figure 
4C). As the observed smear might represent 
exclusively ubiquitinated Triad1 species 
instead of ubiquitinated proteins bound to 
Triad1, we repeated the experiment using 
GFP-Triad1 and Flag-Ub. Subsequent GFP IP 
followed by Triad1 staining in Western blot 
analysis revealed the presence of unmodified 
Triad1 while Flag staining revealed a smear 
of ubiquitinated proteins, including proteins 
with sizes smaller compared to Triad1. As 
the smaller proteins do not represent Triad1 
we concluded that Triad1 binds ubiquitinated 
proteins (Figure 4D). To further test whether 
Triad1 functions as E3 Ub ligase, we 
performed an in vitro ubiquitination assay 
using reticulocyte fraction IIA (enriched in 
E1 and E2 activity and devoid of Ub and 
proteasome activity), with or without Ub and 
His-Triad1. Staining of reaction mixtures 
with a Ub specific antibody in Western blot 
analysis revealed the presence of Triad1-
dependent ubiquitinated proteins (Figure 
4E). Triad1 binds to UbcH7. In concert with 
E3 Ub ligases, UbcH7 supports the formation 
of Ub chains linked through lysine 48 (K48) 
that are recognized by the proteasome. To test 
whether Triad1 can catalyze the formation 
of Ub chains linked through K48, we also 
used recombinant Ub carrying only one 
lysine residue at position 48 (UbK48-only), 
showing that Triad1 catalyzes the formation 
of Ub chains linked through K48. The 
interaction between Triad1 and UbcH7 as 
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well as ubiquitinated proteins and the in vitro 
ubiquitination assay strongly suggest that 
Triad1 functions as E3 Ub ligase that may 
target proteins for proteasomal degradation.
Triad1 is targeted by the Ub -proteasome 
pathway
In addition to their substrates, many Ub 
ligases are ubiquitinated themselves13. 
Ubiquitination of Triad1 was studied by 
co-expressing Triad1 and His-tagged Ub 
(His-Ub) followed by selection of His-
tagged proteins under denaturing conditions. 
Staining with a Triad1 specific antibody 
detected discrete bands with higher 
molecular weight compared to unmodified 
Triad1 indicating that Triad1 is ubiquitinated 
(Figure 5A). Proteasome inhibition resulted 
in an increase in ubiquitinated Triad1 forms, 
indicating that ubiquitinated Triad1 is subject 
to proteasomal degradation. Similar results 
were obtained when Triad1 and Flag-Ub 
were co-expressed followed by Flag IP under 
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Figure 4, Triad1 is an Ub ligase. 
A. Human Triad1 interacts with UbcH in yeast-two-hybrid assays as shown by growth on double 
histidine and adenine selection (left plate). The Triad1 mutants H158A and C161A fail to bind to 
UbcH7 (right plate). Used bait- (left plate) and prey-constructs (right plate) are indicated. EV = empty 
vector control. B. GST-Triad1 efficiently captures UbcH7 from human NB4 cell lysates while GST alone 
does not. C. Co-transfection of Triad1-myc and Flag-Ub followed by myc IP and Flag staining detects a 
smear of ubiquitinated proteins [X-(ub)n] bound to Triad1. The amount of ubiquitinated proteins bound 
to Triad1 is more intense when cells were treated with a proteasome inhibitor (12.5 µM MG132). D. 
Cotransfection of GFP-Triad1 and Flag-Ub followed by GFP IP. Immunoprecipitates were split in two 
parts and run on same gel as indicated and independently stained for Triad1 and Flag respectively 
revealing GFP-Triad1 (arrowhead) and a smear of ubiquitinated proteins ([X-(ub)n] including proteins 
with sizes smaller compared to Triad1. Asterisk represents IgH. E. In vitro Ub ligase assay. Reticulocyte 
fraction IIA, Triad1 (0.03 ug) or 10*Triad1 (0.3 ug) without Ub (-), with wild type Ub (WT) or UbK48-
only (K48) were incubated followed by staining of ubiquitinated proteins. Note the marked increase of 
both wild type and K48-only ubiquitinated species after addition of Triad1. Increased dose of Triad1 
correlates with increase in ubiquitinated proteins. Equal protein transfer between the tested conditions 
is indicated by the Ub band (lower panels).
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non-denaturing conditions (Figure 5B). The 
discrete Triad1 Ub-modified forms observed 
in these IPs combined with the smear of 
ubiquitinated proteins detected upon Triad1 
IP when cotransfected with Ub as shown in 
Figures 4C and D further indicate that, apart 
from being ubiquitinated itself, Triad1 also 
binds ubiquitinated proteins.
The Ub ligase activity of Triad1 regulates 
myelopoiesis
To determine the biological relevance of 
the induction of Triad1 during myeloid 
differentiation, we tested whether Triad1 
expression affected the clonogenic growth 
of primary immature murine bone marrow 
cells in CFU-GM assays. Primary murine 
bone marrow cells were transduced with 
pLZRS-derived viruses containing a GFP-
IRES-Triad1 sequence allowing for separate 
GFP and Triad1 expression. Fractions with 
low, intermediate and high GFP expression 
were sorted. GFP expression correlated with 
Triad1 expression as shown by Western 
blot analysis (Figure 6A and supplementary 
Figure 3A). Compared to empty vector 
controls (GFP alone), Triad1 expression 
resulted in a concentration-dependent 
inhibition of clonogenic growth. While low 
Triad1 expression did not inhibit clonogenic 
growth, intermediate Triad1 expression 
resulted in an inhibition of over 60%, whereas 
highest Triad1 expression resulted in a strong 
inhibition of clonogenic growth of over 80% 
(Figure 6A). In addition, colonies derived 
from high and intermediate Triad1 expressing 
cells were significantly smaller compared 
to empty vector controls (supplementary 
Figure 3B). To determine whether Triad1 
affects myeloid differentiation, colonies 
were recovered from semi-solid medium and 
morphologically analyzed. This revealed 
a modest Triad1-dependent increase in the 
percentage of granulocytes and decrease 
in erythroblasts compared to empty vector 
transduced cells (Figure 6B).
The observed inhibition of clonogenic 
growth suggests a role for Triad1 in the 
development of immature committed murine 
bone marrow cells towards mature myeloid 
cells. In many Ub ligases the RING finger 
is essential for Ubc binding as well as 
Triad1
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Figure 5, Triad1 is ubiquitinated 
and targeted for degradation by 
the proteasome. 
A. Cotransfection of Triad1 and 
His-Ub followed by selection of 
ubiquitinated proteins using His-
select beads under denaturing 
conditions followed by Triad1 
staining detects multiple discrete 
ubiquitinated Triad1 forms 
[Triad1-(ub)n]. Proteasome inhibition (12.5 µM MG132) results in an increase in Triad1 ubiquitination. 
Left lane contains positive control containing lysate from Triad1 (arrowhead) transduced 293T cells. 
Asterisk indicates an a-specific band. B. Cotransfection of Flag-Ub and Triad1 followed by Flag IP and 
staining for Triad1 detects multiple ubiquitinated Triad1 species (Triad1-(ub)n) that were more intense 
when cells were treated with a proteasome inhibitor prior to cell lysis. Note that unmodified Triad1 
(arrow) co-immunoprecipitates with ubiquitinated Triad1.
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Figure 6, The Ub ligase activity of Triad1 
inhibits clonogenic growth of primary 
murine bone marrow cells. 
A. Empty vector (EV) or Triad1 retrovirally 
transduced murine bone marrow cells with 
increasing expression (Triad1 I, II and III, 
respectively) were used in CFU-GM revealing 
a Triad1 concentration dependent inhibition 
of clonogenic growth (n=3). Triad1 staining using lysates from 100,000 transduced bone marrow cells revealed no 
detectable levels in EV transduced cells and increasing expression in cells with increasing GFP positivity (fractions II and 
III, respectively). NC = negative control. B. Morphological analysis of cells grown in CFU-GM shows a modest increase 
in the percentage of granulocytes and decrease in erythroblasts upon Triad1 expression. C. Triad1 RING mutants H158A 
and C161A do not inhibit clonogenic growth showing that the N-terminal RING finger is essential for the clonogenic 
inhibition exerted by wild type Triad1 (n=2). Comparable expression of wild type Triad1 and mutants was shown by 
Western blotting using lysates from 100,000 transduced bone marrow cell (equal loading was checked by Ponceau staining, 
not shown). D. Treatment of murine bone marrow cells grown in liquid medium with MG132 indicates maximal tolerated 
dose with limited toxicity of 10-8 M. 5,000 cells were seeded in 96 wells and cultured for 3 days. Relative cell numbers were 
determined by flowcytometer using fluorescent beads (Beckman Coulter). E. Treatment of primary murine bone marrow 
cells with 10-8 M MG132 for two days resulted in an increase in ubiquitinated proteins (x-(ub)n). F. Proteasome activity 
measurements (indicated as fluorescence units (FU)) on lysates taken from primary murine bone marrow cells that were 
treated with 10-8 M MG132 for one or two days showed clear proteasomal inhibition. G. Proteasome inhibition (MG132) 
relieves the suppressive effect of Triad1 in CFU-GM (n=3). MG132 was added to cells prior to cell seeding. For all tested 
conditions observed numbers of colonies were indicated relative to number of empty vector (EV) obtained colonies (set 
at 100). H. Treatment of Triad1 transduced cells with independent proteasome inhibitors counteracted the suppressive 
effects of Triad1 on colony formation. The number of obtained colonies of mock treated Triad1 transduced cells was set 
at 100 and relative colony numbers obtained for cells treated with indicated proteasome inhibitors are indicated (10-8 M 
MG132 (n=3), 10-9 M PS341 (n=2), 5*10-10 M epoxomycin = epox (n=1) and 10-8 M lactacystin = lacta (n=1)).
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Ub ligase activity20. Mutations in RING 
fingers abrogating the interaction with Ubcs 
result in impaired ubiquitination. To test 
whether the Ub ligase activity of Triad1 
was involved in the clonogenic inhibition of 
myeloid progenitor cells, we introduced the 
H158A and C161A RING finger mutations 
that abrogate UbcH7 binding in full-length 
Triad1 coding sequences in the retroviral 
vectors and used these constructs in CFU-
GM colony assays. Strikingly, in contrast to 
normal Triad1, expression of the Triad1 point 
mutants did not affect the clonogenic growth 
of primary immature cells (Figure 6C). 
Because the mutant proteins were expressed 
at levels comparable to wild type Triad1 as 
shown by Western blot analysis this indicates 
that the N-terminal RING finger of Triad1 
plays an important role in the regulation 
of proliferation and or differentiation of 
myeloid progenitor cells. In E3 Ub ligases, 
the RING finger structure has been shown 
to be essential for Ub ligase activity20. As 
UbcH7 can catalyze the formation of Ub 
chains resulting in protein degradation and 
the Triad1 RING finger mutations abrogate 
the inhibitory effect on clonogenic growth, 
our data suggest that the ubiquitination and 
subsequent proteasomal degradation of 
Triad1 target proteins results in clonogenic 
inhibition. To test this, we determined whether 
the inhibition of clonogenic growth exerted 
by Triad1 could be relieved by proteasome 
inhibition. For these experiments 10-8 M 
of the proteasome inhibitor MG132 was 
used because at this concentration limited 
toxicity on empty vector transduced cells 
was observed in liquid assays (Figure 6D). 
At this concentration, the bone marrow cells 
showed an increase in ubiquitinated species 
and decreased proteasomal activity (Figures 
6E and F, respectively). Interestingly, 
proteasome inhibition partially reversed 
the Triad1-induced suppression of colony 
formation (Figure 6G). When corrected for 
the suppressive effects of MG132 on empty 
vector transduced cells, an over two-fold 
increase in Triad1 positive colonies was 
observed when the proteasome was inhibited 
(Figure 6H). Moreover, the colonies derived 
from MG132 treated Triad1 transduced cells 
were significantly larger as compared to non-
treated cells (supplementary Figure 3B). In 
addition to the proteasome, MG132 inhibits 
other proteases. To rule out the possibility 
that the increase in colony numbers of Triad1 
transduced cells after treatment with MG132 
depended on other mechanisms rather 
then inhibition of the 26S proteasome, we 
repeated the experiments using other more 
specific proteasome inhibitors including 
PS-341, epoxomycin, and lactacystin. 
This yielded similar results as observed 
for MG132 (Figure 6H). Thus the growth 
inhibitory effect exerted by Triad1 relies 
on the N-terminal RING finger and can 
be counteracted by proteasome inhibition 
indicating that degradation of Triad1 targets 
are implicated in myelopoiesis.
To further investigate how Triad1 affected 
CFU-GM colony formation, we cultured 
Triad1 retrovirally transduced bone marrow 
cells in liquid medium and measured 
proliferation, cell cycle progression (DNA 
histograms), differentiation and apoptosis. 
Compared to empty vector control, Triad1 
expression resulted in a dramatic inhibition 
of proliferation (Figure 7A). This was 
accompanied by a marked increase in the 
percentage of cells in G0/G1 phase, and an 
increase in annexin V positivity (Figures 7B 
and C). In these experiments no significant 
changes in myeloid differentiation as 
indicated by Mac1 positivity was observed 
(Figure 7D). Thus, the inhibition of 
clonogenic growth by Triad1 is probably 
caused by a cell cycle arrest associated 
with increased apoptosis. Based on these 
findings we conclude that the ubiquitination 
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and degradation of Triad1 target proteins 
contributes to the development of early 
committed myeloid progenitors towards 
mature monocytes and granulocytes.
 
Discussion
The modification of proteins with ubiquitin 
plays an important role in a variety of basic 
cellular processes, including cell division, 
differentiation and apoptosis. Protein 
poly-ubiquitination linked through lysine 
48 of Ub results in degradation of tagged 
proteins by the 26S proteasome. Proteins are 
ubiquitinated by E2-E3 Ub ligase complexes. 
The E3 Ub ligases play a key-role in this 
process as these enzymes determine which 
cellular proteins are ubiquitinated. We report 
here that the E3 Ub ligase Triad1 is induced 
during both granulocytic and monocytic 
differentiation (Figures 1-3). Triad1 contains 
two RING finger structures. By providing 
an interface for interaction with E2 Ub 
conjugating enzymes, the RING finger 
constitutes an essential domain in many E3 
Ub ligases. In line with this, we found that 
Triad1 physically interacts with the E2 Ub 
conjugating enzyme UbcH7 through its N-
terminal RING finger and to ubiquitinated 
proteins (Figure 4A-D). Moreover, in vitro 
ubiquitination experiments showed that 
Triad1 supports ubiquitination of both wild 
type and UbK48-only (Figure 4E). Ub chains 
linked through lysine 48 are efficiently 
recognized by the proteasome resulting in 
substrate degradation. This indicates that 
Triad1 may mark proteins for proteasomal 
degradation. 
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Supplementary Figure 3, Retroviral tranduction 
of murine bone marrow cells. 
A. Representative example of GFP expression 
in pLZRS-Triad1 transduced primary murine 
bone marrow cells. Sorted fractions (Triad1 I, 
II and III) with increasing GFP positivity are 
indicated. B. Representative result of CFU-GM 
colony size derived from Triad1 and empty vector 
(EV) transduced cells. Treatment of Triad1 
transduced cells with 10-8 M MG132 prior to cell 
seeding results in significantly larger colonies. C. 
Representative DNA histograms of empty vector 
(EV) and Triad1 transduced cells after 3 days of 
culture are indicated (see Figure b).  
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Triad1 exhibits a predominantly nuclear 
staining in all cell types tested (Figure 3). 
In stromal cells (L88/5) and in primary 
monocytes the nuclear staining is diffuse, 
while a ring-shaped localization is observed 
within the nuclear lobes of primary 
granulocytes (Figure 3). Although these 
data may suggest that Triad1 substrates 
are primarily nuclear proteins a protein-
interaction map of the Drosophila proteome34 
revealed that Drosophila Triad1 (CG5709) 
binds in addition to Ubc7 (CG12799) to both 
cytoplasmic and nuclear proteins. These 
include cytoplasmic orthologs of signaling 
molecule Traf3 involved in TNF-receptor 
mediated signal transduction and E3 ub 
ligase Hakai involved in ubiquitination 
of E-cadherin (respectively, CG4394 
and CG10263), but also nuclear proteins 
including the ortholog of the transcription 
factor HOX11L2 (CG7937) implicated in 
acute lymphoblastic leukemia development 
and the ortholog of the helix-loop-helix 
transcription factors NHLH1 and NHLH2 
(CG3052) implicated in neurogenesis35-38.
Forced Triad1 expression in primary murine 
bone marrow cells inhibited colony formation 
in CFU-GM assays. Two N-terminal RING 
finger point mutants that are unable to bind 
the E2 UbcH7 did not inhibit clonogenic 
growth indicating that the N-terminal RING 
finger of Triad1 is involved in the inhibition 
of clonogenic growth (Figures 6A and C). As 
the RING finger is involved in the catalytic 
activity (i.e. Ub conjugation)13,20 in virtually 
all E3 RING Ub ligases, this suggested that 
the ubiquitination of Triad1 target proteins 
caused the inhibition of clonogenic growth. 
In conjunction with E3 Ub ligases, UbcH7 
is known to catalyze the formation of Ub 
chains that result in proteasomal degradation 
of tagged proteins. To further study the 
clonogenic inhibition of Triad1 in CFU-GM 
assays we repeated the experiments in the 
presence of proteasome inhibitors and found 
that this partially reversed the effects of 
Triad1 (Figures 6G and H). We conclude that 
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Figure 7, Triad1 inhibits 
proliferation of committed myeloid 
progenitors in liquid cultures. 
A. Proliferation of transduced bone 
marrow cells in liquid medium 
indicating dramatic growth inhibition 
of Triad1 transduced cells compared 
to empty vector transduced cells. 
Cell number at start of culture was 
set at 100 and relative numbers 
during culture time (days) were 
plotted. Open diamonds and closed 
boxes represent respectively empty 
vector and Triad1 transduced cells. 
B. Reduced growth rate of Triad1 
transduced cells is accompanied by 
an increase in the percentage of cells 
in G0/G1 phase (DNA histograms 
were determined by flowcytometer 
using propidium iodide staining, see supplementary Figure 3c). C. Triad1 transduced cells grown in 
liquid medium show enhanced annexin V positivity compared to empty vector transduced cells. D. 
Triad1 expression does not result in alterations in the percentage of Mac1 positive cells compared to 
empty vector transduced cells. 
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proteasomal degradation of Triad1 targets 
plays an important role in myelopoiesis. 
In liquid cultures of transduced bone 
marrow cells, Triad1 expression resulted 
in a strong inhibition of proliferation while 
differentiation remained unaltered. The 
inhibition of proliferation was associated 
with a G0/G1 accumulation and increased 
apoptosis (Figure 7).
Triad1 is a member of the class of TRIAD 
(or RING-IBR-RING) proteins31,32. Since the 
description of this class of proteins several 
TRIAD proteins have been reported to 
function as E3 Ub ligase including Triad3, 
Parkin, Parc and p53RFP39-42. These Ub 
ligases are involved in various biological 
processes including immunity, neuronal 
development, and p53 functioning. Triad3 
targets Toll-like receptors 4 and 9 for 
ubiquitination40. By sensing antigens, Toll-
like receptors play a role in both innate 
and adapted immunity. Ligand binding of 
these receptors result in NF-κB activation 
and Triad3 regulates the ubiquitination and 
concomitant turnover of these receptors 
thereby controlling the intensity and duration 
of Toll-like receptor function40. Another 
well-studied TRIAD protein is Parkin which 
is, like Triad1, highly expressed in fetal brain 
and involved in neuronal development43. 
Congenital mutations in Parkin cause 
juvenile parkinsonism and acquired loss-
of-heterozygosity of Parkin has been 
described in various human malignancies44-
48. The TRIAD proteins Parc and p53RFP are 
involved in p53 function41,42. Parc functions 
as E3 Ub ligase that binds to p53. Although 
Parc does not ubiquitinate p53, it sequesters 
this protein in the cytoplasm. The other 
TRIAD protein, p53RFP, is a p53 target gene. 
p53RFP binds to the cyclin-dependent kinase 
inhibitor p21waf1. As p53RFP overexpression 
results in reduced p21waf1 levels, p53RFP 
might function as Ub ligase for p21waf141. 
The majority of the reported TRIAD proteins 
have been shown to interact with UbcH7, 
which is in line with the observation that 
Triad1 also interacts with UbcH7. By using 
less stringent conditions in yeast-two-hybrid 
assays, we also observed an interaction 
between Triad1 and UbcH13 (not shown). 
Interestingly, UbcH13 catalyzes the formation 
of Ub chains (linked through lysine 63) that 
are not recognized by the proteasome but 
that alter the activity of proteins49-51. Two 
recent studies have shown that the TRIAD 
protein Parkin also binds to UbcH13 in 
addition to UbcH7 and that it can catalyze the 
formation of both lysine 48- and 63-linked 
Ub chains30,52. As Triad1 may bind UbcH13 
it will be important to test whether it also 
exhibits activity that supports ubiquitination 
linked through lysine 63 of Ub. Nevertheless, 
the inhibition of clonogenic growth exerted 
by Triad1 described here depends at least for 
a part on targeting proteins for proteasomal 
degradation because proteasome inhibition 
partially reversed the effects of Triad1. To 
further understand how the Ub-proteasome 
pathway contributes to myelopoiesis, it will 
be of great interest to identify which cellular 
proteins are targeted for ubiquitination by 
Triad1.
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Triad1 functions as a dual ubiquitin ligase regulating 
myelopoiesis through UbcH7 and Ubc13 interactions
Abstract
TRIAD proteins constitute an unique class of ubiquitin E3 ligases that contain a 
conserved tripartite structure consisting of two RING fingers separated by a distinct 
cysteine/histidine rich motif (DRIL/IBR). Although it is known that RING finger domains 
of E3 ubiquitin ligases are docking sites for E2 conjugating enzymes, it is currently 
unclear why TRIAD proteins harbor two RING fingers. We studied the function of 
these domains in the ubiquitin E3 ligase Triad1, a TRIAD family member implicated in 
hematopoiesis. Deletion mutants showed that the N-terminal RING finger is essential 
for the interaction with E2 conjugating enzyme UbcH7, while the C-terminal RING 
finger is necessary for the interaction with Ubc13. UbcH7 mediates poly-ubiquitin chain 
formation linked via lysine-48 (K48), which marks proteins for proteasomal degradation. 
Ubc13 mediates poly-ubiquitination via lysine 63 (K63), which alters protein function. 
In line with these interactions, in vitro ubiquitination experiments showed that Triad1 
has dual ubiquitin ligase activity; it can catalyze both lysine-48 as well as lysine-63 
linked poly-ubiquitination. Triad1 is induced during myeloid differentiation of blood 
cells and its expression in U937 cells resulted in a strong reduction in clonogenic capacity. 
Expression of deletion constructs showed that both RING fingers were essential for this 
phenotype. This indicates that the interaction with both UbcH7 and Ubc13 are essential 
for the function of Triad1. The strong conservation of the TRIAD structure indicates 
that the two RING fingers are functionally linked and suggests that TRIAD proteins 
operate through integrated lysine-48 and lysine-63 ubiquitination.
Introduction
The covalent linkage of ubiquitin to substrate 
proteins plays a role in many aspects 
of cell biology, including cell division, 
communication/signaling, movement and 
apoptosis 1. Different types of ubiquitination 
result in different changes in function of the 
ubiquitinated proteins. For example, proteins 
marked with poly-ubiquitin chains linked 
via lysine 48 of ubiquitin are recognized by 
the 26S proteasome providing the cell with 
a specific and efficient way to eliminate 
these proteins. The addition of ubiquitin 
chains linked via lysine 63 of the preceding 
ubiquitin results in altered function, but does 
not trigger proteasomal degradation  of the 
modified protein 2.
The covalent linkage of an ubiquitin 
peptide to a specific substrate protein is 
mediated by a multi-enzyme pathway. 
First, the E1 activating enzyme activates 
ubiquitin, which is subsequently transferred 
to an E2 ubiquitin-conjugating enzyme. In 
concert with the E2 conjugating enzymes, 
ubiquitin E3 ligases catalyze the final step 
by facilitating the covalent attachment of 
ubiquitin to a substrate protein. The E3 
ligases are responsible for the specificity of 
the ubiquitination process as they recognize 
the substrates. Since numerous proteins may 
be ubiquitinated, many different ubiquitin 
E3 ligases exist. E3 ligases are characterized 
by specific motifs, including HECT, U-
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box or RING domains 3. The RING finger 
containing E3 ligases represent the largest 
family. This family can be subdivided in 
E3 ligases which function as multi-subunit 
complexes like the APC/C, SCF or the 
CBC subfamilies, or as single RING-finger 
protein 1. This last group includes several 
well-characterized E3 ligases like Mdm2 4, 
Cbl 5, Siah-1 and IAPs 6. The RING finger 
domain in RING finger containing E3 ligases 
is responsible for the interaction with the E2 
conjugating enzyme 1. 
The TRIAD protein family was described as 
a novel subclass of RING finger E3 ligases. 
This group of E3 ligases is characterized by 
a TRIAD domain encompassing a conserved 
DRIL (a.k.a. IBR) domain flanked by two 
RING fingers 7,8,9. Genome analysis showed 
that TRIAD proteins are an ancient family. 
Over 140 proteins are found in eukaryotic 
species ranging from yeast to human 7,10. One 
of the best-characterized TRIAD proteins is 
Parkin. Mutations in Parkin cause the early 
onset of autosomal juvenile Parkinsonism 
(AR-JP) 11. Like Parkin also other TRIAD 
family members were shown to contain 
ubiquitin E3 ligase activity. For example 
Triad3, which is the E3 ligase of Toll 
like receptors 4 and 9 12. Another TRIAD 
member, Hoil-1, ubiquitinates specifically 
the oxidized form of Iron regulatory protein 
2 involved in iron metabolism in mammalian 
cells 13. 
Recent studies showed that the C-terminal 
RING finger (RING2) of TRIAD proteins 
has a novel and completely different 
topology compared to the classical RING 
finger. RING2 is stabilized by only one 
zinc atom and uses a different hydrophobic 
nature, while the classical RING fingers (like 
RING1) harbors two zinc atoms. Importantly, 
RING2 exhibits E3 ligase activity in vitro 7. 
Currently, it is unclear why TRIAD proteins 
contain 2 RING finger structures while the 
vast majority of RING finger containing E3 
ligases only contain one RING finger.
 
Triad1 was identified as an ubiquitin E3 
ligase with an important role during blood 
cell development. Triad1 expression is 
induced during granulocytic and monocytic 
differentiation. Furthermore, expression of 
Triad1 in immature murine bone marrow cells 
resulted in the inhibition of the granulocytic/
monocytic clonogenic potential of these 
cells 14. To gain insight in the functional 
role of the different motifs present in the 
TRIAD domain, we tested various deletion 
constructs of Triad1 in different biochemical 
and cellular assays. The data presented in this 
paper provide new insights into the function 
of the different domains in TRIAD proteins.
Materials and methods
Cell culture
U937, HEK293, COS-1 and NIH3T3 
cells were cultured as described 14,15. For 
monocytic differentiation U937 cells were 
differentiated with 1 µg/ml PMA (Phorbol 
12-myristate 13-acetate)(Sigma) or ATRA 
(all-trans retinoic acid) 16. U937 cells were 
transduced as described 15 with retroviruses 
containing full length Triad1 and the different 
mutants in the pLZRS vector 14. Transduced 
U937 cells were isolated by magnetic cell 
sorting (MACS) on the basis of ∆NGFR 
positivity 15. Flow cytometric analysis of 
∆NGFR expression of the MACS-sorted 
cells showed a purity of more than 95% in 
all experiments.
Western blotting and immunofluorescence 
microscopy 
Whole cell lysates were made in RIPA-
buffer as described 15, and separated by 
SDS-PAGE. Blots were probed with rabbit 
antibodies to Triad1 14, GFP (Roche), Poly-
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Ubiquitin (FK1, Affinity), Ubiquitin (6C1) or 
Actin (Sigma, I-19). Cytospins of U937 cells 
were fixed, permeabilized and stained with 
anti-Triad1 antibody followed by Donkey 
anti-Rabbit PE (Jackson), washed 3 times 
with PBS and embedded in Vectashield with 
DAPI (Vector Lab.) 14. NIH3T3 cells were 
grown on coverslips and transfected using 
lipofectamine 2000. Cells were stained 
using α-FLAG (M2, Sigma) α-UbcH7 
(Transduction Lab.) followed by donkey-α-
mouse TexasRed (Jackson) staining. Pictures 
were obtained using a Leica DMRBE 
microscope and Leica FW4000 software.
Generation of Triad1 expression vectors 
A full length Triad1 construct as described 
14 was used to generate Triad1 mutants 
∆RING1, ∆DRIL, ∆RING2 and ∆TRIAD 
(figure 4A) using sexual PCR as described 
in 17 using Pfu and Taq polymerase. The 
∆CC2 and ∆CC1+2 mutants were made by 
introducing a stop codon using PCR primers. 
Sequences of used primers can be found 
in Table 1. Triad1 full length and deletion 
mutants were cloned into the pLZRS-IRES-
∆NGFR retroviral expression vector 15, 
pGAD-C1 for yeast-two-hybrid analysis and 
in pECFP-C1 (Clontech, Palo Alto, CA) for 
localization studies. Full length Triad was 
cloned in frame in pFAST-BAC-HTA to 
generate baculovirus. 
Colony forming assays and differentiation 
and cell cycle characteristics
Clonogenic growth of tranduced and 
MACS-sorted U937 cells was measured 
by plating 1000 cells/ml in semisolid 
(0.75% agar) culture medium. Colonies 
were counted after 6 days. Differentiation 
of U937 cells was assessed using CD11c 
(Immunotech, Marseille, France). Apoptosis 
and DNA histograms were determined by 
flowcytometry using AnnexinV (Molecular 
Probes, Eugene, OR) and propidium iodide 
staining, respectively 14. The percentage of 
∆NGFR positive cells was monitored by 
FACS analyis using the α-NGFR antibody 
and Goat-α-mouse PE.
 
In vitro ubiquitination assay
For in vitro ubiquitination assays His-tagged 
Triad1 was produced using the baculovirus 
system (Baculovirus Bac-to-Bac system, 
Invitrogen) in Hi-5 cells 14. 3 days after 
infection cells were harvested and lysed in 
RIPA buffer with Complete protease inhibitor 
cocktail. After centrifugation His-Triad1 was 
isolated from Hi5 cells using His-select spin 
columns followed by elution with 250 mM 
imidazole. Imidazole was removed from His-
Triad1 protein eluates using a Microcon YM-
10 filter (Amicon) and protein concentrations 
were determined with the Bradford assay. 
Ubiquitination assays were performed as 
∆Triad1 F ACA TCC CAT CCC CCT CAC CAC CTA GGA GAT TGG AAG ACT CAT GGC AGT
∆Triad1 R ATG AGT CTT CCA ATC TCC TAG GTG AGG GGG ATG GGA TGT GGG AAC
∆RING1 F ACA TCC CAT CCC CCT CAC CAC CCA CTC CGT ACA CCA GAG GAC TTT GTG
∆RING1 R GTC CTC TGG TGT ACG GAG TGG GTG GTG AGG GGG ATG GGA TGT GGG AAC
∆DRIL F AGT CAT TAC CAG CTC CAG CTG GCC ACA ATC CGG AAA TGG CTC ACG AAG
∆DRIL R GAG CCA TTT CCG GAT TGT GGC CAG CTG GAG CTG GTA ATG ACT CTC CAC
∆RING2 F ATT AGT GCT CAC ACT AAA GAC CTA GGA GAT TGG AAG ACT CAT GGC AGT
∆RING2 R ATG AGT CTT CCA ATC TCC TAG GTC TTT AGT GTG AGC ACT AAT GTA GTT
∆CC2 R TCG CGA ATT C TTA TCC GGA CTC CAT GTA ATA TGC ATA 
∆CC1+2 R TCG CGA ATT C TTA GAT GTC AGG ATT CTC CTT GTA ACG
Table 1, 
Primers used for making the deletion mutants of Triad1 as depicted in figure 4A.
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described in 18,14 using 1.6 µg reticulocyte 
fraction IIA (Boston Biochem), recombinant 
Wild type Ub, K0-Ub, K48-Ub or K63-Ub 
(Boston Biochem) with freshly prepared 
His-Triad1 for 60 min at 37°C followed by 
staining of ubiquitinated proteins in Western 
blot analysis using a poly-ubiquitin specific 
antibody (FK1, Affinity).
Yeast-Two-Hybrid assays
For yeast-two-hybrid analyses UbcH7 
and Ubc13 bait 19 and Triad1 prey deletion 
constructs were transfected to the yeast strain 
AH109 (Clontech). This strain contains 
the selectable marker histidine and a lacZ 
reporter. A positive interaction in yeast was 
defined by growth of blue colonies after 
plating cells on leucine, tryptophane and 
histidine deficient SD medium containing 
X-α-gal.
Results
Triad1 is induced during monocytic 
differentiation of U937 cells 
To study the contribution of the domains of the 
TRIAD structure of Triad1 in hematopoiesis, 
we used the U937 cell line. Triad is induced 
during myeloid differentiation of monocytes 
and granulocytes and inhibits the clonogenic 
growth of primary murine bone marrow 
cells 14. We tested whether Triad1 was also 
induced during PMA induced monocytic 
differentiation of the myelo-monocytic cell 
line U937. U937 differentiation was confirmed 
by FACS analysis of CD11c expression. 
Triad1 became detectable after 24 hours 
of PMA induced monocytic differentiation 
and protein levels increased up to 72 hours 
of differentiation (Figure 1A). Also ATRA 
induced monocytic differentiation of U937 
cells resulted in an increase of Triad1 
protein levels (data not shown) indicating 
that the effect is differentiation specific. The 
0 6 7224 hours PMA
Į-Triad1
Į-actin
U937
Figure 1, Triad1 is induced during monocytic 
differentiation of U937 cells
A, Cells were stimulated with PMA for the indicated 
time points. Whole cell lysates were stained for 
Triad1. Triad1 protein levels were induced after 24 
hours upon PMA induced differentiation of U93 
cells and are further upregulated after 2 hours of 
differentiation. The same blot was reprobed with 
actin antibody to demonstrate equal loading. B. 
Cytospins of unstimulated and PMA treated U93 
cells were stained with Triad1 antibody showing 
a clear induction of the nuclear Triad1 protein 
levels. Secondary antibody alone resulted in no 
signal (data not shown). The nucleus was stained 
with DAPI. 
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increase in protein expression during PMA 
induced differentiation was confirmed with 
immunofluorescence microscopy. After 
24 and 72 hours of differentiation, Triad1 
protein levels were increased during U937 
differentiation and were found to localize 
predominantly in the nucleus (figure 1B). 
Triad1 inhibits the clonogenic growth of 
U937 cells
To confirm the biological relevance of the 
induction of Triad1 during differentiation 
we retrovirally expressed Triad1 in U937 
cells. Triad1 coding sequences were cloned 
in front of an IRES-∆NGFR cassette, which 
allowed us to MACS select transduced cells 
using an α-NGFR antibody. Two independent 
batches of Triad1 expressing retrovirus were 
used (Triad1 A and B), while empty vector 
(EV) and GFP expressing viruses were used 
as control. U937 cells were retrovirally 
transduced and MACS sorted after 24 hours 
resulting in more than  95% ∆NGFR positive 
cells. Stable expression of Triad1 in these 
cells after 2 weeks of culture was confirmed 
Triad1 B
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Figure 2, Triad1 inhibits clonogenic growth of U937 cells
A, Whole cell lysates of EV (Empty Vector), GFP, Triad1A and B transduced and MACS sorted U93 
cells were stained for Triad1 to check for correct expression. Cells were harvested 14 days after 
transduction. Equal loading was confirmed by restaining the blot with actin antibody. B, Whole cell 
lysates of PMA treated untransduced U93 cells and Triad1 transduced and MACS sorted U93 
cells (24 hours after transduction) were immunoblotted. Triad1 protein levels of transduced cells are 
comparable with the endogenous protein levels in 2 hours PMA treated U93 cells. Actin staining was 
used to check for equal loading. C, Colony forming assays were performed on EV, GFP, Triad1A and B 
transduced and MACS sorted U93 cells. 1000 cells were seeded in semi-solid medium. Colonies were 
counted  days after seeding. Triad1 transduction resulted in a 50% reduction of U93 colonies. D, 
Pictures of the formed colonies after  days. Clearly visible is that the colonies are smaller when cells 
were transduced with Triad1, compared to EV or GFP transduced cells. 
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by Western blotting (Figure 2A). Triad1 
expression levels in transduced cells were 
comparable to endogenous protein levels 
observed after 24 to 72 hours of PMA induced 
differentiation, indicating that the experiments 
were performed at physiologically relevant 
protein levels (Figure 2B). The effect of 
Triad1 on the clonogenic growth potential of 
U937 cells was studied by seeding U937 cells 
in semi-solid medium directly after MACS 
sorting. The expression of Triad1 in U937 
cells resulted in a 50% decrease in colony 
numbers compared to the empty vector and 
GFP transduced control cells. Moreover, the 
colonies derived from the Triad1 transduced 
cells were significantly smaller compared 
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Figure 3, Triad1 inhibits proliferation of U937 
cells
A, Colony forming assays were performed on EV, 
GFP, Triad1A and B transduced and MACS sorted 
U93 cells with the indicated concentrations 
of PMA. Colonies were counted  days after 
seeding. No clear difference was observed in 
sensitivity to PMA of the transduced U93 cells. 
B, EV, GFP, Triad1A and B transduced and 
MACS sorted cells were grown in a mixed culture 
with 50% untransduced U93 cells. The amount 
of ∆NGFR positive cells was analyzed by FACS at the indicated time points. The amount of Triad1A 
and B transduced cells were reduced to 11% and 14% respectively of the total amount of cells in culture 
after 20 days. The percentage of GFP and EV transduced cells remained stable, indicating that Triad1 
inhibits proliferation of U93 cells. C, DNA histograms of U93 transduced and MACS sorted cells 
showed a 10% increase of Triad1 transduced cells in G1/G0 phase of the cell cycle compared to GFP 
or EV transduced cells. 
to control transduced cells (figure 2D). This 
indicates that Triad1 inhibits the growth rate 
of the transduced cells. 
Triad1 inhibits proliferation of U937 
cells, without affecting differentiation and 
apoptosis
In clonogenic assays, Triad1 transduced cells 
were equally sensitive to PMA as control 
transduced cells, indicating that Triad1 
expression does not influence the sensitivity 
of U937 cells to differentiation stimuli like 
PMA (figure 3A). To investigate how Triad1 
affects the clonogenic growth of U937 
cells, we tested the effect of Triad1 on the 
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proliferation of U937 cells in competitive 
growth experiments. Triad1 and control 
transduced U937 cells were tested in liquid 
cultures consisting of 50% transduced and 
50% untransduced cells and analyzed for 
the percentage of transduced cells over a 
period of 20 days. While the percentage 
of EV and GFP transduced cells remained 
stable, the percentage of Triad1 transduced 
cells decreased to less than 15%, indicating 
that these cells have a growth disadvantage 
compared to non-transduced cells (figure 
3B). Differentiation, cell cycle status and 
apoptosis of transduced cells was measured 
in liquid medium. DNA histograms of the 
Triad1 transduced cells on day 3 showed 
a 10% accumulation of cells in G1/G0 
phase compared to GFP and empty vector 
transduced cells (figure 3C). No effects 
of Triad1 on differentiation (CD11c) or 
apoptosis (Annexin V) were found (Table 2). 
We conclude that Triad1 expression results 
in a accumulation of cells in G1/G0 but has 
no effect on differentiation, which is in line 
with the observed inhibitory effect of Triad1 
on the growth rate of U937 cells. 
Table 2,
Annexin-V and CD11c staining of transduced and 
sorted U93 cells showed no clear differences 
in the amount of apoptotic cells when Triad1 
transduced cells were compared to EV of GFP 
transduced control cells. 
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Figure 4, RING1 and RING2 of 
Triad1 are essential for clonogenic 
inhibition of U937 cells
A, Schematic representation of the 
generated Triad1 deletion constructs. 
The Triad1 deletion constructs were 
cloned into the pGAD and pLZRS 
vectors and sequence verified. B, 
U93 cells were transduced with full 
length Triad1 and indicated deletion 
constructs. The MACS sorted cells 
were seeded in semi-solid medium 
and the number of colonies were 
analyzed after  days. Clearly visible 
is that deletion of the RING1 or 
RING2 domains abolishes the Triad1 
induced inhibition of clonogenic 
growth. Deletion of the coiled coils 
or the DRIL domain had no effect on 
the clonogenic inhibition of Triad1. 
B
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Culture Days 2 3 4 5
% annexin V positive cells 
EV/GFP 1.4 0.9 1.4 3.9
Triad1 2.9 1.0 1.4 4.8
% CD11c positive cells 
EV/GFP 2.4 3.3 4.0 2.6
Triad1 4.3 4.7 4.5 3.0
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Both RING fingers of Triad1 are essential 
for clonogenic inhibition 
To study which domains of Triad1 are 
essential for the inhibition of clonogenic 
growth, several deletion constructs were 
generated (figure 4A). U937 cells were 
transduced with viruses expressing these 
deletion mutants, MACS sorted and used in 
a clonogenic assay in semi-solid medium. 
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Figure 5, RING1 of Triad1 is essential for interaction with UbcH7 and RING2 for Ubc13
A, Ubch7 interactions with EV, ∆acidic Triad1 and indicated Triad1 deletion constructs were studied in 
yeast-two-hybrid assays. AH109 yeast cells were transformed and assayed for interaction by growing 
on histidine selection and X-α-gal positivity. The complete TRIAD domain and RING1 were essential 
for the interaction with UbcH. The Empty vector pGAD showed no interaction with the Triad deletion 
constructs (data not shown). B, Ubc13 interaction with EV, ∆acidic Triad1 and indicated Triad1 
deletion constructs. Both the TRIAD domain and RING2 are essential for interaction with Ubc13. C, 
Immunolocalization of with GFP-Triad1 and UbcH or FLAG-Ubch13 in co-transfected NIH3T3 cells. 
Triad1 is present in the same cellular compartments as UbcH and FLAG-Ubc13. DAPI staining was 
used to stain the Nucleus.
As shown in figure 4B, wild type Triad1 
transduced cells showed a more than 50% 
reduction of colonies compared to GFP and 
empty vector transduced cells. The deletion 
of the coiled coils had no effect on the Triad1-
induced inhibition of  clonogenic growth. 
Remarkably, Triad1 lacking the conserved 
DRIL domain inhibited the clonogenic 
growth equally well as the wild type Triad1. 
However, the deletion of either RING1 or 
Triad1-GFP Triad1-GFP
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RING2 completely abolished the observed 
clonogenic inhibition of Triad1. Together, 
these data define a crucial role for both RING 
fingers of Triad1 in clonogenic inhibition.
RING1 is essential for UbcH7 interaction, 
RING2 for Ubc13
The interaction between E2 conjugating 
enzymes and E3 ligases is essential for the 
ubiquitination of substrate proteins. The RING 
finger domain of E3 ligases is involved in 
the interaction with E2 conjugating enzymes 
20. Triad1 specifically interacts with the E2 
conjugating enzymes UbcH7 and Ubc13 14. 
As both RING fingers of Triad1 are essential 
for clonogenic growth of U937 cells (figure 
4B); we tested their contribution to UbcH7 
and Ubc13 interaction. Deletion constructs 
of Triad1 were cloned in frame in the pGAD 
vector and co-transformed with UbcH7 or 
Ubc13 to analyze the interactions in a yeast-
2-hybrid assay. Both UbcH7 and Ubc13 
interacted with a Triad1 mutant lacking the 
N-terminal acidic domain (∆acidic) (figure 
5A and B). Ubc13 transformed yeast grew 
slower suggesting that Triad1 interacts with 
lower affinity to Ubc13 compared to UbcH7. 
The deletion of the complete TRIAD domain 
abolished the interaction with both UbcH7 
and Ubc13, while both the coiled coil and 
the acid domains were not necessary for E2 
interaction. Interestingly, for the interaction 
with UbcH7, RING1 was essential, while 
the deletion of RING2 did not disturb the 
UbcH7 interaction. Conversely, yeast-two-
hybrid analysis showed that the other RING 
finger (RING2) was essential for Ubc13 
interaction. These data suggest that RING1 
binds UbcH7 and RING2 binds Ubc13.
To see whether Triad1, Ubc13 and UbcH7 
would localize in the same subcellular 
compartment, we co-transfected GFP-
Triad1 together with Flag-Ubc13 21 or 
UbcH7 in NIH3T3 cells. Triad1 localized 
predominantly in the nucleus with exclusion 
from nucleoli, and to a weaker extent to the 
cytoplasm (figure 5C). Immuno-staining 
for UbcH7 and Ubc13 revealed a similar 
localization as Triad1. Ubc13 and UbcH7 
showed a strong nuclear staining with 
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Figure 6, The C-terminal coiled coil is essential for the nuclear localization of Triad1 
A, CFP-tagged Triad1 and Triad1 deletion mutants were transfected to 3T3 cells. All deletion construct 
localized mainly in the nucleus with exclusion of the nucleoli. However, a weak cytoplasmic staining 
was visible. The putative NLS in the CC2 domain is important for the nuclear localization of Triad1, 
since deletion of this domain results in cytoplasmic localization of Triad1, although some Triad1 protein 
was also detectable in the nucleus. B, Lysates of transfected NIH3T3 cells were resolved with Western 
blot. Staining with α-GFP and α-Triad1 antibodies showed that the CFP-Triad1 fusion proteins were 
expressed correctly. 
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exclusion from nucleoli. Together, these 
data suggest that Triad1 interacts with both 
UbcH7 and Ubc13. 
Coiled Coil 2 is essential for the  nuclear 
localization of Triad1
CFP-tagged Triad1 deletions mutants were 
used to study the relevant domains for the 
observed nuclear localization. Western blot 
analysis showed that the CFP-Triad1 and 
the CFP tagged deletion constructs were 
expressed correctly (Figure 6C). Triad1 
contains two putative nuclear localization 
signals (NLS), at amino acid position 282-
330 located in the DRIL domain and at 
position 442-488 located in CC2 domain 14. 
Like full length Triad1, the ∆RING1, ∆DRIL 
and ∆RING2 deletion mutants localized 
predominantly in the nucleus (Figure 6B). 
In contrast, the ∆CC2 and ∆CC1+2 mutants 
localized mainly in the cytoplasm, although 
a weak nuclear staining with exclusion of 
nucleoli was visible. These data suggest that 
the NLS in the CC2 domain is essential for 
the nuclear localization, and that the putative 
NLS in the DRIL domain is not important for 
nuclear localization. 
Triad1 catalyses both K48 and K63 linked 
poly- ubiquitination
The E3 ligase Triad1 interacts with both 
UbcH7 and Ubc13. UbcH7 has been 
implicated in K48 linked poly-ubiquitination 
and Ubc13 in K63 linked poly-ubiquitination. 
Using in vitro ubiquitination assays we 
tested which type of ubiquitin modifications 
are catalyzed by Triad1. Increasing amounts 
of purified His-Triad1 were incubated with 
rabbit reticulocyte fraction IIA (enriched in 
E1 and E2 activity and devoid of ubiquitin 
and proteasome activity 22) in the presence 
of  different recombinant ubiquitin mutants. 
Reaction mixtures were resolved with 
Western blot and stained with an antibody 
that recognizes only poly-ubiquitinated 
proteins (Figure 7). When incubated with 
wild-type ubiquitin we observed a Triad1 
dependent increase in poly-ubiquitinated 
proteins. Restaining of the same blot with 
an α-Triad1 antibody indicated that these 
poly-ubiquitinated proteins are not Triad1. 
No Triad1 mediated poly-ubiquitination 
could be detected using the K0 ubiquitin, 
which is devoid of lysine residues. To test 
whether Triad1 can catalyze the formation of 
Ub chains linked through K48 or K63, we 
used recombinant ubiquitin carrying only 
one lysine residue at position 48 (K48-Ub) 
or at position 63 (K63-Ub). This showed 
that Triad1 catalyzes the formation of Ub 
chains linked through both K48 and K63. 
We conclude that the biological activity of 
Triad1 depends on interactions with UbcH7 
and Ubc13 and that is functions as a dual 
ubiquitin ligase. 
Discussion
Proteins can be marked with different types 
of poly-ubiquitin chains. Depending on 
which lysine within ubiquitin is used for 
poly-ubiquitination, different types of chains 
can be generated. To date two types of poly-
ubiquitin chains have been studied in detail: 
ubiquitin chains linked through lysine 48 of 
ubiquitin and chains linked through lysine 
63. These two types of chains have different 
effects on the fate of the marked proteins. 
Chains linked through lysine 48 mark 
proteins for 26S proteasomal  degradation 
23 whereas chains linked through lysine 
63 alter the function of the target protein 2. 
Different types of E2 conjugating enzymes 
are involved in these different types of 
poly-ubiquitination. Several E2 conjugating 
enzymes can mediate the K48 linked poly-
ubiquitination, like UbcH5 or UbcH7 1. 
When heterodimerized with Uev-1 or Mms2, 
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Ubc13 is the only E2 enzyme known to date to 
mediate poly-ubiquitination linked via lysine 
63 24,25. The contact between E2 conjugating 
enzymes and E3 ligases is mediated through 
specific domains in the E3 ligases. In RING 
finger containing E3 ligases the RING finger 
is the essential domain for the interaction 
with the E2 conjugating enzymes 1. TRIAD 
proteins are a novel class of proteins that 
are characterized by a specific structure 
that contains two RING finger domains and 
a DRIL domain 9,7.  Until now it remained 
unknown why members of this family of E3 
ligases contain two RING fingers. In this 
study we determined that both RING fingers 
of Triad1 function as an interface for binding 
to different E2 conjugating enzymes. RING1 
is essential for UbcH7 interaction, whereas 
RING2 is necessary for the binding with 
Ubc13 (figure 4). In addition, we found that 
Triad1 promotes the assembly of both K48 
and K63 poly-ubiquitin chains in in vitro 
ubiquitination assays (figure 7). Since RING1 
is implicated in interacting with UbcH7 and 
RING2 with Ubc13, this might imply that 
also the K48 and K63 ligase activity are 
D-Triad1
D-polyubiquitin
WT-Ub K0-Ub K48-Ub K63-Ub
Ponceau-red
D-ubiquitin (free)
His-Triad1
0
His-Triad1
0
His-Triad1
0
His-Triad1
0
Figure 7, Triad1 catalyses the assembly of both K48 and K63 linked poly-ubiquitin chains
The conjugation of polyubiquitin in rabbit reticulocyte fraction IIA was tested using recombinant wild-
type ubiquitin and ubiquitin containing only lysine 48 (K48-Ub), only lysine 63 (K63-Ub) or no lysines 
at all (K0-Ub). Ubiquitin was added to Fraction IIA in the presence of  0, 1 or 10 µl of purified His-
Triad1 and incubated for 1 hour at 3°C. Western blot analysis of the samples, using an antibody that 
recognizes only poly-ubiquitinated proteins, indicated that Triad1 promotes the assembly of different 
poly-ubiquitin chains linked via both lysine 48 and 63 of ubiquitin. The same blot was restained with 
an α-Triad1 antibody and did not detect high molecular bands. This indicated that the detected poly-
ubiquitinated proteins are not only ubiquitinated forms of Triad1. Ponceau-red staining was used 
to check the loading of His-Triad1. Staining with an antibody recognizing single ubiquitin moieties 
showed the presence of equal amounts of the wild type and mutant ubiquitin.  
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mediated by these different domains. 
Triad1 levels are induced during the terminal 
differentiation of myeloid blood cells 14. We 
found that Triad1 is also induced during 
monocytic differentiation of U937 cells 
(figure 1). Expression of Triad1 resulted in 
the inhibition of clonogenic growth of these 
cells. Using various deletion constructs, 
we found that RING1 and RING2 were 
essential for this observed phenotype. The 
other conserved motif of the TRIAD domain, 
the DRIL motif, was not required for the 
clonogenic inhibition of U937 cells. This 
indicates that both the K48 and K63 ubiquitin 
ligase activity is essential for the effect of 
Triad1 during myeloid differentiation. This 
hypothesis is in line with earlier studies 
where we showed that addition of proteasome 
inhibitors to CFU-GM cultures partially 
rescued the Triad1 mediated clonogenic 
inhibition 14. This suggests that Triad1 not 
only functions by targeting substrate proteins 
to the 26 proteasome, but may also affect the 
activity of substrate proteins by conjugating 
them with K63 linked ubiquitin chains. 
The E2 ubiquitin conjugating enzyme 
UbcH7 was also shown to interact with other 
TRIAD family members like Dorfin 26, Parc 
27, HHARI 27, Parkin 11, Hoil 28 and Triad3 
12. This indicates that UbcH7 is a generally 
used E2 conjugating enzyme of the TRIAD 
family of E3 ligases. We show here that 
Triad1 also interacts with Ubc13 through its 
RING2 domain. Parkin also interacts with 
Ubc13 via RING2 and is able to catalyze 
both K48 and K63 linked ubiquitination 
18,29,30. The RING2 of the TRIAD family has a 
completely distinct topology compared to the 
classical RING finger structure like RING1 
7. RING2 is only found in TRIAD proteins 
which suggests that this domain requires the 
complete TRIAD structure to function 7,8,9. 
The different topologies might explain the 
specificity for the two RING fingers to interact 
with different E2 conjugating enzymes. The 
presence of the strongly conserved TRIAD 
domain suggests that this is a common 
phenomenon, characteristic for more or all 
TRIAD protein family members. Furthermore, 
this may imply that K63 linked ubiquitination 
is intimately linked to K48 ubiquitination and 
that disturbance of either UbcH7 or Ubc13 
interactions affect the function of the complete 
protein. This is in line with mutations in 
Parkin which are found in both RING 
fingers in patients suffering from autosomal 
juvenile Parkinsonism 11. An interesting 
question concerning the dual ligase function 
remains; are different subsets of substrates 
ubiquitinated by different types of ubiquitin 
chains, are the same substrates modified with 
different types of ubiquitin chains, or do they 
mediate the conjugation of mixed ubiquitin 
chains 31,32. It will be interesting to study what 
determines the activity of the different E3 
ligase activities of TRIAD E3 ligases. Future 
research should clarify the different functions 
of the K48 and K63 ligase activities of the dual 
ubiquitin ligase Triad1 and their role during 
myelopoiesis. The identification of substrate 
proteins of Triad1 will give more insight 
into these questions. Together, these data 
suggest that members of the TRIAD family of 
ubiquitin E3 ligases heve the specific ability 
to catalyze two different types of ubiquitin 
chains, by interacting with two different E2 
conjugating enzymes. 
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The ubiquitin E3 ligase Triad1 homodimerizes and 
heterodimerizes with Triad4 and Trim62
Abstract
In the past few years it has become increasingly clear that post transcriptional regulation 
of proteins by ubiquitin modification plays an essential role in various biological 
processes. Ubiquitin is coupled to a substrate in a multi-enzyme reaction by the activity 
of ubiquitin E3 ligases. The largest group of ubiquitin ligases encompasses the group of 
RING finger containing E3 ligases. RING fingers are essential domains as they mediate 
the interaction with the E2 conjugating enzymes. Although many RING finger E3 ligases 
are thought to function as a single proteins, RING fingers proteins are known to form 
supramolecular structures by homo- and heterodimerization with other RING finger 
proteins. Triad1 is the founding member of an unique class of ubiquitin E3 ligases that 
contain a conserved tripartite structure, the TRIAD domain. This domain consists of two 
RING fingers separated by a distinct cysteine/histidine rich motif (DRIL/IBR). Using 
a yeast-two-hybrid screen we have searched for Triad1 interacting proteins. Besides 
Triad1 itself, we identified two other RING finger proteins, Triad4 and Trim62, to 
interact with Triad1. Interaction studies with deletion mutants showed that the complete 
Triad1 protein was important for the interaction with Trim62. The C-terminal RING 
finger of Triad1 was essential for the interaction with Triad4 and for homodimerization. 
These studies show that Triad1 may function in different complexes. RNA expression 
analysis showed a positive correlation in expression of Triad1, Triad4 and Trim62 in 
many human tissues. These data might suggest that TRIAD proteins do not necessarily 
operate as a single E3 ubiquitin ligase. Through homo- and heterodimerization they 
may target different subsets of proteins for ubiquitination.
Introduction
The conjugation of ubiquitin to proteins is 
a common post-transcriptional modification 
which plays an important role in various 
biological pathways. Ubiquitin is a small 
peptide of 76 amino acids which can be 
linked to substrate proteins through a 
multi-step process. This process starts 
with the activation of ubiquitin by an E1 
activating enzyme. The activated ubiquitin 
is subsequently transferred to one of the E2 
ubiquitin activating enzymes. In concert with 
the E3 ubiquitin ligases, the E2 conjugating 
enzymes mediate the ubiquitination of 
substrate proteins. The E3 ligases constitute 
the largest class of proteins involved in 
ubiquitination and play a crucial role since 
they determine the specificity of this system 
by recognizing the substrate. These E3 
ligases can be subdived into several classes 
based on the presence of specific domains, 
like HECT, U-box or RING domains. The 
family of E3 ligases containing a RING 
finger encompasses the largest family. 
The RING finger family of E3 ligases can be 
classified in proteins which function as single 
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RING-finger proteins 1 like the E3 ligases 
Mdm2 2, Cbl 3, Siah-1 and several IAPs 4. 
The other group of E3 proteins feature only 
E3 ligase activity when complexed with other 
proteins. These other proteins like the SOCS-
box, F-box and cullin proteins play a role in 
the recognition of substrates 1. Recently, is 
has been shown that RING finger proteins 
may form complexes with other RING 
finger proteins. Several RING finger proteins 
are found to homodimerize via their RING 
domain whereas others heterodimerize, 
with other RING-finger proteins 5. For 
example BRCA1, interacts with the BRCA1-
associated RING domain 1 (BARD1) protein 
forming a stable heterodimeric complex via 
their RING fingers allowing to exert their 
biological function 6. BRCA1/BARD1 
needs to heterodimerize in order to function 
as an ubiquitin ligase 7,8. In line with this, 
mutations in BARD1 show the same defects 
in homology-directed DNA repair as BRCA1 
mutations 9. Another example of functional 
interactions between RING finger proteins is 
the human polycomb repressive complex 1-
like (hPRC1L) protein. This complex consists 
of 3 RING finger proteins: BMI-1, RING 1a 
and 1b. All three play an important role in the 
ubiquitination of histone H2A, which results 
in inhibition of transcription 10,11.
We identified a novel subclass of RING finger 
proteins; the TRIAD family 12. This family 
is characterized by a TRIAD domain which 
consist of two RING fingers flanking a DRIL 
(a.k.a. IBR) domain 13,12. Genomic analysis 
showed that the TRIAD domain is an ancient 
family, with more than 140 proteins that are 
found in eukaryotic species ranging from 
yeast to human 14,15. Several of these proteins 
have shown to function as E3 ubiquitin 
ligases. One of the best characterized TRIAD 
proteins is Parkin. Mutations in Parkin 
cause early onset of autosomal juvenile 
Parkinsonism (AR-JP) 16. Like Parkin, also 
other TRIAD proteins were shown to harbor 
E3 ligase activity. For example Triad3, 
which was identified as the E3 ligase for Toll 
like receptors 4 and 9 17. Another TRIAD 
member, Hoil-1, ubiquitinates the oxidized 
form of iron regulatory protein 2 thereby 
playing an essential role in iron metabolism 18. 
This report focuses on the founding member 
of the TRIAD family of E3 ligases; Triad1. 
Triad1 is a 493 amino acid long protein 
containing in addition to the TRIAD domain, 
a N-terminal acid domain and two C-terminal 
coiled-coils. Triad1 is induced during myeloid 
differentiation and ectopic expression results 
in severe reduction of clonogenic growth of 
primary murine bone marrow cells 19. The 
biological activity of Triad1 in hematopoietic 
cells depends on both RING fingers, which 
both interact with different E2 conjugating 
enzymes. The N-terminal RING finger binds 
to UbcH7 while the C-terminal RING finger 
interacts with Ubc13 20. While UbcH7 has 
been implied in poly-ubiquitination of chains 
linked via lysine at position 48 (K48) of 
ubiquitin, Ubc13 can mediate ubiquitination 
via the lysine 63 (K63) of the preceding 
ubiquitin. K48 poly-ubiquitinated proteins 
are recognized by the 26S proteasome, 
whereas K63 ubiquitination results in altered 
function or localization of the substrate 
proteins. In vitro ubiquitination experiments 
showed that Triad1 mediates both K48 as 
well as K63 linked poly-ubiquitination 20. To 
gain further insight in the function of Triad1 
we performed  yeast-two-hybrid screens to 
identify Triad1 interacting proteins and we 
identified two novel RING finger containing 
proteins in addition to Triad1 itself. 
Materials and Methods
Yeast-two-hybrid screening
For yeast-two-hybrid analysis, the 
Pretransformed MATCHMAKER two-
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F-100 cctggtttcctgacaccgcF-20 cgttcctccgaaattgggt
F173 gcgaggctggggctgac
F480 gtactggcgtggtgtcaagt
F945 catcccgtgctcatcacct
F1512 agccccattccagcacaacF1978 gggtctctccaggcattgttcF2524 ccagatgcctatgcgttgttcF3003 gcgggactggactgctctc
R490 taataaccctgtctttcgcagca
R576 cccatctggttgctcctctgR1185 gctgtaaggggttggggttgR1646 gacaagatgcgggaagaaggc
R2147 cgtctacgcactccccagcR2595 gtgtgcccagtgctcctttgR3109 cgagtgatagagcagaaggaggttR3475 ccagcaccaataaagaggcatc
hybrid-system (Clontech) was used. The 
amino acids 109-493 of Triad1 were cloned 
in pGBD as described and the plasmid 
was transformed into AH109 yeast cells. 
This construct was shown not to result in 
auto-activation 19. AH109 yeast cells were 
used to mate with the Y187 yeast strain 
containing a pre-transformed human bone 
marrow cDNA library in pACT2 according 
to manufacturer’s instructions (Clontech). 
A positive interaction in yeast was defined 
by growth of blue colonies within 12 days 
after plating cells on leucine, tryptophane, 
adenine and histidine deficient SD medium 
containing X-α-gal. Plasmids were isolated 
from yeast by Plasmid Mini Kit (Qiagen), 
with an additional incubation step with 
lysozyme. Isolated plasmids were tested in 
rescreens to confirm the specificity of the 
interaction. The relevant binding partner 
sequences identified in the yeast two-hybrid 
screen were cloned into the pGBD vector to 
perform the reciprocal yeast-two-hybrid test 
with Triad1 in pGAD. 
Cell selection
Human hematopoietic subsets were isolated 
by FACS sorting using appropriate antibodies. 
For T-cell selection α-CD3 (Beckman 
Coulter), for monocytes α-CD14 (Beckman 
Coulter) and for B-cells α-CD19 (Beckman 
Coulter) antibodies were used. Granulocytes 
were selected based on CD45 (Beckman 
Coulter) positivity and scatter characteristics 
21. After selection cell purity was confirmed 
to be more than 95% by FACS analysis.
Quantitative PCR
RNA from cell lines was isolated using 
RNA-bee (ISO-TEX Diagnostics). RNA 
from primary cells was isolated using the 
mini-RNA isolation II kit (Zymo research). 
The human total RNA master panel II 
(Clontech) was used as a source for mRNA 
from human tissues. cDNA was generated 
Table 1, Primers sequences used for Triad4 
cDNA PCR 
in a reverse transcription reaction as 
previously described 22. Triad1 mRNA levels 
were measured with real-time quantitative 
PCR using the primers: Triad1-F 5’-
TGGTCCTTTCTTTTGTGCCAGTA-3’ 
and Triad1-R 5’-GCAGCAAGACAGTGT 
CAGGTTT-3’. Triad4 and Trim62 mRNA 
expression were measured using pre-
developed TaqMan Gene Expression Assay 
no. Hs00215938 and Hs00217089 (Applied 
Biosystems) respectively.  qPCRs were 
performed in universal master mix using 
SYBR-green (Roche). Conditions were 
as follows: 10 min. 95°C followed by 45 
cycles of 15 sec. 95°C and 1 min. 62°C. For 
normalization ß-actin was used as a reference 
gene (Applied Biosystems). 
Triad4 cloning
Total RNA of NB4 23 and EOL 24 cell lines was 
isolated using RNAzol (Campro Scientific, 
Veenendaal, The Netherlands) according to 
the manufacturer’s instructions. For cDNA 
synthesis, 1 µg total RNA was incubated 
for 2 hours at 42°C with 3.2 µg random 
hexamers (Pharmacia, Uppsala, Sweden), 
1 mmol/l of each dNTP, 1 mmol/l DTT, 
and 40 U RNAsin Ribonuclease Inhibitor 
(Promega, Madison, WI, USA) with 200 U 
superscript RT (GIBCO BRL, Gaithersburg, 
MD, USA) in the manufacturer's buffer in a 
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total volume of 40 µl. Primers depicted in 
Table 1 were used to amplify and sequence 
the overlapping PCR fragments of the Triad4 
transcripts. A contig containing the complete 
Triad4 transcript was generated using the 
Genestudio software (GeneStudio, Inc.).
Results
Triad1 interacts with RING finger 
containing proteins
To identify proteins that interact with Triad1 
we screened a human bone marrow cDNA 
library in a yeast-two-hybrid assay using 
amino acids 109-493 of Triad1 as bait. This 
part of Triad1 comprises the TRIAD domain 
and the two coiled coils. It was expressed 
correctly in yeast since it was able to interact 
with UbcH7 in these cells 19. To identify Triad1 
interacting proteins 5.8*106 transformants 
were screened and plated on selection 
medium without adenine and histidine in the 
presence of X-α-gal. From blue stained yeast 
colonies, pACT plasmid DNA was isolated 
and sequenced. Database searches using the 
BLAST algorithm 25 showed that Triad1 itself 
and two other RING finger containing proteins 
were identified as Triad1 interacting proteins. 
The two RING finger containing sequences 
were identified as TRIM62 (nm_018207) and 
Triad4, the latter also known as RNF31 (nm_
017999), FLJ10111 26, Zibra 27 or Paul 28. As 
this protein encompasses a TRIAD domain 
comparable to that of Triad1 19,20, Triad2 and 
Triad3 17 we renamed this protein Triad4, to 
emphasize the presence of the conserved 
TRIAD domain. To confirm the interactions, 
DNA from the positive clones were used in a 
rescreen. This showed an interaction of Triad1 
with itself, Triad4 and Trim62, but not with 
the empty vector (Figure 1A). 
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Figure 1, Triad1 interacts with 
Triad1, Triad4 and Trim62
A. Triad1 amino acids 109-493 
cloned in pGAD were used as bait. 
Positive interacting cDNAs from a 
human bone marrow cDNA library 
were selected on X-α-gal containing 
plates lacking histidine and adenine. 
Triad1, Triad4 and Trim62 were 
identified as binding partner of 
Triad1 in a yeast-two-hybrid screen, 
while Triad1 did not interact with the 
empty vector pACT2. B. BglII digest 
of the cDNA from the interacting 
clones of Triad4 and Trim62. The 
Triad4 clone is 1 Kb long, the 
Trim62 2,600 Kb. C. The Triad1 
positive clone contained the cDNA 
of Triad1 starting from basepair 
915 of the open reading frame until 
basepair 1098 (AF099149), were the 
ORF stopped due to a stopcodon. 
The Triad4 encoding cDNA started 
at base pair 2644 (nm_01999). 
The Trim62 cDNA started at the 
beginning of the ORF.
C
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Characterization of the Triad1 interacting 
domains 
The positive yeast two hybrid Triad1 clone 
contained an open reading frame (ORF) 
encoding the DRIL domain from amino acid 
257 and the largest part of the C-terminal 
RING finger (RING2) until a stop codon at 
amino acid position 318 (Figure 1C), which 
was caused by a deletion resulting in a frame 
shift followed by a stop codon. To validate 
the interaction of Triad1 with itself the yeast-
two-hybrid clone of Triad1, was cloned into 
the pGAD vector and tested for interaction in 
a yeast-two-hybrid assay with Triad1 in the 
pGBD vector. The Triad1 fragment (109-493) 
lacking the acidic domain interacted with 
Triad1 (Figure 2B). To identify the domains 
in Triad1 essential for homodimerization 
we generated several deletion mutants 
(Figure 2A). As expected, the C-terminal 
RING finger of Triad1 was essential for 
homodimerization, while all other studied 
domains including the DRIL and the coiled 
coils were not necessary (Figure 2B). 
Characterization of the Triad1-Triad4 
interaction
Based on cDNA sequences in public 
databases we amplified and sequenced 
Triad4 from cDNAs generated from the acute 
promyelocytic leukaemia cell line (NB4) and 
the eosinophilic leukaemia cell line (EOL-1). 
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Figure 2, The C-terminal RING finger of Triad1 interacts with Triad1 and Triad4
A. Deletion constructs of Triad1 in pGAD were generated that lack the acidic domain (∆ acidic), the 
complete TRIAD domain (∆TRIAD), the N-terminal RING finger (∆RING1), the DRIL domain (∆DRIL), 
the C-terminal RING finger (∆RING2) or both coiled-coils (∆CC1+2). B. The deletion of the complete 
TRIAD domain or RING2 alone resulted in loss of interaction with Triad1. An empty vector was used 
as negative control. C. The RING2 domain is essential for the interaction with Triad4.  D. The complete 
TRIAD domain and the coiled-coils of Triad1 are necessary for the interaction with TRIM62.
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   1  gtcgttcctc cgaaattggg tcgcagtccc accctctctc ctagtacttc
  51  ctgttctcgg ctaaccctgg cgctgggccg ggggctggag agtgaccgtg
 101  gtctgagtga cctgggacgg ctgcgtgggc cggggtgggc ctcaaagccg
 151  ggcaccagac gggaggggcg gcgctcgggc cgcgcgctgc ccgcgccggg
 201  tcctggcggg cggcgaggct ggggctgact cctgcctcag gatgccgggg
                                                     M  P  G
 251  gaggaagagg agcgggcctt cctggtggcc cgcgaggagc tggcgagcgc
        E  E  E   E  R  A   F  L  V  A   R  E  E   L  A  S
 301  cctgaggagg gattccgggc aggcgttttc cctggagcag ctccggccgc
      A  L  R  R   D  S  G   Q  A  F   S  L  E  Q   L  R  P
 351  tactagccag ctctctgccg ctagccgccc gctacctgca gctggacgcc
       L  L  A   S  S  L  P   L  A  A   R  Y  L   Q  L  D  A
 401  gcacgccttg tccgctgcaa cgctcatggg gagccccgaa actacctcaa
        A  R  L   V  R  C   N  A  H  G   E  P  R   N  Y  L
 451  caccctgtcc acggctctga acatcctgga gaaatatggc cgcaaccttc
      N  T  L  S   T  A  L   N  I  L   E  K  Y  G   R  N  L
 501  tcagccctca gcggcctcgg tactggcgtg gtgtcaagtt taataaccct
       L  S  P   Q  R  P  R   Y  W  R   G  V  K   F  N  N  P
 551  gtctttcgca gcacggtgga tgctgtgcag gggggccgag atgtgctgcg
        V  F  R   S  T  V   D  A  V  Q   G  G  R   D  V  L
 601  attatatggc tacacagagg agcaaccaga tgggttgagc ttccccgaag
      R  L  Y  G   Y  T  E   E  Q  P   D  G  L  S   F  P  E
 651  ggcaggagga gccagatgag caccaggttg ctacagtcac actggaagta
       G  Q  E   E  P  D  E   H  Q  V   A  T  V   T  L  E  V
 701  ctgctgcttc ggacagagct cagcctgcta ttgcagaata ctcatccaag
        L  L  L   R  T  E   L  S  L  L   L  Q  N   T  H  P
 751  acagcaggca ctggagcagc tgttggaaga caaggttgaa gatgatatgc
      R  Q  Q  A   L  E  Q   L  L  E   D  K  V  E   D  D  M
 801  tgcagctttc agaatttgac cccctattga gagagattgc tcctggcccc
       L  Q  L   S  E  F  D   P  L  L   R  E  I   A  P  G  P
 851  ctcaccacac cctctgtccc aggctccact cctggtccct gcttcctctg
        L  T  T   P  S  V   P  G  S  T   P  G  P   C  F  L
 901  tggttctgcc ccaggcacac tgcactgccc atcctgtaaa caggccctgt
      C  G  S  A   P  G  T   L  H  C   P  S  C  K   Q  A  L
 951  gtccagcctg tgaccacctg ttccatggac acccatcccg tgctcatcac
       C  P  A   C  D  H  L   F  H  G   H  P  S   R  A  H  H
1001  ctccgccaga ccctgcctgg ggtcctgcag ggtacccacc tgagccccag
        L  R  Q   T  L  P   G  V  L  Q   G  T  H   L  S  P
1051  tttacctgcc tcagcccaac cacggcccca gtcgacctcc ctgctggccc
      S  L  P  A   S  A  Q   P  R  P   Q  S  T  S   L  L  A
1101  tgggagacag ctctctttct tcccctaatc ctgcaagtgc tcatttgccc
       L  G  D   S  S  L  S   S  P  N   P  A  S   A  H  L P
1151  tggcactgtg ctgcctgtgc catgctaaat gagccttggg cagtgctctg
W  H  C   A  A  C   A  M  L  N   E  P  W   A  V  L
1201  tgtggcctgt gatcggcccc gaggctgtaa ggggttgggg ttgggaactg
C  V  A  C   D  R  P   R  G  C   K  G  L  G   L  G  T
1251  agggtcccca aggaactgga ggcctagaac ctgatcttgc acggggtcgg
       E  G  P   Q  G  T  G   G  L  E   P  D  L   A  R G  R
1301  tgggcctgcc agagctgtac ctttgagaat gaggcagctg ctgtgctatg
        W  A  C   Q  S  C   T  F  E  N   E  A  A   A  V  L
1351  ttccatatgt gagcgacctc ggctggccca gcctcccagc ttggtggtgg
      C  S  I  C   E  R  P   R  L  A   Q  P  P  S   L  V  V
1401  attcccgaga tgctggcatt tgcctgcaac cccttcagca gggggatgct
       D  S  R   D  A  G  I   C  L  Q   P  L  Q   Q  G  D  A
1451  ttgctggcct ctgcccagag tcaagtctgg tactgtattc actgtacctt
        L  L  A   S  A  Q   S Q  V  W   Y  C  I   H  C  T
1501  ctgcaactcg agccctggct gggtgtgtgt tatgtgcaac cggactagta
F  C  N  S   S  P  G   W  V  C   V  M  C  N   R  T  S
1551  gccccattcc agcacaacat gccccccggc cctatgccag ctctttggaa
       S  P  I   P  A  Q  H   A  P  R   P  Y  A   S  S  L  E
1601  aagggacccc ccaagcctgg gcccccacga cgccttagtg cccccctgcc
        K  G  P   P  K  P   G  P  P  R   R  L  S   A  P  L
1651  cagttcctgt ggagatcctg agaagcagcg ccaagacaag atgcgggaag
      P  S  S  C   G  D  P   E  K  Q   R  Q  D  K   M  R  E
1701  aaggcctcca gctagtgagc atgatccggg aaggggaagc cgcaggtgcc
       E  G  L   Q  L  V  S   M  I  R   E  G  E   A  A  G  A
1751  tgtccagagg agatcttctc ggctctgcag tactcgggca ctgaggtgcc
        C  P  E   E  I  F   S  A  L  Q   Y  S  G   T  E  V
1801  tctgcagtgg ttgcgctcag aactgcccta cgtcctggag atggtggctg
      P  L  Q  W   L  R  S   E  L  P   Y  V  L  E   M  V  A
1851  agctggctgg acagcaggac cctgggctgg gtgccttttc ctgtcaggag
       E  L  A   G  Q  Q  D   P  G  L   G  A  F   S  C  Q  E
1901  gcccggagag cctggctgga tcgtcatggc aaccttgatg aagctgtgga
        A  R  R   A  W  L   D  R  H  G N  L  D   E  A  V
1951  ggagtgtgtg aggaccaggc gaaggaaggt gcaggagctc cagtctctag
E  E  C  V   R  T  R   R  R  K   V  Q  E  L   Q  S  L
2001  gctttgggcc tgaggagggg tctctccagg cattgttcca gcacggaggt
       G  F  G   P  E  E  G   S  L  Q   A  L  F   Q  H  G  G
2051  gatgtgtcac gggccctgac tgagctacag cgccaacgcc tagagccctt
D  V  S   R  A  L   T  E  L  Q   R  Q  R   L  E  P
2101  ccgccagcgc ctctgggaca gtggccctga gcccacccct tcctgggatg
      F  R  Q  R   L  W  D   S  G  P   E  P  T  P   S  W  D
2151  ggccagacaa gcagagcctg gtcaggcggc ttttggcagt ctacgcactc
       G  P  D   K  Q  S  L   V  R  R   L  L  A   V  Y  A  L
2201  cccagctggg gccgggcaga gctggcactg tcactgctgc aggagacacc
        P  S  W   G  R  A   E  L  A  L   S  L  L   Q  E  T
2251  caggaactat gagttggggg atgtggtaga agctgtgagg cacagccagg
      P  R  N  Y   E  L  G   D  V  V   E  A  V  R   H  S  Q
2301  accgggcctt cctgcgccgc ttgcttgccc aggagtgtgc cgtgtgtggc
       D  R  A   F  L  R  R   L  L  A   Q  E C   A  V C  G
2351  tgggccctgc cccacaaccg gatgcaggcc ctgacttcct gtgagtgcac
        W  A  L   P  H  N   R  M  Q  A   L  T  S C  E C
2401  catctgtcct gactgcttcc gccagcactt caccatcgcc ttgaaggaga
T  I C  P   D C  F   R  Q  H   F  T  I  A   L  K  E
2451  agcacatcac agacatggtg tgccctgcct gtggccgccc cgacctcacc
       K  H  I   T  D  M  V C  P  A C  G  R   P  D  L  T
2501  gatgacacac agttgctcag ctacttctct acccttgaca tccagcttcg
        D  D  T   Q  L  L   S  Y  F  S   T  L  D   I  Q  L
2551  cgagagccta gagccagatg cctatgcgtt gttccataag aagctgaccg
      R  E  S  L   E  P  D   A  Y  A   L  F  H  K   K  L  T
2601  agggtgtgct gatgcgggac cccaagttct tgtggtgtgc ccagtgctcc
       E  G  V   L  M  R  D   P  K  F   L  W C   A  Q C  S
2651  tttggcttca tatatgagcg tgagcagctg gaggcaactt gtccccagtg
F  G  F   I  Y  E   R  E  Q  L   E  A  T C  P  Q
2701  tcaccagacc ttctgtgtgc gctgcaagcg ccagtgggag gagcagcacc
C  H  Q  T   F C  V   R C  K   R  Q  W  E   E  Q H
2751  gaggtcggag ctgtgaggac ttccagaact ggaaacgcat gaacgaccca
R  G  R   S C  E  D   F  Q  N   W  K  R   M  N  D  P
2801  gaataccagg cccagggcct agcaatgtat cttcaggaaa acggcattga
        E  Y  Q   A  Q  G   L  A  M  Y   L  Q  E   N  G  I
2851  ctgccccaaa tgcaagttct cgtacgccct ggcccgagga ggctgcatgc
      D C  P  K C  K  F   S  Y  A   L  A  R  G   G C  M
2901  actttcactg tacccagtgc cgccaccagt tctgcagcgg ctgctacaat
H  F  H C  T  Q C   R  H  Q   F C  S   G C  Y  N
2951  gccttttacg ccaagaataa atgtccagag cctaactgca gggtgaaaaa
        A  F  Y   A  K  N   K  C  P  E   P  N  C   R  V  K
3001  gtccctgcac ggccaccacc ctcgagactg cctcttctac ctgcgggact
      K  S  L  H   G  H  H   P  R  D   C  L  F  Y   L  R  D
3051  ggactgctct ccggcttcag aagctgctac aggacaataa cgtcatgttt
       W  T  A   L  R  L  Q   K  L  L   Q  D  N   N  V  M  F
3101  aatacagagc ctccagctgg ggcccgggca gtccctggag gcggctgccg
        N  T  E   P  P  A   G  A  R  A   V  P  G   G  G  C
3151  agtgatagag cagaaggagg ttcccaatgg gctcagggac gaagcttgtg
      R  V  I  E   Q  K  E   V  P  N   G  L  R  D   E  A  C
3201  gcaaggaaac tccagctggc tatgccggcc tgtgccaggc acactacaaa
       G  K  E   T  P  A  G   Y  A  G   L  C  Q   A  H  Y  K
3251  gagtatcttg tgagcctcat caatgcccac tcgctggacc cagccacctt
        E  Y  L   V  S  L   I  N  A  H   S  L  D   P  A  T
3301  gtatgaggtg gaagagctgg agacggccac tgagcgctac ctgcacgtac
      L  Y  E  V   E  E  L   E  T  A   T  E  R  Y   L  H  V
3351  gcccccagcc tttggctgga gaggatcccc ctgcttacca ggcccgcttg
       R  P  Q   P  L  A  G   E  D  P   P  A  Y   Q  A  R  L
3401  ttacagaagc tgacagaaga ggtacccttg ggacagagta tcccccgcag
        L  Q  K   L  T  E   E  V  P  L   G  Q  S   I  P  R
3451  gcggaagtag ctgagggcaa gggtcccgat gagggtccca tggcctgctc
      R  R  K  -
3501  cctcaggaac agctccagca ccaataaaga ggcat 
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Triad1 homo- and heterodimerizes
Overlapping PCR products of the NB4 and 
EOL cDNA were used to generate a contig 
containing the complete ORF of Triad4 
(Figure 3A and B). The Triad4 gene contains 
an ORF of 3219 base pairs which encodes 
for a 1037 amino acid protein consisting 
of several conserved domains including 3 
zinc-fingers, an ubiquitin associated domain 
(UBA) and a TRIAD domain (Figure 
3B). The structurally important cysteines 
and histidines of the TRIAD domain are 
conserved between Triad4 and other TRIAD 
proteins. In contrast to most TRIAD proteins 
the N-terminal RING finger of Triad4 
Figure 3, Triad4 is a member of the TRIAD family
A. Schematic representation of the overlapping PCR products (numbered 1-8) of the Triad4 cDNA. The 
ORF in the sequenced cDNA is represented by an open box. PCR amplification was tested on agarose 
gel electrophoresis. PCR product 1 and 5 could not be amplified from EOL-1 cDNA. The PCR products 
were sequenced and aligned with each other to get the complete sequence of Triad4 in EOL-1 and NB4. 
B. The Triad4 sequence from the NB4 cell line. The ORF is localized from basepair 241 until 3535. 
The Zinc fingers (boxed) can be found at amino acid positions 302-326, 352-376 and 411-435. The 
UBA domain (boxed) is localized at amino acid position 564-615. The TRIAD domain starts at amino 
acid position 699 and ends at 916. It contains two RING fingers at amino acid positions; 699-747 and 
81-916 and a DRIL/IBR domain at position 9-841. The conserved cysteine and histidine amino acid 
in the the TRIAD domain are encircled. C. Homology of the TRIAD domain of Triad4 with the other 
TRIAD members; Triad1, Triad2, Triad3, Parc, Dorfin and AriH1. The N-terminal RING of Triad4 
consist of a C8 topology, while the other TRIAD proteins have a C3HC4 topology.
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contains no histidine, but contains a variant 
RING with eight cysteines.
 
The yeast-two-hybrid clone of Triad4 started 
at amino acid 798. A BglII digest of the 
clone showed that this clone was 1 kb large 
indicating that it contained the complete 
TRIAD domain (Figure 1B and C). The 
interaction was validated by performing the 
reciprocal yeast-two-hybrid experiment. To 
this end the Triad4 fragment, was cloned into 
the pGAD vector and tested for interaction 
in a yeast-two-hybrid assay with Triad1 in 
the pGBD vector (Figure 3C). We also tested 
the Triad1 deletion constructs for interaction 
with Triad4 and found that the the C-terminal 
RING finger of Triad1 is essential for Triad4 
interaction. Together, this indicates that the 
TRIAD domain of Triad4 interacts with the 
C-terminal RING finger of Triad1.
Characterization of the Triad1-Trim62 
interaction
The BglII digest of the Trim62 clone revealed 
a 2,6 Kb long insert (Figure 1B). The yeast-
two-hybrid clone contained the start codon 
of Trim62. Since the ORF consists of 1427 
basepairs this indicates that the complete 
Trim62 ORF is present in this cDNA clone. 
Like Triad1 and Triad4 this interaction 
was also confirmed by a reciprocal yeast-
two-hybrid experiment. Remarkably, for 
the interaction with Trim62 all Triad1 sub-
domains were essential (Figure 2D). 
Expression of Triad4 and Trim62 mRNA
To study whether and where these interactions 
could take place in vivo we tested whether 
Triad1, Triad4 and Trim62 were co-expressed 
in different tissues. To this end we assessed 
the mRNA expression of Triad4 and Trim62 
in different tissues using quantitative RT-
PCR. Expression was normalised for PBGD 
expression and we compared the expression 
of Triad1 mRNA as determined earlier 
19. Trim62 appeared most differentially 
expressed with over 100-fold differences in 
mRNA expression between salivary glands 
and whole brain. Another observation is that 
Triad4 is 10-fold higher expressed compared 
to Triad1 or Trim62 in most tissues (Figure 
4A). Expression of Triad1 was compared 
with Triad4 (Figure 4B) and Trim62 (Figure 
4C). While in most tissue all three genes 
are co-expressed, in fetal brain Triad1 was 
highly expressed compared to the Triad4 and 
Trim62 expression. On the other hand, in 
placenta Triad4 expression was much higher 
compared to Triad1. In both whole brain and 
heart the mRNA expression of Trim62 was 
higher as Triad1.
 
Since Triad1 is differentially expressed 
during hematopoiesis and plays a role in 
myeloid development, we measured the 
expression of Trim62 and Triad4 in different 
hematopoietic subsets. In hematopoietic 
cells Trim62 is expressed at a lower level 
than Triad1 and 4. During differentiation 
of immature CD34+ hematopoietic cells 
towards granulocytes, B or T cells Trim62 
mRNA expression is strongly induced. 
Triad4 is also induced during differentiation 
and is especially highly expressed in B-
cells (Figure 5). As described earlier Triad1 
is induced during differentiation towards 
mature granulocytes 19.   
Discussion
RING finger E3 ubiquitin ligases may 
function as single proteins, hetero-dimers or 
in multi protein complexes. TRIAD proteins 
represent a novel class of RING finger 
containing E3 ubiquitin ligases, characterized 
by a TRIAD domain that consists of 2 RING 
fingers flanking a DRIL domain. Triad1 
is induced during the differentiation of 
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Figure 4, Expression pattern of Triad1, Triad4 and Trim62 in different tissues
A. Triad4 and Trim62 Real-time quantitative PCR was performed on cDNA from different mammalian 
tissues. Triad1 expression from an earlier study 19 was incorporated to correlate it with Triad4 and 
Trim62 expression. We ordered the tissues by increasing Triad1 expression. The expression of Triad1, 
Triad4 and Trim62 was normalized for the reference gene PBGD. B. The log transformed expression 
of Triad1 was plotted against the log transformed expression of Triad4. Clearly visible is that Triad1 
and Triad4 co-express in many tissues except in fetal brain and in placenta. C. The log transformed 
expression of Triad1 was plotted against the log transformed expression of Trim62. Clearly visible is 
that Triad1 and Trim62 co-express except in fetal brain, whole brain and heart.
CB
A
90
Chapter 4
myeloid cells and inhibits their proliferation 
19. The N-terminal RING is essential for the 
interaction with UbcH7, while the C-terminal 
RING mediates the interaction with Ubc13. 
UbcH7 mediates poly-ubiquitin chain 
formation linked via lysine-48, which marks 
proteins for proteasomal degradation. Ubc13 
mediates poly-ubiquitination via lysine 63, 
which alters protein function 20. In this paper 
we have identified that Triad1 can bind itself 
and that it heterodimerizes with the RING 
finger proteins Triad4 and Trim62. 
Recently, it has been shown that RING finger 
proteins may homodimerize 29. However, 
it remains unclear what the function or 
physiological relevance of these interactions 
are. Using a yeast-two-hybrid analysis we 
have found that Triad1 also interacts with 
itself. Homodimerization was specifically 
dependent on the presence of the C-terminal 
RING finger, defining different functions 
for the two RING fingers in Triad1. 
Homodimerization was also observed for 
the TRIAD E3 ligase Parc 30. Whether this 
occurs through the C-terminal RING finger 
of Parc remains to be seen. 
Recently, it was shown that RING finger 
proteins function as heterodimer. Some E3 
ligases are only active as heterodimer, like 
for example BCRA1/BARD1 6,9,8,31. The 
heterodimers are more stable compared 
to BRCA1 and BARD1 separately 9,7,8. 
Furthermore, heterodimerization of RING 
fingers can result in altering the type of 
ubiquitin chain conjugated by the E3 ligase 
complex. This is the case for the RAD5/
RAD18 heterodimer which mediates K63-
linked ubiquitination, while the RAD5 
homodimer can only mediate K48-linked 
ubiquitination 32. Triad1 interacts with 
itself and Triad4 via the C-terminal RING 
finger of Triad1. Recent work showed that 
this RING finger also binds with the E2 
conjugating enzyme Ubc13 20. If the binding 
between Triad1 and Triad4 inhibits the 
interaction with Ubc13, this could imply that 
Triad1 can no longer mediate K63-linked 
ubiquitination due to disturbed of Ubc13 
interaction. However, UbcH7 interacts with 
the N-terminal RING finger and probably 
still interacts with Triad1 when hetero- or 
homodimerized. Through their interactions 
the ubiquitin ligase activity may be switched 
from lysine-63 to lysine-48 linked poly-
ubiquitination.
Triad1 also interacts with Trim62, a novel 
protein which is a member of the tripartite 
motif proteins. This protein family is 
characterized by three conserved motifs 
in the N-terminus in the following order: 
RING finger, B-box and coiled-coil. The 
coiled-coil of these proteins is often used 
for homodimerization. The C-terminus of 
proteins of this family is variable, although 
two thirds of these proteins contain a PRY 
domain followed by a SPRY domain 33. The 
functions of both domains are unknown. The 
functions of the TRIM protein family vary, 
but most function as E3 ubiquitin ligase. The 
RING finger is essential for E2 interaction 
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Figure 5, Different expression or Triad1, Triad4 
and Trim62 in different hematopoietic subsets
Real-time quantitative expression of Triad1, 
Triad4 and Trim62 in different FACS sorted 
hematopoietic cells. Expression was PBGD 
normalized.
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while the B-box 34 and coiled-coils 35 mediate 
the substrate recognition.
As part of the highly conserved TRIAD 
domain, the C-terminal RING of Triad1 
is very homologous with the C-terminal 
RING finger of other TRIAD proteins. 
An interesting questions is whether other 
TRIAD proteins can heterodimerize with 
other members of this family as well, like 
for example Triad3 17, Hoil-1 36, Parkin 16 or 
Parc 37. Beside their TRIAD domain, these 
proteins contain various other domains. 
The heterodimerization might bring other 
domains together like for example the 
ubiquitin associated domain (UBA) 38,39 
which is present Triad4. 
Triad4, has previously been described as 
Zibra 27, Paul 28 or FLJ10111 26. Triad4 is 
expressed in several distinct cancers and is 
co-expressed with several genes implicated 
in the ubiquitin proteasome route like for 
example,  PSMD7 which is part of the 19S 
proteasome lid 40. Furthermore, it was shown 
that Triad4 protein levels are inhibited upon 
proteasome inhibition 27. Triad4 interacts 
with the muscle-specific receptor tyrosine 
kinase 28 but whether it targets this kinase for 
proteasomal degradation is unknown. 
Since Triad4 and Trim62 are expressed at 
different levels in hematopoietic tissues this 
could imply that Triad1 heterodimerizes 
with either Triad4 or Trim62 based on 
concentration, thereby specifically regulating 
the activity of each other. Another possibility 
is that Triad1, Triad4 or Trim62 target each 
other for ubiquitination. Due to ubiquitination 
and for example subsequent proteasomal 
degradation the activity of one or more of 
these E3 ligases could be regulated. Our 
studies may suggest that heterodimerization 
of RING finger proteins may be more 
common as previously thought. Further 
research is warranted to study the functional 
interplay of the here described RING finger 
ubiquitin E3 ligases. 
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Gfi1 ubiquitination and proteasomal degradation is 
inhibited by the ubiquitin ligase Triad1
Abstract
Growth factor independence 1 (Gfi1) is a transcriptional repressor essential for the 
proper function and development of many hematopoietic cell types, including stem cells, 
neutrophils, T-cells and dendritic cells. Recent studies showed that Gfi1 protein levels are 
regulated by the ubiquitin proteasome system (UPS). For example, in granulocytes Gfi1 
is rapidly degraded by the proteasome, while it is far more stable in primary monocytes. 
Currently, it is unclear how the ubiquitination and proteasomal degradation of Gfi1 is 
regulated. Here we show that the E3 ubiquitin ligase Triad1 interacts with the DNA 
binding domain of Gfi1. Therefore, we tested whether Triad1 regulates the ubiquitination 
and proteasomal degradation of Gfi1. Unexpectedly, ubiquitination experiments showed 
that Triad1 expression resulted in a strong decrease in Gfi1 ubiquitination resulting in 
a significantly prolonged Gfi1 half-life. Downregulation of endogenous Triad1 levels 
by siRNA resulted in increased Gfi1 ubiquitination. We conclude that Triad1 protects 
the important hematopoietic regulator Gfi1 from proteasomal degradation. Because 
neither proteasome activity- nor Triad1 ubiquitin ligase activity was required for the 
inhibition of Gfi1 ubiquitination, these data strongly suggest that Triad1 competes for 
Gfi1 binding with as yet to be identified E3 ubiquitin ligases that do mark Gfi1 with 
ubiquitin for proteasomal degradation.
Introduction
Hematopoiesis is characterized by the 
continuous generation of mature, functional 
blood cells from a pool of stem cells that 
reside in the bone marrow. Changes in 
the balance between proliferation and 
differentiation may result in hematological 
malignancies like acute myeloid leukemia. In 
leukemia, mutations may be found in genes 
that control proliferation, apoptosis and 
differentiation like transcription factors 1. 
Several transcription are crucial for myeloid 
differentiation like PU.1 2;3, C/EBPα 4 and 
C/EBPε 5. Recently, also the transcriptional 
repressor Gfi1 was found to be essential during 
hematopoiesis (including myelopoiesis). 
Gfi1 was originally identified as a proviral 
insertion site resulting in IL2 independent 
growth of T-cells 6. The mammalian Gfi1 
gene encodes a 55-kDa nuclear protein that 
contains six C-terminal C2-H2 zinc finger 
domains important for DNA binding and 
a characteristic N-terminal 20-amino acid 
SNAG-domain responsible for the activity 
as a transcriptional repressor. Overexpressed 
Gfi1 acts as a dominant oncogene and 
cooperates with known oncoproteins like 
Myc and Pim-1 in lymphoma development 
7;8. In normal hematopoiesis, Gfi1 is essential 
for T-cell development and regulates the 
self-renewal and long term reconstituting 
potential of HSC 9;10;11. Gfi1 was also shown 
to be important for lymphocyte-derived 
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dendritic cell development 12. Furthermore, 
Gfi1 plays an essential role during 
granulocytic differentiation. Gfi1-/- knockout 
mice are severely neutropenic due to a block 
in myeloid differentiation, which results in 
the accumulation of an atypical immature 
myeloid cell population 9;13. Recently also 
other essential Gfi1 functions outside the 
hematopoietic system were identified, like in 
the inner ear 14;15 and in intestinal secretory 
lineage differentiation 16.
As has been shown for other key regulators of 
hematopoietic differentiation like AML1 17, 
C/EBPα 18 and RARα 19, it was recently shown 
that Gfi1 protein levels are controlled by the 
ubiquitin proteasome system (UPS) 20;21. 
The ubiquitin proteasome system catalyzes 
the conjugation of ubiquitin to substrate 
molecules in a multi-enzyme process. First, 
E1 enzymes activate free ubiquitin, a small 
peptide of 76 amino acids. The activated 
ubiquitin is subsequently transferred to an 
E2 ubiquitin-conjugating enzyme. In concert 
with the E2 enzyme, E3 ubiquitin ligases 
catalyze the covalent conjugation of ubiquitin 
to specific substrate proteins 20;22. Depending 
on the type of ubiquitin chain conjugated to 
the substrate, ubiquitination can regulate the 
activity or stability of substrate proteins 23. 
A crucial role of ubiquitin E3 ligases is the 
specific recognition of substrate proteins, 
which should be marked with ubiquitin. 
Therefore, the specificity of the UPS is 
mainly determined by the activity of E3 
ubiquitin ligases.
Gfi1 protein levels are regulated by the 
UPS during myeloid differentiation. The 
Gfi1 protein is relatively stable in primary 
monocytes, while in mature granulocytes it is 
efficiently degraded by the 26S proteasome. 
This results in low Gfi1 protein levels 
in granulocytes, while mRNA levels are 
high. However, in primary monocytes Gfi1 
protein levels are much higher while mRNA 
levels are significantly lower compared to 
granulocytes 20;24. Recent work showed that 
Gfi1 protein levels are also controlled by 
the UPS in neuronal cells. In these studies 
it was shown that Ataxin-1 (Atx-1) interacts 
with Gfi1 resulting in enhanced degradation 
via the 26S proteasome. Mutations of Atx-
1 in spinocerebellar ataxia type 1 (SCA1) 
results in decreased Gfi1 levels in neuronal 
cells, which is implicated in the onset of 
this neurodegenerative disease 21. However, 
till now no E3 ligase activity of Atx-1 was 
found. While Gfi1 protein levels are regulated 
by the UPS in different cellular processes, 
the proteins involved are unknown. In this 
report we show that Gfi1 interacts with the 
ubiquitin E3 ligase Triad1 and that Triad1 
controls Gfi1 protein levels.
Materials and Methods
Yeast two hybrid screening
The pretransformed matchmaker two-hybrid 
system (Clontech) was used for yeast two 
hybrid analyses. Sequences encoding amino 
acids 109-493 of Triad1 were cloned in 
pGBD as described 25 and the plasmid was 
transformed to yeast strain AH109.  AH109 
yeast cells were used to mate with the Y187 
yeast strain that was pre-transformed with 
a Human bone marrow cDNA library in 
pACT2 (Clontech). Mating and yeast-two-
hybrid screening was performed according 
to the manufacturer’s instruction. Putative 
interactions in yeast were defined by growth 
of blue colonies within 12 days after plating 
the cells on leucine, tryptophane, adenine and 
histidine deficient SD medium, containing X-
α-gal. Plasmids were isolated from positive 
yeast colonies using the plasmid mini kit 
(Qiagen), with an additional pre-incubation 
step with lysozyme. Isolated plasmid DNA 
was tested in rescreens to confirm the 
specificity of the interaction. The Gfi1B 
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clone isolated from the yeast two-hybrid 
screen was cloned in the pGBD vector to 
perform the reciprocal yeast-two-hybrid test 
with Triad1 in pGAD.
Constructs and cell culture
All used constructs were described earlier 
20;25;25, except for Flag-Gfi1B, Flag-Gfi1B 
∆ zinc finger and Flag-Gfi1B 6 zinc 
finger which were kindly provided by Dr. 
Osawa 26 . COS-1 cells were cultured in 
Iscove’s Modified Dulbecco’s Medium 
(IMDM) (Life Technologies, Gaithersburg, 
MD) supplemented with 10% fetal calf 
serum (FCS), penicillin (50 I.U./ml) and 
streptomycin (50 ug/ml) (Life Technologies). 
HEK293 cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) (Life 
Technologies) supplemented similar as 
described for IMDM with the addition of 
2mM glutamine. When indicated, cells were 
treated with 50µg/ml cycloheximide (Sigma) 
for the indicated time. Sf-9 and Hi-5 insect 
cells were grown in TNM-FH medium 
(Sigma) supplemented as indicated for 
IMDM. For Sf-9 cells, 0.5% Bovine Serum 
Albumine was added. Cells were grown at 
27°C in a completely humidified atmosphere. 
Sf-9 cells were used to generate baculovirus 
expressing His-Triad1. Hi-5 cells were 
grown to 75% confluency and infected with 
baculovirus. 
In vitro pull down assays
His-tagged Triad1 was isolated from 4-5 
days infected Hi-5 cells, which were lysed 
in RIPA buffer (PBS containing 1% Nonidet 
P-40 (NP-40), 0.5% natrium-deoxycholaat, 
0.1% SDS and complete protease 
inhibitor cocktail (Roche Diagnostics, 
Basel, Switzerland)) followed by 2 hours 
incubation at 4°C with pre-washed His-
select beads (Sigma) in the presence of 5 
mM imidazole (Sigma). Beads were washed 
4 times with RIPA buffer supplemented 
with 10 mM imidazole. His-Triad1 loaded 
beads were incubated with 10 µl in vitro 
translated, 35S methionine labeled proteins 
for 16 hours at 4°C. The labeled proteins 
were produced using the rabbit reticulocyte 
lysate TnT Quick Coupled Transcription/
Translation System (Promega). After four 
wash steps with RIPA in the presence of 10 
mM imidazole. Proteins were eluted by the 
addition of 2 x laemnibuffer and heating of 
the samples for 5 min at 95°C. Samples were 
resolved by SDS-PAGE, gels were fixed, 
treated with NAMP-100 (Amersham), dried 
and exposed. 
Co-immunoprecipitation and Western 
blotting
COS-1 cells cultured in 10-cm dishes were 
transiently transfected as indicated using the 
calcium phosphate precipitation method. 
Cells were lysed 36 hours after transfection 
in RIPA buffer with complete protease 
inhibitors (Roche). GFP tagged proteins 
were incubated with GFP-antibody (Roche, 
clones 7.1 and 13.1) and Prot-A beads for 4 
hours at 4°C with gentle rotation. Beads were 
washed 5 times with RIPA. Bound proteins 
were eluted in loading buffer by heating 
for 5 min at 95°C. Immunoprecipitates and 
protein lysates were separated on SDS-
polyacrylamide gels, electrophoretically 
transferred onto polyvinylidenefluoride 
(PVDF) membranes (Bio-Rad, Hercules, 
CA) and blocked with 2% ELK (Campina) 
and 0.5% BSA (Sigma). Blots were probed 
with mouse monoclonal antibodies to Flag 
(Sigma, M2), Ubiquitin (Ub) (Sigma, 6C1), 
His-tag (penta-his, Qiagen) or GFP.  
In vivo ubiquitination assay
COS-1 cells grown in 10-cm dishes were 
transfected with 10 μg of His-Ub and 10 μg 
of human Gfi1-GFP or Gfi1-Flag expression 
constructs, using calcium phosphate 
precipitation. For ubiquitination assays in 
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which siRNAs were used, HEK293 cells were 
cotransfected with the indicated siRNA and 
His-Ub using lipofectamine 2000 (Invitrogen). 
The following siRNAs were used; siRNA 
Triad1: UUGUGAGGAAGAGGAAGAA, 
siRNA GFP: GCAAGCUGACCCUGAA 
GUUCAU, control siRNA: AGGAGUUGG-
UGGCAAUAAU (designed against SP1). 
Where indicated, proteasome activity was 
inhibited by the addition of MG132 16 
hours prior to harvesting cells. 36 hours 
after transfection cells were harvested for 
purification of His-tagged proteins. The cell 
pellet was lysed in buffer A (6 M guanidinium-
HCl, 0.1 M Na2HPO4, 10 mM imidazole, 10 
mM β-mercaptoethanol, complete protease 
inhibitor (Roche)) and incubated with His-
select NTA beads (Sigma) for 4 h at 4°C. 
The beads were washed 2 times with buffer 
A, 2 times with a mixture of 4 parts buffer A, 
and 1 part of buffer B (50mM Tris pH 6.8, 
20 mM imidazole) and 2 times with buffer 
B. Bound proteins were eluted with 200 
mM imidazole in laemlibuffer. The eluted 
proteins were analyzed by immunoblotting 
for the presence of Ub-conjugated Gfi1 using 
α-Flag, α-His or α-Gfi1 antibody.
Results
Triad1 interacts with the zinc fingers of 
Gfi1 and Gfi1B
Triad1, is an E3 ubiquitin ligase implicated 
in myelopoiesis 25. To identify Triad1 binding 
partners we searched for interacting proteins 
by screening a human bone marrow cDNA 
library in a yeast-two-hybrid assay using 
amino acids 109-493 of Triad1 as bait. This 
part of Triad1 comprises the TRIAD domain 
and the two coiled coils regions25. Candidate 
Triad1 interacting proteins were identified 
by screening 5.8*106 transformants on SD 
medium without adenine and histidine in 
the presence of X-α-gal. From blue stained 
yeast colonies, pACT plasmid DNA was 
isolated and sequenced. One of the positive 
interacting proteins was identified as 
Growth factor indepence 1B (Gfi1B) 27. The 
interacting clone spanned amino acids 91 
AD: Gfi1B
BD: Triad1
Triad1Empty
vector
AD: Triad1
BD: Gfi1B
Triad1
'TRIAD
'DRIL
'RING2 'RING1
Empty
vector
'CC1+2
AD: Gfi1B
BD: Triad1
Triad1Empty
vector
Figure 1, Gfi1B binds Triad1 in yeast-two-hybrid assays
A. Yeast-two-hybrid screen with the Gfi1B clone that interacts with Triad1 (109-493 a.a.) and not with 
the empty vector control on double histidine and adenine selection medium containing X-α-gal. B. 
Gfi1B was cloned into pGBD and tested for interaction in the reciprocal experiment with full length 
Triad1 or deletion constructs in pGAD. The C-terminal RING finger (RING2) of Triad1 was the smallest 
essential domain for Gfi1B interaction.
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to 330, containing 6 C2H2 zinc fingers of 
the DNA binding domain. Gfi1B interacted 
specifically with Triad1 and not with the 
empty vector (figure 1A). The interaction 
was validated by the reciprocal experiment 
using Gfi1B cloned in the pGAD bait vector 
and Triad1 in the pGBD prey vector (Figure 
1B). To pinpoint the interacting domains we 
tested the interaction of Gfi1B with various 
Triad1 deletion constructs. Deletion of the 
N-terminal RING, DRIL/IBR domain or 
both coiled-coils of Triad1 did not influence 
the interaction. In contrast, deletion of the C-
terminal RING finger abolished the observed 
interaction with Gfi1B, indicating that this 
domain of Triad1 is essential for the Gfi1B 
interaction (figure 1B).
To confirm the Triad1 Gfi1B interaction with 
alternative methods, full-length His-tagged 
Triad1 was expressed in HI-5 insect cells 
and purified with His-select beads (figure 
2A). Western blot analysis indicated that the 
purified band represented His-Triad1 (data 
not shown). The His-Triad1 beads were 
incubated in RIPA buffer with 35S labeled in 
vitro translated Gfi1B. As depicted in figure 
2B, Gfi1B interacted with Triad1 but not 
with the control beads. These experiments 
showed that Gfi1B interacts directly with 
Triad1 without intermediate proteins. In 
vitro translated fragments of Gfi1B were 
used to detect the part of Gfi1B responsible 
for interaction with Triad1. As expected, 
the Gf11b zinc finger part interacted with 
Triad1 while the Gfi1B fragment containing 
the SNAG and non zinc finger domain did 
not (Figure 2B). The interaction was further 
verified by co-expressing GFP or GFP-
tagged Triad1 with N-terminally Flag-tagged 
Baculovirus
infected Hi-5 - +
His-Triad1
SDS-page
Coomassie brilliant 
blue
35S in vitro translated
10% 
input
Empty 
beads
Triad1 
beads
Full length Gfi1B
' zinc finger Gfi1B
6 zinc finger Gfi1B
GFP-Triad1
GFP
Flag-Gfi1B
WB Į-Flag
IP Į-GFP
WB Į-GFP
IP Į-GFP
WB Į-Flag
+-
-+
++
wce
Figure 2, Gfi1B interacts with Triad1
A. His-Triad1 was isolated from baculovirus infected Hi-5 cells using His-Select beads. Proteins bound 
to beads were detected with SDS-page followed by coomassie staining. A clear His-Triad1 band is 
visible, while no proteins can be detected when beads were incubated with uninfected Hi-5 cells. B. In 
vitro translated and 35S labeled Gfi1B was incubated with empty beads or His-Triad1 loaded beads. 
Full length Gfi1B and the 6 zinc-finger domain interacted with Triad1, but not the ∆zinc finger domain. 
C. GFP-Triad1 or GFP was cotransfected with Flag-Gfi1B in COS cells. α-GFP immunoprecipitated 
proteins were immunoblotted and stained with α-GFP to check the immunopreciptiation (SantaCruz 
biotech). α-Flag staining showed that Gfi1B interacts with GFP-Triad1 but not with GFP alone. Whole 
cell extract (WCE) was blotted with α-Flag antibody to show equal Gfi1B expression.
CBA
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Gfi1B in COS cells followed by anti-GFP 
co-immunoprecipitation. The subsequent 
Flag staining (Figure 2C) showed that 
Gfi1B interacts with GFP-Triad1 and did not 
interact with GFP alone. Together, these data 
indicate that the zinc finger domain of Gfi1B 
interacts directly with the C-terminal RING 
finger of Triad1.  
Gfi1B is a transcriptional repressor essential 
for proper erythroid and megakaryocytic 
differentiation and plays a role in T-cell 
activation 28;29. The Triad1 interacting zinc 
finger domain of Gfi1B is 97% identical 
to the DNA binding domain of the Gfi1B 
homologue Gfi1 (figure 3A) 30. To test 
whether Gfi1 also interacts with Triad1 we 
performed in vitro pull down experiments. 
This showed that 35S in vitro translated 
Gfi1 also interacted with purified Triad1 on 
His-select beads via its zinc finger domain 
(figure 3B). This interaction was verified 
by co-immunoprecipitating N-terminally 
Flag-tagged Gfi1 with GFP or GFP-Triad1 
in transfected COS cell lysates. Gfi1 co-
immunoprecipitated with GFP-Triad1, 
but not with GFP (Figure 3C). Expression 
constructs encoding only the zinc-finger 
domain of Gfi1 and Gfi1B could also be 
co-immunoprecipitated with Triad1 (data 
not shown). These experiments show that, 
similar to Gfi1B, the zinc-fingers of Gfi1 
interact directly with Triad1.
Triad1 inhibits the ubiquitination of Gfi1
Since Triad1 functions as an ubiquitin E3 
ligase in myelopoiesis 25;25 and Gfi1 was 
found to be ubiquitinated and degraded by 
the 26S proteasome in myeloid cells 20;21, we 
studied whether Triad1 ubiquitinates Gfi1. 
To this end, we transfected COS cells with 
GFP-Gfi1, Flag-ubiquitin with or without 
Triad1. After GFP immunoprecipitation the 
amount of ubiquitinated proteins bound to 
Y2H clone
Gfi1:    422 aa
= zinc finger
Gfi1B:  330 aa
= repressor domain
'zinc finger 6zinc finger
10% 
input
Empty 
beads
Triad1
beads
35S in vitro translated
Full length Gfi1
' zinc finger Gfi1
6 zinc finger Gfi1
GFP-Triad1
GFP
Flag-Gfi1
IP Į-GFP
WB Į-Flag
IP Į-GFP
WB Į-GFP
WB Į-Flag
+-
-+
++
wce
 
Figure 3, Gfi1 interacts  with Triad1 
A. Schematic representation of Gfi1 and Gfi1B. 
The Triad1 interacting part of Gfi1B found in 
yeast two hybrid (indicated with the solid line 
Y2H), contains the 6 zinc-fingers that are 97% 
identical to Gfi1. B. Like Gfi1B also full length 
and the 6 zinc finger domain of Gfi1 interacts with 
His-Triad1. No interaction was detected with the 
∆ zinc finger domain of Gfi1. C.  GFP-Triad1 or 
GFP was cotransfected with Flag-Gfi1 in COS 
cells. α-Flag staining of whole cell extract (wce) 
showed equal expression of Gfi1. α-Flag staining 
of the α-GFP immunoprecipitates showed that 
Gfi1 interacts with Triad1 but not with GFP 
alone. α-GFP staining of the immunoprecipitated 
proteins showed successful immunoprecipitation.
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Gfi1 and ubiquitinated forms of Gfi1 itself 
were revealed by Flag staining in Western 
blot analysis. This resulted in a protein smear 
including proteins with a lower molecular 
mass compared to Gfi1-GFP probably 
representing ubiquitinated proteins bound 
to Gfi1. This indicates that Gfi1 is present 
in ubiquitinated protein complexes (figure 
4A). The intensity of the protein smear 
increases dramatically above the size of 
Gfi1-GFP, which suggest that Gfi1 itself is 
ubiquitinated. Remarkably, co-expression of 
Triad1 resulted in a severe reduction in the 
amount of ubiquitinated proteins. 
We performed additional in vivo 
ubiquitination assays to further study the 
effect of Triad1 on Gfi1 ubiquitination. 
His-tagged ubiquitin was transfected with 
GFP-Gfi1 with or without Triad1. Under 
denaturing conditions ubiquitinated proteins 
were isolated and subsequently analyzed on 
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+
+
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Triad1
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MG132 
*
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-
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+
-
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+
+
-
- - - -
- + + +
+
- -
+
+ -
+
+
-
- + +
+ + +
GFP-Triad1
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Figure 4, Triad1 inhibits Gfi1 ubiquitination
A. Gfi1-GFP and Flag-Ub were cotransfected with or 
without Triad1. Gfi1 was immunoprecipitated with α-GFP. 
Ubiquitinated Gfi1 or ubiquitinated proteins bound to Gfi1 
were detected by α-Flag staining. The high molecular smear 
suggests that ubiquitinated proteins are bound to Gfi1, or that 
Gfi1 itself is ubiquitinated (--> marks molecular weight of 
unmodified GFP-Gfi1). The co-expression of Triad1 severely 
inhibits the amount of ubiquitinated Gfi1 or ubiquitinated 
proteins bound to Gfi1. α-GFP staining of whole cell extract 
(wce) was used to check for equal expression. B. COS cells 
were transfected as indicated. Ubiquitinated proteins were 
isolated with His-select beads under denaturing conditions 
(6 M guanidium chloride). The high molecular smear represents poly-ubiquitinated forms of Gfi1. Co-
expression of Triad1 or the H158A point mutant severely inhibited the ubiquitination of Gfi1. Incubation 
of cells with MG132 resulted in an accumulation of ubiquitinated forms of Gfi1 indicating that poly-
ubiquitintation of Gfi1 results in proteasomal degradation. Triad1 still inhibited the ubiquitination of 
Gfi1 in the presence of MG132. (*) Marks non-specific interaction of Gfi1 with the His-select beads. C. 
In vivo ubiquitination assay of endogenous proteins with His-Ub. Selection of ubiquitinated proteins 
(His-select beads) followed by an α-His staining showed that overall ubiquitination is not inhibited 
by Triad1. α-Ubiquitin staining showed equal expression of His-tagged ubiquitin. Lower band is 
endogenous ubiquitin, slower migrating band is His-Ub. 
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Western blot. This showed that the amount 
of ubiquitinated Gfi1 was clearly diminished 
upon co-expression of Triad1 (Figure 4B). 
Also the expression of the H158A Triad1 
mutant, which can not interact with the E2 
conjugating enzyme UbcH7 25, diminished 
Gfi1 ubiquitination. This suggests that the 
inhibition of Gfi1 ubiquitination is independent 
of the E3 ligase activity of Triad1. Addition 
of the proteasome inhibitor MG132 resulted 
in a clear increase in ubiquitinated forms of 
Gfi1 indicating that ubiquitination of Gfi1 
results in 26S proteasomal degradation. In 
the presence of MG132 Triad1 still inhibited 
the ubiquitination of Gfi1, indicating that 
proteasome activity is not necessary for 
the observed effect. Similar results were 
obtained when Gfi1-Flag instead of Gfi1-
GFP was used (supplementary figure 1) 
thereby excluding any non-specific effects in 
ubiquitination due to the GFP tag. 
To rule out the possibility that the observed 
decrease of Gfi1 ubiquitination by Triad1 
was caused by a non-specific effect on total 
cellular-ubiquitination, the effect of Triad1 
on the total amount of ubiquitinated proteins 
was studied. To this end, His-tagged ubiquitin 
was transfected in COS cells with or without 
Triad1, followed by capture and staining of 
ubiquitinated proteins in Western blotting. As 
can be seen in figure 4C the total amount of 
ubiquitinated proteins was not altered upon 
co-expression of Triad1. Together, these data 
indicate that Triad1 specifically inhibits the 
ubiquitination of Gfi1.  
 
Downregulation of Triad1 levels results in 
an increase of Gfi1 ubiquitination 
Synthetic siRNAs were developed to 
down regulate endogenous Triad1 levels 
in HEK293 cells. The efficiency of these 
siRNAs was first tested by co-expressing 
them with GFP-Triad1. The siRNA designed 
to down regulate Triad1 was equally efficient 
in down regulating GFP-Triad1 as a control 
siRNA targeting GFP (figure 5A). The 
Triad1 siRNA was co-transfected with Gfi1-
Flag and His-Ub in an in vivo ubiquitination 
assays followed by capture of ubiquitinated 
proteins and staining for Gfi1 in Western 
blot analysis. Clearly visible in figure 5B are 
the ubiquitinated forms of Gfi1. Knocking 
down endogenous levels of Triad1 resulted 
in a clear increase in ubiquitinated forms of 
Gfi1. A control siRNA had no effect on the 
Gfi1 ubiquitination. These data show that 
decreasing endogenous Triad1 levels results 
in an increase in Gfi1 ubiquitination and 
indicate that limitation of essential cofactors 
is not the cause of the observed inhibition 
of Gfi1 ubiquitination when Triad1 is 
overexpressed (figure 4). Together, these 
data indicate that Triad1 specifically inhibits 
the ubiquitination of Gfi1.  
Gfi1-Flag
His-Ub
Triad1
*
Gfi1-(Ub)n
Gfi1-(Ub)1
+
+ -
-
+
+
- - -
+
+
+
NTA bead pulldown
WB Į-Flag
Supplementary Figure 1, 
In vivo ubiquitination experiments with Flag-
Gfi1. Triad1 inhibits poly-ubiquitination of Gfi1. 
Interestingly, the mono-ubiquitinated form (<--) of 
Gfi1 is unaffected by Triad1. In this experiment we 
also observed a diminished poly-ubiquitination of 
Gfi1 upon Triad1 co-expression as is depicted in 
Figure 4b. Under these circumstances, the mono-
ubiquitination of Gfi1 was less affected by Triad1, 
indicating that Triad1 predominantly inhibits 
the poly-ubiquitination of Gfi1. (*) Marks non-
specific interaction of Flag-Gfi1 with the beads. 
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Triad1 inhibits Gfi1 protein turnover 
The ubiquitination of Gfi1, which results in 
proteasomal degradation, was inhibited by 
Triad1. Therefore, we studied the effect of 
Triad1 on Gfi1 protein levels. To address this 
question we co-expressed GFP tagged Gfi1 
with different amounts of Triad1. GFP-Gfi1 
protein amounts were measured at the single 
cell level by flow cytometry. GFP-Gfi1 
protein levels were increased after Triad1 
co-expression, while Triad1 had no effect on 
GFP alone (Figure 6A). The increase of Gfi1 
protein levels caused by Triad1 suggests 
that Triad1 stabilizes Gfi1 by inhibiting its 
proteasomal degradation. To address this 
question in more detail we studied the effect 
of Triad1 on Gfi1 stability. Gfi1-Flag was 
transfected to COS cells with or without 
Triad1. The stability of Gfi1-Flag protein 
was determined in the presence or absence 
of Triad1 after addition of the inhibitor 
of protein translation cycloheximide. In 
these experiments we found that the Gfi1 
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Figure 5, Inhibition of Triad1 expression results in increased Gfi1 ubiquitination
A. HEK293 cells were transfected with combinations of GFP-Triad1 with indicated siRNA constructs. 
36 hours after transfection the mean fluorescence intensity (MFI) was measured by flow cytometer. The 
MFI of GFP-Triad1 transfected cells was set at 100. Transfection with siRNA developed against Triad1 
or GFP resulted in downregulated GFP-Triad1 protein levels, while the control siRNA showed no effect 
on GFP-Triad1 levels. B. In vivo ubiquitination experiments in HEK293 cells showed that Triad1 siRNA 
expression resulted in increased poly-ubiquitination of Gfi1. Co-transfection with a control siRNA had 
no effect on Gfi1 ubiquitination.
protein half-life increased significantly 
after proteasome inhibition indicating 
that the short half-life of Gfi1 is caused 
by proteasomal degradation (Figure 6B). 
Importantly, co-expression of Triad1 resulted 
also in a dramatic increase in the half-life of 
Gfi1. Together, these data indicate that Gfi1 
is stabilized by Triad1, due to decreased 
ubiquitination and subsequent proteasomal 
degradation.
Discussion
Triad1, was recently reported as an ubiquitin 
E3 ligase implicated in hematopoiesis 
25. Triad1 is the founding member of a 
subclass of RING finger E3 ligases 31;32. 
This subclass contains a TRIAD domain 
which is characterized by a RING-DRIL/
IBR-RING signature 31;33-35. Recent studies 
showed that the N-terminal RING finger 
of Triad1 interacts with the E2 conjugating 
enzyme UbcH7. UbcH7 mediates poly-
ubiquitin chain formation linked via lysine-
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48 of ubiquitin. In line with this interaction 
we showed that Triad1 functions as ubiquitin 
ligase and that it can catalyze the formation 
of poly-ubiquitin chains (linked via lysine-
48), that mark proteins for proteasomal 
degradation 25. Triad1 mRNA and protein 
is expressed in various different tissues. 
Triad1 is upregulated upon monocytic 
and granulocytic differentiation 25. Triad1 
expression resulted in a severe reduction 
of clonogenic growth of primary murine 
bone marrow cells 25, which could be 
partially rescued by proteasome inhibitors. 
Furthermore, the interaction with the E2 
conjugating enzyme UbcH7 was essential 
for the observed Triad1 effect. In this report, 
we show that the C-terminal RING finger 
of Triad1 interacts specifically with the zinc 
fingers of Gfi1 (Figure 3). Strikingly, we 
found that Triad1 inhibits the ubiquitination 
of Gfi1 (Figure 4). This indicates that Triad1 
does not function as an E3 ligase for Gfi1 
and that other, currently unknown, E3 ligases 
are responsible for Gfi1 ubiquitination and 
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Figure 6, Triad1 regulates Gfi1 stability 
A. GFP, or GFP-Gfi1 was transfected with different amounts of Triad1 in HEK293 cells. 24 hours 
after transfection the GFP-Gfi1 protein levels per cell were measured by flow cytometer. The MFI of 
transfected cells without Triad1 was set at 100%. The GFP-Gfi1 protein levels increased when Triad1 
was co-expressed, while Triad1 co-expression had no effect on the x-mean of GFP transfected cells. 
B. HEK293 cells were transfected with Flag-Gfi1 with or without Triad1 as indicated. 36 hours after 
transfection cells were treated with 50 µg/ml cycloheximide for indicated time points. Total cell lysates 
were analyzed by Western blotting followed by α-Flag staining. Gfi1 stability increased severely upon 
proteasome inhibition or after Triad1 co-expression. This indicates that Triad1 stabilizes the Gfi1 
protein.   
subsequent proteasomal degradation. Triad1 
may inhibit the ubiquitination of Gfi1 by 
ubiquitinating these Gfi1 E3 ligases. Such 
a mechanism was recently described for 
the TRIAD E3 ligase Hoil-1 36 that interacts 
with SOCS6. Hoil-1 stabilizes SOCS6 
protein by mediating the ubiquitination and 
degradation of SOCS6 associated proteins 
37. These associated proteins are normally 
responsible for the degradation of SOCS6. 
Our results show that the Triad1 H158A 
point mutant, which has lost its ability to 
bind with UbcH7 25, or wild type Triad1 in 
the presence of proteasome inhibitors could 
still inhibit the ubiquitination of Gfi1 (Figure 
4b). Together, these data strongly suggest 
that Triad1 inhibits the ubiquitination of 
Gfi1 independent of its E3 ligase activity. A 
model in which an E3 ligase inhibits protein 
ubiquitination independent of its ligase 
activity was recently described for the Von 
Hippel-Lindau E3 protein (pVHL). The 
pVHL ligase as well as a mutant lacking E3 
ligase activity inhibited the ubiquitination 
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of the tumor supressor p53 by disturbing 
the interaction between the ubiquitin ligases 
MDM2 and p53 38. As indicated above, 
Triad1 inhibits Gfi1 ubiquitination in the 
presence of proteasome inhibitors and does 
not require UbcH7 to do this. This suggests 
that Triad1 competes for Gfi1 binding with 
other ubiquitin ligases that do mark Gfi1 for 
ubiquitination and subsequent proteasomal 
degradation. It also indicates that E3 
ligases feature more functions than solely 
ubiquitinating proteins. 
Recently, it was show that Atx-1 also influences 
Gfi1 protein stability in neuronal cells 21. In 
contrast to Triad1, Atx-1 destabilized Gfi1 by 
enhancing its degradation via the proteasome. 
Atx-1 has no reported E3 ligase activity and 
is like Triad1 capable of influencing the 
ubiquitin-proteasome mediated degradation 
of Gfi1 proteins. While Triad1 inhibits the 
degradation of Gfi1, Ataxin-1 can enhance 
its degradation. 
Gfi1 protein levels are mainly regulated 
by the ubiquitin proteasome route during 
myelopoiesis. Gfi1 is degraded in granulocytes 
by the 26S proteasome. However, in CD14+ 
monocytes it is more stable due to diminished 
degradation  resulting in an accumulation 
of Gfi1 protein levels 20. Whether Triad1 is 
a crucial factor in this process is currently 
unknown. Triad1 protein levels are induced 
during terminal monocytic differentiation 25. 
Thus, Triad1 may inhibit the ubiquitination 
of Gfi1 in mature monocytes, which could 
result in the accumulation of Gfi1 protein 
levels. However, in granulocytes Triad1 is 
also highly expressed although Gfi1 protein 
levels are low. A possible reason why 
Triad1 cannot protect Gfi1 for degradation 
in mature granulocytes is the fact that the 
proteins may not colocalize. Triad1 localizes 
to specific sub-nuclear DAPI dull-regions 
(euchromatin) in the nucleus of granulocytes 
25. Recent studies showed that the paralogue 
of Gfi1, Gfi1B localizes to heterochromatin 
39. If Gfi1 localizes to the same compartment 
as Gfi1B this implies that Triad1 and 
Gfi1 are located in different sub-cellular 
structures in mature granulocytes which may 
hamper the inhibitory effects of Triad1 on 
Gfi1 ubiquitination. Recent studies showed 
that Atx-1 enhances Gfi1 ubiquitination. 
Upon granulocytic differentiation Atx-1 
levels are induced 40. We found that Atx-1 
mRNA expression levels are 4-fold higher 
in granulocytes compared to monocytes 
(supplementary figure 2). Thus, higher 
Atx1 expression in granulocytes might 
overcome Triad1-mediated inhibition of Gfi1 
ubiquitination, while Triad1 can stabilize 
Gfi1 in monocytes due to lower Atx-1 
expression.   
In this report we have described that the 
ubiquitin E3 ligase Triad1 can stabilize Gfi1, 
which results in an accumulation of Gfi1 
protein levels. This suggests that Triad1 is an 
important post-transcriptional regulator of 
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Supplementary Figure 2, 
Relative Ataxin-1 mRNA  expression in primary 
monocytes and granulocytes. Ataxin-1 is 4 fold 
higher expressed in granulocytes compared to 
monocytes. Ataxin-1 expression was measured 
using a pre-designed taqman gene expression 
assay and were GAPDH normalised. 3 paired 
samples of healthy volunteers were measured.   
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the transcriptional repressor Gfi1 and in this 
way may regulate indirectly Gfi1 function. 
Because Triad1 and Gfi1 are not only 
expressed in the hematopoietic compartment 
these effects may also play a role in the 
nervous system 14;21, lung development 41;42, 
intestinal cells 16. To better understand how 
Triad1 and Ataxin-1 affect the ubiquitination 
and protein stability of Gfi1 it will be 
important to identify the ubiquitin E3 
ligase(s) that mark Gfi1 for proteasomal 
degradation. 
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Diminished proteasomal degradation results in 
accumulation of Gfi1 protein levels in monocytes
Abstract
Gfi1 is a transcriptional repressor essential during myeloid differentiation. Gfi1-/- mice 
exhibit a block in myeloid differentiation resulting in the accumulation of an immature 
myelo-monocytic cell population and the complete absence of mature neutrophils. Even 
though mRNA levels of Gfi1 appear to be very low in monocytes, Gfi1 might play a role 
in the monocytic lineage as Gfi1-/- mice exhibit diminished monocyte-derived dendritic 
cells and disturbed cytokine production by macrophages in response to LPS. We show 
here that Gfi1 protein levels are mainly regulated by the ubiquitin-proteasome system. 
Upon forced monocytic differentiation of U937 cells Gfi1 mRNA levels dropped but 
protein levels increased due to diminished proteasomal turnover. Similarly, Gfi1 mRNA 
levels are low in primary monocytes while the protein is clearly detectable. Conversely, 
Gfi1 mRNA levels are high in granulocytes but the protein is swiftly degraded by the 
proteasome in these cells. Chromatin immunoprecipitation experiments showed that 
Gfi1 binds to the promoter of several granulocytic specific genes in primary monocytes, 
including C/EBPα, neutrophil elastase and Gfi1 itself. The binding of the repressor 
Gfi1 to these promoters correlated with low expression of these genes in monocytes 
compared to granulocytes. Our data fit a model in which Gfi1 protein levels are induced 
in primary monocytes, due to diminished proteasomal degradation, to repress genes 
that play a role in granulocytic differentiation. 
Introduction
The generation of mature myeloid cells from 
hematopoietic stem cells (HSC) is a tightly 
regulated process. HSC may differentiate 
in common myeloid progenitors (CMP) 
that in turn differentiate towards common 
granulocyte/monocyte progenitor cells 
(GMP). These latter cells may differentiate 
into mature, functional myeloid blood 
cells. Different regulatory mechanisms are 
responsible for maintaining the correct levels 
of mature blood cells. Lineage determining 
factors stimulate specific transcription 
factors that direct progenitors cells towards 
a specific cell type, while simultaneously 
they may actively suppress alternative 
lineage programs. In myelopoiesis, several 
transcriptional regulators have been found 
to play an essential role including PU.1 1,2, 
C/EBPα 3 and C/EBPε 4. 
Recently, the transcription factor Growth 
factor independence 1 (Gfi1) has also been 
shown to play an essential role during 
myelopoiesis. Gfi1-/- knockout mice are 
severely neutropenic and exhibit a block 
in myeloid differentiation resulting in the 
accumulation of an atypical immature 
myeloid cell population 5,6. This is in line 
with reported heterozygous GFI1 missense 
mutations in patients suffering from 
hereditary neutropenia 7. Gfi1 may function 
as a transcriptional repressor and regulates 
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genes that play a role in cell cycle regulation 
like E2F5 and cMyc and in granulopoiesis 
like C/EBPα, C/EBPε and neutrophil elastase 
8. Furthermore, Gfi1 can repress its own 
promoter and the promoter of its paralogue 
Gfi1B 9,10. 
Gfi1 was originally identified as a proviral 
insertion site resulting in IL2 independent 
growth of T-cells 11. Overexpressed Gfi1 
acts as a dominant oncogene and cooperates 
with known oncoproteins like Myc and 
Pim-1 in lymphoma development 12,13. In 
normal hematopoiesis, Gfi1 is essential for 
T-cell development and for self-renewal and 
long term reconstituting potential of HSC 
5;14,15. Recently, Gfi1 was also shown to be 
important for lymphocyte-derived dendritic 
cell (DC) development 16. 
Whether Gfi1 plays a role in the monocytic 
lineage is under debate. Although the 
immature atypical myeloid population in 
Gfi1-/- mice exhibits both granulocytic 
and monocytic characteristics, it has been 
speculated that Gfi1 is not relevant in 
monocytic differentiation. This is mainly 
based on low Gfi1 mRNA expression patterns 
in the monocytic lineage as measured by 
RT-PCR or indirectly by measuring Gfi1 
promoter activity using GFP:Gfi1 knock-in 
mice. During granulocytic and monocytic 
differentiation Gfi1 mRNA expression is 
strongly induced at the GMP stage and 
expression is detected in mature granulocytes, 
while low expression is found in monocytic/
macrophage cells 6,17,15. However, recent 
studies suggest a role for Gfi1 in monocyte-
derived DC differentiation. Gfi1-/- progenitor 
cells fail to differentiate into DCs in in vitro 
assays 16. In addition, Gfi1-/- macrophages 
exhibit aberrant cytokine expression profiles 
and are hyperresponsive to LPS 18,6. These 
data suggest that Gfi1 may be important in 
the monocytic lineage. To clarify this issue, 
we analyzed Gfi1 protein expression and 
found that Gfi1 is very efficiently targeted 
for ubiquitin-proteasomal degradation in 
immature myeloid cells and that diminished 
proteasomal degradation in primary 
monocytes results in significant Gfi1 protein 
levels, despite low RNA levels. 
Materials and Methods
Cell culture and selection
U937, NB4 and HL60 cells were grown in 
RPMI 1640 medium (Life Technologies) 
supplemented with 10% fetal calf serum 
(Invitrogen), 50 I.U./ml penicillin and 50 
µg/ml streptomycin (ICN). Cells were 
differentiated for indicated time points 
with 10-6 M ATRA (all-trans retinoic acid) 
(Sigma) or 10 ng/ml PMA (Phorbol 12-
myristate 13-acetate )(Sigma). The 26S 
proteasome activity was inhibited overnight 
with 5 µM MG132. For Gfi1 half-life 
determination, cycloheximide was used at 
a concentration of 25 µg/ml. COS-1 and 
HEK293 cells were grown in IMDM (Life 
Technologies) supplemented as described 
above. All cells were grown at 37°C at 
5% CO2. Differentiation of U937 cells 
was assessed by the expression of CD11c 
(Immunotech, Marseille, France). Apoptosis 
was determined by flow cytometer using 
AnnexinV (Molecular Probes, Eugene, OR) 
and propidium iodide staining, respectively. 
Primary cells were obtained from healthy 
volunteers. Human monocytes, used for 
RNA isolation, were stained with CD14 
antibodies and isolated by FACS sorting and 
granulocytes were FACS sorted based on 
CD45 positivity and scatter characteristics. 
For Chromatin Immunoprecipitation (ChIP), 
degradation assays and Western blot analysis 
monocytes were MACS sorted using CD14 
magnetic beads and  granulocytes were 
isolated using Ficoll 1077 density gradient 
centrifugation followed by erythrocyte lysis 
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using NH4Cl. Cell purities were confirmed 
to be more than 95% by flow cytometric 
analysis. 
Plasmids
Gfi1 expression plasmids containing FLAG-
Gfi1, FLAG-Gfi1∆Zn, FLAG-Gfi1-Zn (Dr. 
Osawa 19) Gfi-GFP and Gfi1-FLAG (Dr. T. 
Möröy) and Gfi1 wild type and Gfi1 A382S 
and  K403R point mutants (Dr. M. Horwitz 7) 
were used as indicated. Expression plasmids 
for His-tagged ubiquitin (His-Ub) and 
FLAG-tagged ubiquitin (FLAG-Ub) were 
obtained from Dr. M. Scheffner.    
Quantitative PCR
RNA from cell lines was isolated at different 
time points during differentiation using 
RNA-bee (ISO-TEX Diagnostics). At all 
time points cell death was less than 10% 
as assessed by Annexin V and propidium 
positivity measured by flow cytometer. RNA 
from primary cells was isolated using the mini 
RNA isolation II kit (Zymo research). cDNA 
was generated in a reverse transcription 
reaction as previously described 20. Gfi1 
mRNA levels were measured with real-time 
quantitative PCR using the primers: Gfi1-
F 5’-GAGCCTGGAGCAGCACAAAG-
3’ and Gfi1-R 5’-GTGGATGACCTCTT 
GAAGCTCTTC-3’. Ela2 mRNA 
levels were measured with real-time 
quantitative PCR using primers: Ela2-F 5’-
CACTGCGTGGCGAATGTAAA-3’ and 
Ela2-R 5’-CGACGTGCCGCTTGTGG-3’. 
C/EBPα mRNA expression was measured 
using pre-developed TaqMan Gene 
Expression Assay no. Hs00269972_s1 
(Applied Biosystems).  PCRs were performed 
in universal master mix using SYBR-green 
(Roche). Conditions were as follows: 10 
min. 95°C followed by 45 cycles of 15 sec. 
95°C and 1 min. 62°C. For normalization ß-
actin or 18S rRNA was used as a reference 
gene (Applied Biosystems)21. 
Co-immunoprecipitation and 
Immunoblotting assays
For co-immunoprecipitations, COS-1 cells 
were grown in 10-cm culture dishes and 
transiently transfected with FLAG-Ub and 
GFP-Gfi1 using the calcium phosphate 
precipitation method. Cells were lysed 36 
hours after transfection in RIPA buffer with 
Complete protease inhibitors (Roche) and 
lysates were incubated with GFP-antibody 
and Prot-A beads for 4 hours at 4°C with 
gentle rotation. Beads were washed 5 times 
with RIPA. Bound proteins were eluted in 
loading buffer by heating for 5 min at 95°C. 
The immunoprecipitates were resolved by 
SDS-page, transferred to PVDF membranes, 
blocked with 2% ELK (Campina) and 0.5% 
BSA (Sigma) and immunoblotted with an α-
FLAG antibody (M2, Sigma). Proteins were 
visualized using ECL (BIO-RAD). Protein 
levels on Western blot were quantified 
using ImageJ software (NIH, Bethesda). 
For detection of endogenous Gfi1, C/EBPα, 
C/EBPε, Actin, Lamin and Ubiquitin 
Western blots were stained with α-Gfi1 (N-
20, Santa Cruz Biotechnology), C/EBPα 
(Santa Cruz Biotechnology), C/EBPε (Santa 
Cruz Biotechnology), α-Actin (Sigma), α-
Lamin (Becton Dickinson) and α-Ubiquitin 
(6C1, Sigma) antibodies, respectively. For 
preparation of lysates, granulocytes were 
treated with 10% trichloroacetic acid (Sigma) 
for 30 minutes at 4°C, followed by lysis in 
50 µl 2 times loadingbuffer (including 5 µl 1 
M Tris) and heated at 95°C for 5 minutes 22. 
In vitro degradation assay
Hematopoietic cell lines, granulocytes and 
MACS sorted CD14+ cells were lysed in 
RIPA buffer supplemented with Complete 
protease inhibitor mix (Roche). Cell 
lysates taken at different time points during 
differentiation were normalized for equal 
protein content using the Bradford protein 
quantification assay. 2  µl of 35S methionine 
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labeled in vitro translated Gfi1, made 
using the rabbit reticulocyte lysate TnT 
Quick Coupled Transcription/Translation 
System (Promega), was added to cell lysate 
containing 100 µg protein (BioRad protein 
quantification assay) in a total volume of 35 
µl. 100 µM MG132, 100 µM Velcade (PS341/
bortezomib) or DMSO (1µl/ml vehicle) was 
added prior to incubation at 37°C. Reactions 
were stopped at the indicated time-points by 
the addition of loading buffer and heating 
the samples for 5 min at 95°C. Samples were 
resolved by SDS-PAGE, gels were fixed, 
treated with NAMP-100 (Amersham), dried 
and exposed.
Proteasome activity assay
Proteasome activity was determined in U937 
cell lysates after PMA-induced differentiation. 
67.5 µg protein (concentration determined 
using BioRad protein quantification assay) 
was incubated with the proteasome substrate 
Suc-Leu-Leu-Val-Tyr-AMC (Boston 
Biochem) for 2 hrs at 37°C as described 
23,21.  AMC liberated from the substrate by 
proteasome activity was determined by 
measuring fluorescence (Fluorstar, BMG, 
Isogen Life Sciences).
In vivo ubiquitination assay 
COS-1 cells grown in 10-cm dishes were 
transfected with 10 μg of His-Ub and 10 μg 
of human Gfi1-FLAG expression constructs, 
using calcium phosphate precipitation. 36 
hours after transfection, cells from each dish 
were collected in two aliquots. One aliquot 
(10%) was used in Western blotting to assess 
the expression of transfected proteins, while 
the remaining cells (90%) were used for 
purification of His6-tagged proteins by His-
select (NTA) beads (Sigma). The cell pellet 
was lysed in buffer A (6 M guanidinium-
HCl, 0.1 M Na2HPO4, 10 mM imidazole, 10 
mM β-mercaptoethanol, Complete protease 
inhibitor (Roche)) and incubated with His-
Select beads (Sigma) for 4 h at 4°C. The 
beads were washed 2 times with buffer A, 
2 times with a mixture of 4 parts buffer A, 
and 1 part of buffer B (50mM Tris pH 6.8, 
20 mM imidazole) and 2 times with buffer 
B. Bound proteins were eluted with 200 mM 
imidazole in loading buffer. Ub-conjugated 
Gfi1 was visualized on Western blot using an 
α-FLAG antibody.
Electrophoretic Mobility-Shift Assay 
(EMSAs)
FLAG-Gfi1 was synthesized in vitro by using 
the TnT SP6 transcription/translation system 
(Promega). Double-stranded oligonucleotides 
(5’ CCACATAAATCACTGCCTATCCTGTG-
3’) were 32P end-labeled using T4 
polynucleotide kinase. Binding reactions (10 
µl vol) contained labeled DNA probes in 10 
mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM 
MgCl2, 1 mM ZnSO4, 0.5 mM DTT, 0.5 mM 
EDTA, 10% glycerol, 0.05% Nonidet P-40, 
and 1 µg of poly(dI-dC), with 1 µl of the 
synthesized protein and were performed for 
20 min at room temperature. 
Chromatin immunoprecipitation 
Chromatin immunoprecipitations (ChIP) 
were executed as described previously24. 
Cells were cross-linked for 30 min at 37°C 
by adding formaldehyde (1%) to the culture 
medium. Cross-linking was stopped by the 
addition of glycine to a final concentration 
of 125 mM. Cells were washed with cold 
phosphate-buffered saline, buffer B (10 mM 
EDTA, 0.5 mM EGTA, 0.25% Triton X-100, 
20 mM HEPES [pH 7.6]), buffer C (1 mM 
EDTA, 0.5 mM EGTA, 0.15 M NaCl, 50 
mM HEPES [pH 7.6] ) and incubated in buf-
fer D (0.15% SDS, 1% Triton X-100, 0.15 
M NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 
mM HEPES [pH 7.6] and complete prote-
ase inhibitor (Roche)) at 33*106 cells/ml. 
Chromatin was sonicated using the Biorup-
tor (Cosmo Bio, Tokyo, Japan), high, for 15 
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min with 0.5 min interval. Insoluble material 
was removed by centrifugation at 13k at 4°C 
for 15 min. 100 µl of chromatin was incu-
bated with 15 µl protein G sepharose beads 
(Amersham), 0.1% BSA, 36 µl 5* buffer D, 
complete protease inhibitors (Roche) and 10 
µl antibody and rocked at 4°C for 16 hours. 
The beads were harvested by centrifugation 
and washed twice with wash-buffer 1 (0.1% 
SDS, 0.1% NaDOC, 1% Triton X-100, 0.15 
M NaCl, 1 mM EDTA, 0.5 mM EGTA and 
20 mM HEPES [pH 7.6]), once with wash-
buffer 2 (0.1% SDS, 0.1% NaDOC, 1% Tri-
ton X-100, 0.5 M NaCl, 1 mM EDTA, 0.5 
mM EGTA and 20 mM HEPES [pH 7.6]), 
once with wash-buffer 3 (0.25 M LiCl, 0.5% 
NaDOC, 0.5% NP-40, 1 mM EDTA, 0.5 mM 
EGTA and 20 mM HEPES [pH 7.6]), and 
twice with wash-buffer 4 (1 mM EDTA, 0.5 
mM EGTA and 20 mM HEPES [pH 7.6]). 
Chromatin antibody complexes were eluted 
from the G Sepharose beads by addition of 
1% SDS and 0.1 M NaHCO3 to the pellet and 
incubated for 20 min at room temperature. 
Cross-linking was reversed by addition of 
NaCl (0.44 M final concentration) and incu-
bation of the eluted samples for 4 hours at 
65°C. DNA was recovered by a phenol-chlo-
roform-isoamylalcohol extraction followed 
by a chloroform-isoamylalcohol extraction 
and precipitation with sodium acetate (pH 
5.2) and ethanol. Precipitated DNA was sub-
ject to quantitative PCR. Total DNA from 
the IP input was included in the PCR and all 
PCR signals were corrected for this. Quanti-
tative PCR following ChIP was done using 
SYBR green PCR (Applied Biosystems). 
Genomic primer sequences for the Gfi1 
target genes were: Gfi1-F2 5’-TTCTCTC-
GCTGCGGAGTCT-3’, Gfi1-R2 5’-AG-
GCACTAGAAATGACTTGA AAGAAAA-
3’, C/EBPα-F 5’-AGATCAGAGCTAG-
GAGACGCAGA-3’, C/EBPα-R 5’-
ATTCTCTTTCAAAGCCAGAACCA-3’, 
ELA2-F2 5’-CAAGTCCCTCAGGTC-
TAGGT TTG -3’, ELA2-R2 5’-GGGCTG-
GTCTCGACGTTTT-3’. Quantitave PCR 
for the ALBUMIN promoter was performed 
using probe ALB-VIC 5’-TGCTGAAA-
CATTCACCTTCCAT GCAGA-3’ with 
the primers ALB-F 5’-TGAAACATAC-
GTTCCCAAAGAGTTT-3’, ALB-R 5’-
CTCTCCTTCTCAGAAAGTGTGCATAT-
3’.  
Results
Gfi1 protein levels increase during 
monocytic differentiation by post-transcriptional 
mechanisms
Although Gfi1 may play a role in the 
monocytic lineage, the mRNA expression 
is very low in macrophages. To study this 
issue in more detail, we analyzed Gfi1 
mRNA and protein expression during 
forced differentiation of U937 and HL60 
cells. During PMA induced monocytic 
differentiation of these cells Gfi1 mRNA 
levels dropped as measured with quantitative 
RT-PCR (Figure 1A). Also during ATRA 
induced granulocytic differentiation of HL60 
cells Gfi1 mRNA levels decreased, however 
to a lesser extent as was observed during 
PMA induced differentiation. Remarkably, 
upon terminal monocytic differentiation of 
PMA treated U937 cells Gfi1 protein levels 
increased (Figure 1B). To determine the 
length of time required for PMA to induce 
Gfi1 and monocytic differentiation, we 
exposed U937 cells for various time intervals 
to PMA. This showed that a pulse with PMA 
for only four hours already resulted in Gfi1 
protein induction after 72 hours of culturing. 
The Gfi1 protein induction correlated with 
the extent of differentiation as determined by 
CD11c staining (Figure 1C). 
To compare Gfi1 proteins levels during 
monocytic and granulocytic differentiation 
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we analyzed Gfi1 expression in HL60 cells 
that can be forced along the monocytic and 
granulocytic lineage with respectively, PMA 
and ATRA. As in U937 cells, upon monocytic 
differentiation of HL60 cells a clear Gfi1 
protein induction was observed (Figure 1D). 
During ATRA forced differentiation Gfi1 
was not detectable.  However, when 5 times 
more protein was used in Western blotting a 
modest increase in Gfi1 protein levels became 
detectable upon granulocytic differentiation 
of HL60 cells (Figure 1E). This indicates that 
the Gfi1 protein induction is most prominent 
during monocytic differentiation. The 
observed differences between the expression 
of Gfi1 mRNA and protein levels suggests 
that Gfi1 protein expression is regulated at 
the post-transcriptional level during myeloid 
cell differentiation.  
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Figure 1. Gfi1 mRNA levels decrease, 
Gfi1 protein levels increase during 
monocytic differentiation. 
A, Gfi1 quantitative RT-PCR was 
performed on RNA samples of U93 
and HL60 cells during PMA or ATRA 
induced differentiation (n=3). Gfi1 
expression levels in untreated HL60 and 
U93 cells were set at 100% and values 
were normalized for β-actin expression. 
B, Cell lysates of PMA differentiated 
U93 cells taken at indicated time points 
were immunoblotted and stained with 
an α-Gfi1 antibody (N20, Santa Cruz 
Biotechnology). C, U93 cells were 
incubated with PMA. After the indicated 
pulse times cells were washed and 
harvested 2 hours after the beginning of 
the experiment. Numbers below the blot 
indicate the x-mean of CD11c expression. 
D, Gfi1 levels in HL60 cell lysates 
taken after 24, 48, 2 hours treatment 
with ATRA or PMA were compared 
with untreated cells showing that Gfi1 
is strongly induced upon monocytic 
differentiation. Lamin staining shows 
equal loading. E,  A 5 times more protein 
input of lysates from ATRA treated HL60 
cells resulted in the detection of a modest 
increase in Gfi1 protein levels although 
the levels are significantly lower 
compared to monocytic differentiation 
(see panel D).
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Gfi1 is targeted for degradation by the 
ubiquitin-proteasome pathway 
The ubiquitin-proteasome system is an 
important system through which the half-life 
of various proteins is regulated, including 
transcription factors 25. To study whether Gfi1 
is targeted for degradation by the ubiquitin-
proteasome system we transfected HEK293 
cells with a Gfi1-GFP expression construct. 
The mean fluorescence of these cells is 
a measure for the amount of GFP tagged 
Gfi1. FACS analysis of cells treated with 
the proteasome inhibitor MG132 resulted in 
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Figure 2. Gfi1 is degraded by the ubiquitin-proteasome system.
A, HEK293 cells were split after transfection with Gfi1-GFP and overnight grown with or without 
MG132. Cells were measured with the FACS and the mean fluorescence index (MFI) of untreated cells 
was set at 100%. After proteasome inhibition (5 µM MG132) a clear increase of Gfi1-GFP levels per 
cell was observed indicated as MFI. B, COS-1 cells were transfected with FLAG-Ub, Gfi1-GFP or with 
empty vector, followed by immunoprecipitation with an α-GFP antibody. Subsequent immunoblotting 
with an α-FLAG antibody results in the detection of a high molecular smear of proteins [(Ub)n] 
indicating that Gfi1 is present in ubiquitinated complexes, or is ubiquitinated itself. (-->) Indicates the 
height of unmodified Gfi1-GFP. Lower panel with α-GFP staining of whole cell extract (WCE) shows 
a clear distinct Gfi1-GFP band. C, COS-1 cells were transfected with His-Ub and FLAG-Gfi1 and 
MG123 was added as indicated. Ubiquitinated proteins were selected with His-select beads, under 
denaturing conditions, and immunoblotted for α-FLAG. Clearly visible are the ubiquitinated forms 
of Gfi1 [(Gfi1-Ub)n], especially after proteasome inhibition. Whole cell lysate was stained for FLAG 
confirming equal loading. (*) indicates a-specific binding of unmodified Gfi1 to His-select beads.
a 4-fold increase in the mean fluorescence 
showing an accumulation of Gfi1-GFP 
protein levels compared to untreated cells 
(Figure 2A). As proteasome inhibition of cells 
transfected with GFP alone did not result in 
an increase in fluorescence (data not shown), 
these data suggest that Gfi1 protein levels are 
regulated by 26S proteasome activity. 
Proteins destined for proteasomal 
degradation are usually tagged by covalently 
linked poly-ubiquitin chains. To test whether 
Gfi1 can be ubiquitinated, FLAG-Ub was 
co-transfected with Gfi1-GFP in COS-1 
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cells, followed by GFP immunoprecipitation 
and FLAG staining. This revealed a smear 
of ubiquitinated proteins representing 
ubiquitinated Gfi1 species or Gfi1 in a complex 
with other ubiquitinated proteins (Figure 2B). 
In addition, we studied the ubiquitination of 
Gfi1 in an in vivo ubiquitination experiment. 
COS-1 cells were transfected with Gfi1-
FLAG and His-tagged ubiquitin (Ub-His). 
Under denaturing conditions, proteins with 
covalently linked ubiquitin were isolated 
using His-select beads. Subsequent staining 
for Gfi1 in Western blot analysis detected 
a protein smear consisting of (poly-) 
ubiquitinated forms of Gfi1. An increase 
of ubiquitinated Gfi1 forms was observed 
after proteasome inhibition with MG132, 
indicating that ubiquitinated Gfi1 is targeted 
for degradation by the 26S proteasome. The 
latter finding was confirmed by a higher total 
amount of Gfi1 in the whole cell lysate after 
proteasome inhibition (Figure 2C). Similar 
result were obtained with Gfi1-FLAG in 
HEK293 cells (data not shown). 
Gfi1 is degraded in U937 cells in a 
proteasome-dependent manner
To investigate whether proteasomal 
degradation of Gfi1 could explain the 
lower Gfi1 protein levels in immature 
hematopoietic cells despite high mRNA 
levels, we developed an in vitro degradation 
assay. In this assay the stability of a fixed 
amount of 35S labeled in vitro translated 
Gfi1 was studied by incubation for different 
time points with cell lysates derived from 
hematopoietic cell lines 26,27. First, the correct 
folding of Gfi1 was verified by testing the 
DNA-binding capacity of in vitro translated 
Gfi1 in an electrophoretic mobility shift assay 
using a Gfi1 binding consensus sequence 8 as 
probe (Figure 3A). Gfi1 stability was next 
assayed using lysates of undifferentiated 
U937 cells. After 5 minutes most of the Gfi1 
was degraded suggesting that Gfi1 has a short 
half-life in immature blood cells. To show 
that the observed degradation was caused by 
enzymatic factors present in U937 lysate and 
not by factors from the rabbit reticulocyte 
lysate, the same assay was performed with 
U937 extracts heated at 100°C for 5 minutes. 
In these lysates Gfi1 was not degraded, 
indicating that the degradation of Gfi1 is 
dependent on protein activity present in 
U937 cells. When degradation experiments 
were performed in the presence of the 
proteasome inhibitors MG132 or Velcade the 
degradation of Gfi1 was almost completely 
blocked. This showed that the transcriptional 
repressor Gfi1 is rapidly degraded by the 26S 
proteasome in lysates from hematopoietic 
cell lines (Figure 3B). 
The Gfi1 protein consists of a N-terminal 
SNAG repressor domain followed by a 
central domain with unknown function and a 
C-terminal DNA binding domain containing 
6 zinc fingers. Computer based prediction 
(https://emb1.bcc.univie.ac.at/toolbox/
pestfind/pestfind-analysis-webtool.htm) 
identified 2 putative PEST regions in Gfi1, 
located in the N-terminal non-zinc finger part 
at amino acid positions 54-66 and 90-102 
(Figure 3C). PEST domains are associated 
with ubiquitin proteasome mediated 
turnover and are found in several short-lived 
transcription factors 28. To determine the 
involvement of the putative PEST domains 
in Gfi1 degradation, two independent Gfi1 
constructs containing either the zinc fingers 
(ZN Gfi1) or the SNAG and non-zinc 
finger domain (∆ZN Gfi1) were used in the 
degradation assay. This showed that the zinc 
finger part of Gfi1 is degraded at a similar 
rate as the full-length protein, while the non-
zinc finger part of Gfi1 was not affected by 
the ubiquitin-proteasome system (Figure 
3D). This suggests that the proteasomal 
degradation of Gfi1 takes place at the zinc 
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Figure 3. Gfi1 is degraded by the 26S proteasome in hematopoietic cells. 
A, The DNA binding activity of in vitro translated Gfi1 was checked using EMSA after incubation with 
32P labeled oligos containing a consensus Gfi1 binding site. A clear band shift (-->) was only found in 
the lanes containing 1µl or 3µl of Gfi1 programmed reticulocyte lysate. Unprogrammed reticulocyte 
lysate was used as negative control (NC). B, An in vitro degradation assay using 35S labeled in vitro 
translated Gfi1 incubated with U937 lysates at 37°C in the presence of vehicle, or the proteasome 
inhibitors MG132 or Velcade or denatured cell lysate (5 min 100°C). At the indicated time points, 
samples were inactivated in loading buffer and resolved by SDS-page. C, The localization of two 
putative PEST domains in Homo sapiens Gfi1 are underlined. D, 35S labeled in vitro translated full 
length Gfi1, the zinc finger domain of Gfi1 (ZN Gfi1) and the non-zinc finger domain of Gfi1 (∆ZN Gfi1) 
were used in an in vitro degradation assay as described in (B). 
finger domain of Gfi1 and is independent of 
the putative PEST domains.
 
Gfi1 degradation is diminished upon 
monocytic differentiation of U937 cells
To examine whether the induction of Gfi1 
protein levels during myeloid differentiation 
could be explained by a difference in Gfi1 
turnover, the degradation of Gfi1 was 
examined with the in vitro degradation assay 
using lysates from 0, 24 and 72 hours PMA 
stimulated U937 cells. As is shown in Figure 
4A, the turnover rate of Gfi1 was clearly 
diminished after induction of monocytic 
differentiation of U937 cells with PMA. 
This indicates that the degradation of Gfi1 
depends on the differentiation status of the 
hematopoietic cell. To investigate whether 
the observed increase in half-life of Gfi1 
was generally seen during differentiation 
and not a differentiation independent effect 
of PMA, U937 cells were also differentiated 
towards the monocytic lineage with ATRA. 
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Figure 4. Proteasomal Gfi1 degradation is diminished during differentiation.
A, U93 cells were differentiated with PMA and collected at the indicated time points. Cell lysates were 
normalized using Bradford protein quantification assay and used in an in vitro degradation assay with 
35S labeled in vitro translated full length Gfi1. B, Differentiated and undifferentiated U93 cells were 
overnight treated with MG132. Endogenous Gfi1, ubiquitin and lamin levels were quantified by Western 
blot. Note the clear increase in Gfi1 levels in undifferentiated U937 cells after proteasome inhibition. 
Lamin staining was used as a control for equal loading. Ubiquitin staining was performed to confirm 
the global effectiveness of MG132. C, Also in undifferentiated HL60 cells proteasome inhibition results 
in an accumulation of Gfi1 protein levels. The same controls were used as in figure 4B. D, The stability 
of  endogenous Gfi1 was studied in undiffentiated and 48 hours of PMA treated U937 cells. Cells 
were treated with 25 μg/ml cycloheximide for the indicated times. Lamin staining was used to check 
for equal loading and the density of Gfi1 bands was quantified using ImageJ software. The relative 
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protein amount was plotted against the time of cycloheximide treatment. Triangles indicate the relative 
amount of Gfi1 in untreated cells and squares indicate the relative amount of Gfi1 in 48 hours PMA 
differentiated cells. E, 26S proteasome function in lysates from differentiated U93 cells was analyzed 
by measuring the cleavage of Suc-Leu-Leu-Val-Tyr-AMC in the lysate for 2 hours at 3°C. F, U93 cell 
lysates were immunoblotted and stained for ubiquitin. Cell lysates treated over night with MG132 were 
used as a positive control for decreased proteasome activity. Equal loading was confirmed with actin 
staining. G, In vitro translated wild type Gfi1 (WT), and the Gfi1 point mutants A382S and K403R were 
used in an in vitro degradation assay with 2 hours ATRA treated and untreated U93 cell lysates for 
indicated time points. Cell lysates were normalized using Biorad protein quantification assay.
Lysates from U937 cells induced with ATRA 
showed a similar prolonged half-life of Gfi1, 
comparable with PMA stimulated cells (data 
not shown). 
The observed stabilization upon 
differentiation was further studied by 
analyzing the proteasomal turnover of 
endogenous Gfi1 protein levels in U937 cells. 
Gfi1 protein levels could only be detected 
upon proteasome inhibition of immature 
U937 cells. This indicates that Gfi1 is 
degraded in a proteasome-dependent manner 
(Figure 4B). The same result was observed in 
immature HL60 cells (Figure 4C). However, 
in U937 cells treated for 72 hours with PMA, 
Gfi1 levels were not significantly induced 
after MG132 treatment, while an α-ubiquitin 
staining showed that the 26S proteasome was 
successfully inhibited. This indicates that in 
differentiated U937 cells endogenous Gfi1 
is no longer subject to efficient proteasomal 
degradation. Subsequently, the half-life of 
endogenous Gfi1 protein was determined in 
undifferentiated and 48 hours PMA treated 
U937 cells using the protein translation 
inhibitor cycloheximide. In immature U937 
cells Gfi1 has a half-life shorter than 1 hour, 
while in differentiated cells the half-life is 
more than 4 hours (after 4 hours 80% of the 
original amount of Gfi1 was still present, 
Figure 4D). Together these data confirm the 
result obtained with the in vitro degradation 
assays and also explain the observed 
upregulation of Gfi1 protein levels during 
differentiation, in spite of decreasing mRNA 
levels. We conclude that Gfi1 is rapidly 
degraded by the proteasome in immature 
myeloid cells, whereas in mature monocytic 
cells Gfi1 degradation is diminished. 
The decreased turnover of Gfi1 might be due 
to decreased overall proteasomal activity 
during myeloid differentiation. To investigate 
this, we measured the chymotrypsin activity 
of the 26S proteasome in U937 cell lysates 
by measuring the cleavage of the 26S 
proteasome substrate Suc-Leu-Leu-Val-
Tyr-AMC. The proteasomal activity did 
not decrease but rather slightly increased 
during differentiation (Figure 4E). These 
results were confirmed by ubiquitin staining 
of whole cell lysates of PMA-differentiated 
U937 cells. No significant differences in 
the total amount of high molecular mass 
ubiquitinated proteins could be detected 
between differentiated and undifferentiated 
cells, while proteasome inhibition of these 
cells resulted in a clear accumulation of 
ubiquitinated proteins (Figure 4F). Together, 
these observations show that the difference in 
Gfi1 turnover during differentiation is not due 
to overall differences in proteasomal activity, 
indicating that Gfi1 is specifically targeted 
by the ubiquitin-proteasome system. 
Two Gfi1 missense mutations have recently 
been identified in patients suffering from 
neutropenia 7. The two mutations, N382S 
and K403R, occur in the zinc fingers of Gfi1, 
the region that is targeted for degradation. 
The K403R mutation results in the loss of a 
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lysine in the zinc finger region. Since lysine 
residues are the primary targets for ubiquitin 
modification, especially the lysine mutation 
might affect the protein half-life. Therefore, 
the turnover of the two mutated Gfi1 proteins 
were compared with the wild type protein 
in an in vitro degradation assay. No clear 
differences in the degradation of normal 
and mutated Gfi1 in both undifferentiated 
and ATRA differentiated U937 cells was 
observed. This suggests that these mutations 
have no effect on the proteasomal degradation 
of Gfi1 (Figure 4G).                                     
Gfi1 is stable in mature primary monocytes 
and rapidly degraded in granulocytes 
To study the differences in Gfi1 stability 
during monocytic and granulocytic 
differentiation, lysates from bipotential HL60 
cells differentiated towards monocytes with 
PMA and towards granulocytes with ATRA 
were compared. Gfi1 was stabilized during 
both monocytic as well as granulocytic 
differentiation. However, the increase 
in stability of Gfi1 during granulocytic 
differentiation is significantly less compared 
to monocytic differentiation (Figure 5A). 
This explains the higher amount of Gfi1 
protein levels after monocytic differentiation 
compared to granulocytic differentiation 
in these cells (Figure 1C). These data also 
suggest that the observed diminished Gfi1 
degradation is playing a more important role 
during monocytic differentiation than during 
granulocytic differentiation. We tested 
whether this difference in Gfi1 turnover 
was also present in primary monocytes 
compared to granulocytes. To this end, cell 
lysates of monocytes and granulocytes were 
used in an in vitro Gfi1 degradation assay. 
Gfi1 was more stable in lysates from CD14+ 
sorted monocytes compared to granulocytes 
(Figure 5B). Gfi1 degradation in lysates from 
primary granulocytes could be inhibited by 
the addition of Velcade indicating that the 
observed degradation of Gfi1 was due to 
26S proteasomal activity (Figure 5C). In 
accordance with earlier studies 6,17,10,15 we 
found a 60-fold higher Gfi1 mRNA expression 
in granulocytes compared to monocytes 
(Figure 5D). Strikingly, at the protein level 
we could detect Gfi1 only in lysates from 
monocytes and not from granulocytes (Figure 
5E). As control, the same lysates were 
stained for C/EBPα and C/EBPε indicating 
that other nuclear transcription factors could 
be correctly detected in granulocytes. We 
conclude that due to diminished proteasomal 
degradation, Gfi1 protein levels are high 
in primary monocytes despite low mRNA 
levels.
Gfi1 may repress specific target genes in 
mature monocytes
Gfi1 is known to repress its own promoter 
9,10,16 and is present on the promoter of 
several granulocyte-specific genes 8. To study 
whether Gfi1 binds to the promoter of known 
Gfi1 target genes we performed chromatin 
immunoprecipitation (ChIP) experiments 
using primary monocytes. Of the analyzed 
genes GFI1, ELA2 and C/EBPα, all promoters 
could be immunoprecipitated with the α-Gfi1 
antibody (Figure 6A). In line with this, the 
mRNA expression of these genes was lower 
in monocytes compared with granulocytes 
(Figures 5D and 6B). Together these data 
indicate that Gfi1 is present on the promoters 
of granulocyte-specific genes in monocytes, 
suggesting that Gfi1 might function to 
repress the granulocytic phenotype in these 
cells. This hypothesis is in line with the 
observation that during monocytic (PMA) 
differentiation of HL60 cells the expression 
of the Gfi1 target genes ELA2 and C/EBPα 
are lower when compared with granulocytic 
(ATRA) differentiation (Figure 6C). This 
is also the case for Gfi1 itself (Figure 1A). 
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Figure 5. Gfi1 protein levels are high in monocytes compared to granulocytes due to decreased 
proteasomal degradation. 
A, HL60 cells were differentiated with ATRA towards granulocytes for 2 hours. PMA was used to 
stimulate HL60 cells for monocytic differentiation. Cell lysates were used in an in vitro degradation 
assay. B, Lysates of primary monocytes and granulocytes were used in an in vitro degradation assay 
with 35S labeled Gfi1. C, The Gfi1 turnover in granulocyte lysate in an in vitro degradation assay 
was depended on 26S proteasome activity. D, Quantitative Gfi1 RT-PCR was performed on RNA from 
primary monocytes and granulocytes (n=3). E, Cell lysates of isolated monocytes and granulocytes 
were immunoblotted and stained with α-Gfi1 antibody and α-actin staining was used to check for equal 
loading. α-C/EBPα and α-C/EBPε protein levels were stained as positive control for the used protein 
lysates. Cell lysates were normalized using BioRad protein quantification assay.
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Also when Gfi1 protein levels increase after 
proteasome inhibition of HL60 cells, the 
mRNA expression of ELA2, C/EBPα and 
Gfi1 are decreased (Figure 6D). The inverse 
correlation between Gfi1 protein levels and 
the expression of its target genes might 
imply an important role for the here observed 
proteasomal regulation mechanism of Gfi1 
during monocytic differentiation. 
Discussion
Transcription factors play a crucial role 
during hematopoiesis by regulating specific 
differentiation programs. Gfi1 knock 
out studies have shown that Gfi1 plays 
important roles during different stages of 
hematopoiesis. Gfi1-/- mice show a block 
in myeloid cell differentiation and lack 
neutrophils, indicating that Gfi1 is essential 
for neutrophilic differentiation.6,5. Recent 
studies also showed abnormal monocyte-
derived DCs and macrophages in Gfi1-/- mice, 
implying a role for Gfi1 in the monocytic 
lineage 16,18,6. 
We show here that Gfi1 protein levels 
are mainly regulated by the ubiquitin 
proteasome pathway during monocytic 
differentiation. The proteasomal degradation 
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Figure 6. Gfi1 is present on Gfi1 target genes 
in monocytes.
A, ChIP analysis on sonicated chromatin of 
primary monocytes was performed using a 
α-Gfi1 antibody or a goat IgG antibody as 
control (n=2). Quantitative PCR was used to 
measure the amount of immunoprecipitated 
promoter, which was compared to the control 
genomic sequence of Albumin. The percentage 
of recovery of the ChIP-ed promoters was 
plotted as the fold increase over the percentage 
of recovery of Albumin. B, The mRNA levels 
of Gfi1 regulated genes were measured using 
quantitative RT-PCR on mRNA from monocytes 
(n=5) and granulocytes (n=6). C,  ELA2 and 
C/EBPα quantitative RT-PCR was performed 
on RNA samples of HL60 cells during PMA or 
ATRA induced differentiation (n=2). ELA2 and 
C/EBPα expression levels in untreated HL60 
and U93 cells were set at 100% and values 
were normalized for β-actin expression. D, 
ELA2, C/EBPα and Gfi1 mRNA expression was 
measured using quantitative RT-PCR and were 
normalized for 18S rRNA expression. The levels 
in untreated cells (-MG132) were set at 100% 
and compared with MG132 treated HL60 cells. 
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of Gfi1 is diminished upon monocytic 
differentiation of U937 and HL60 cells, 
resulting in an accumulation of protein 
levels (Figures 1 and 4). The dimished 
proteasomal degradation during monocytic 
differentiation is not caused by a decrease 
in general proteasomal activity (Figures 4C 
and D). This strongly suggests that a specific 
mechanism exists that regulates Gfi1 protein 
turn-over. The stability of proteins targeted 
for 26S proteasomal degradation can be 
regulated at different levels, for example by 
de-ubiquitination enzymes or by other post-
translational modifications with e.g. SUMO 
129
Gfi1 degradation during myelopoiesis
29. Alternatively, alterations in E3 ubiquitin 
ligase activity may cause Gfi1 stabilization 
during monocytic differentiation. Which E3 
ubiquitin ligase(s) specifically mark Gfi1 
for proteasomal degradation is unknown. It 
was recently shown that Ataxin-1 expression 
correlates with an increase in proteasomal 
degradation of Gfi130. While Ataxin-1 has no 
known E3 ligase activity by itself, it may be 
part of a multi-protein complex containing 
ubiquitin ligase activity. 
We show that the zinc finger domain of 
Gfi1 is specifically targeted for proteasomal 
degradation (Figure 3D). The Gfi1 paralog 
Gfi1B, is an essential transcription 
factor for erythroid and megakarocyte 
differentiation31,32. Especially the zinc finger 
containing DNA-binding region of Gfi1B is 
very homologous to Gfi1 (97%). Therefore, it 
may be speculated that Gfi1B is also subject 
to proteasomal degradation and it would be 
interesting to study whether Gfi1B protein 
levels are regulated in a similar way during 
erythroid/megakaryocytic differentiation. 
Gfi1-/- mice exhibit a block in neutrophilic 
differentiation, resulting in the accumulation 
of an immature myelo-monocytic population 
featuring both monocytic as well as 
granulocytic characteristics. The observed 
differentiation block results in the absence of 
mature neutrophils and takes place just after 
the promyelocyte stage, demonstrating that 
Gfi1 is essential during the first steps of GMP 
differentiation towards the promyelocyte 
stage. Whether Gfi1 is required after this 
stage of differentiation is currently not 
known. In primary monocytes Gfi1 is more 
stable compared to primary granulocytes, 
in which Gfi1 is swiftly degraded by the 
26S proteasome. This results in higher 
Gfi1 protein levels in monocytes compared 
to granulocytes, despite 60-fold higher 
mRNA levels in granulocytes (Figure 5). 
Whether the observed rapid degradation 
of Gfi1 in mature granulocytes is essential 
for terminal granulocytic function remains 
to be elucidated. A possible role for the 
proteasomal down-regulation of Gfi1 in 
mature granulocytes may be the release of 
Gfi1-dependent repression of granulocyte-
specific genes, like C/EBPα, C/EBPε and 
ELA-2. 
The presence of Gfi1 in primary monocytes 
suggests a role for Gfi1 in these cells. Gfi1 
might serve to repress granulocytic-specific 
genes thereby inhibiting granulocytic 
traits in monocytes. This is in line with the 
observation that Gfi1 target genes (C/EBPα 
and ELA-2) were expressed at higher levels 
in granulocytes compared to monocytes 
(Figure 6B). Moreover, ChIP experiments 
showed that Gfi1 is present on the promoter 
of these genes in primary monocytes (Figure 
6A). The ChIP experiments also showed 
that Gfi1 is present on its own promoter, 
suggesting that Gfi1 is capable of regulating 
its own expression in myeloid cells. If so, this 
could explain the high Gfi1 mRNA levels in 
granulocytes, due to the lack of repression 
by Gfi1, while in mature monocytes Gfi1 
represses its own promoter resulting in low 
mRNA expression. 
The accumulated myelomonocytic population 
in Gfi1-/- mice featuring both monocytic 
as well as granulocytic characteristics was 
originally assumed to consist of arrested 
differentiating neutrophils. However a partial 
block during monocytic differentiation could 
not be dismissed 5,6. This latter explanation 
was suggested to be unlikely since Gfi1 
mRNA was not detected in macrophages and 
Gfi1 mRNA levels are down regulated during 
monocytic differentiation of HL60 cells 33. 
As our results show that the Gfi1 protein is 
present in monocytes it will be interesting to 
readdress this question and study whether 
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the mixed myeloid population in Gfi1-/- mice 
also consists of arrested monocytes. As Gfi1 
functions in many steps during hematopoiesis 
but also in the development of the intestine 34 
and inner ear 35,36, it will be interestingly to 
test whether the here described degradation 
of Gfi1 also plays an important regulatory 
role in these processes. 
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Summary and Discussion
The modification of proteins with ubiquitin is 
involved in the regulation of various important 
biological pathways as is described in 
chapter 1. Protein ubiquitination is mediated 
by a multi enzyme cascade. A crucial step in 
this process is the conjugation of ubiquitin 
to a specific substrate protein by E3 ligases. 
Depending on the type of ubiquitin chains 
conjugated, proteins are either targeted 
for degradation by the 26S proteasome or 
their activity is specifically altered. Various 
proteins playing an important role during 
hematopoiesis are regulated by ubiquitination. 
Recently, alterations in ubiquitination and 
proteasomal degradation have also been 
implicated in hematological malignancies. 
These findings resulted in novel therapeutical 
approaches that are currently being tested in 
various hematological malignancies. During 
hematopoiesis, various important proteins 
are subject to ubiquitination. However, most 
of the responsible ubiquitin E3 ligases are 
still unknown. The human genome encodes 
for 700 proteins with domains implicated 
in the UPS. It is important to broaden our 
knowledge of these genes during normal and 
malignant hematopoiesis to identify novel 
specific, drugable targets. 
This thesis describes the study of the Triad1 
protein and its role in hematopoiesis. Triad1 
is the founding member of a novel family 
of RING finger E3 ubiquitin ligases. These 
TRIAD proteins constitute an unique class of 
ubiquitin E3 ligases that contain a conserved 
tripartite structure consisting of two RING 
fingers separated by a novel distinct cysteine/
histidine rich motif (DRIL/IBR). In addition 
to the TRIAD domain, the 493 amino acid 
Triad1 protein contains a N-terminal acidic 
domain and two C-terminal coiled-coil 
domains. In chapter 2 we describe the 
identification of this protein which is strongly 
induced during myeloid differentiation. 
Triad1 binds the E2 ubiquitin conjugating 
enzyme UbcH7 as well as ubiquitinated 
proteins and supports the formation of 
ubiquitin chains that are recognized by the 
proteasome. The biological function of Triad1 
in myelopoiesis was studied by performing 
colony forming assays (CFU-GM) using 
retrovirally transduced primary murine bone 
marrow cells. Triad1 severely inhibited 
myeloid colony formation. Two Triad1 RING 
finger point mutants that failed to bind UbcH7 
did not affect colony formation. Moreover, 
proteasome inhibition counteracted the 
inhibition of colony formation exerted by 
wild type Triad1. In liquid cultures, Triad1 
did not influence differentiation but strongly 
inhibited proliferation resulting in a G0/G1 
accumulation. We conclude that proteasomal 
degradation of proteins that are ubiquitinated 
by Triad1 affects the clonogenic growth of 
primary myeloid progenitor cells. 
In chapter 3 we studied the function of 
the various domains of Triad1. All TRIAD 
proteins contain two RING fingers and 
a DRIL/IBR domain and although it is 
known that RING finger domains in E3 
ubiquitin ligases are docking sites for E2 
conjugating enzymes, it was unclear why 
TRIAD proteins harbor two RING fingers. 
We studied the function of these domains 
in the ubiquitin E3 ligase Triad1. Deletion 
mutants showed that the N-terminal RING 
finger is essential for the interaction with 
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E2 conjugating enzyme UbcH7, while the 
C-terminal RING finger is necessary for the 
interaction with Ubc13. UbcH7 mediates 
poly-ubiquitin chain formation linked via 
lysine-48 (K48), which marks proteins for 
proteasomal degradation. Ubc13 mediates 
poly-ubiquitination via lysine 63 (K63), 
which alters protein function. In line with 
these interactions, in vitro ubiquitination 
experiments showed that Triad1 has dual 
ubiquitin ligase activity; it can catalyze both 
lysine-48 as well as lysine-63 linked poly-
ubiquitination. Triad1 is induced during 
myeloid differentiation of blood cells and its 
expression in U937 cells resulted in a strong 
reduction in clonogenic capacity. Expression 
of deletion constructs showed that both RING 
fingers were essential for this phenotype. 
This suggests that the interaction with both 
UbcH7 and Ubc13 are essential for the 
function of Triad1. The strong conservation 
of the TRIAD structure indicates that the 
two RING fingers are functionally linked 
and suggests that the lysine-48 and lysine-63 
ubiquitination mediated by TRIAD proteins 
is linked. 
Although many RING finger E3 ligases 
are thought to function as a single protein, 
RING finger proteins are known to form 
supramolecular structures by homo- and 
heterodimerization with other RING finger 
proteins. While RING fingers are essential 
domains as they mediate the interaction with 
the E2 conjugating enzymes, they also play an 
important role in the binding with other RING 
finger proteins by RING-RING interactions. 
In chapter 4 we have studied whether Triad1 
is present in such a supramolecular structure. 
Using a yeast-two-hybrid screen we have 
searched for Triad1 interacting proteins. 
Besides Triad1 itself, we identified two other 
RING finger proteins, Triad4 and Trim62, 
to interact with Triad1. Like Triad1, Triad4 
is a member of the TRIAD family of RING 
containing E3 ligases. Interaction studies 
with deletion mutants showed that the 
complete Triad1 protein was important for 
the interaction with Trim62. Interestingly, 
the C-terminal RING finger of Triad1 is 
essential for homodimerization and for 
the observed interaction with Triad4. This 
suggests that the C-terminal RING finger of 
Triad1 is an important domain for homo- and 
heterodimerization. This may imply a novel 
function for the C-terminal RING finger of 
the TRIAD domain containing E3 ligases.
Triad1 plays a role during the development 
of monocytes and granulocytes. In chapter 
5 we studied which proteins are regulated 
by the ubiquitin E3 ligase Triad1. To address 
this question, we performed a yeast-two-
hybrid assay to identify putative substrates 
of Triad1. We found that the transcriptional 
repressor Gfi1B interacts with the c-terminal 
RING finger of Triad1. Pull down and co-
immunoprecipitation experiments confirmed 
the yeast-two-hybrid interaction and mapped 
the zinc fingers of Gfi1B as the Triad1 
interacting domain. Gfi1, a close homologue 
of Gfi1B, is an essential transcription factor 
during myelopoiesis. Since the zinc fingers 
of Gfi1B and Gfi1 show 97% similarity, we 
tested whether Gfi1 also interacts with Triad1. 
Triad1 indeed interacted with Gfi1 when tested 
in pull down and co-immunoprecipitation 
experiments. Surprisingly, the ubiquitin E3 
ligase Triad1 inhibited the ubiquitination 
of Gfi1 in ubiquitination assays rather than 
enhancing it. Downregulation of endogenous 
Triad1 levels by siRNA resulted in increased 
Gfi1 ubiquitination. In line with these 
findings, Triad1 expression stabilized the 
Gfi1 protein. Together, these data show that 
Triad1 interacts with Gfi1 and Gfi1B, but 
is not the E3 ligase of Gfi1. Conversely, 
Triad1 inhibits the ubiquitination of Gfi1 
thereby protecting Gfi1 from proteasomal 
degradation.   
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Finally, in chapter 6 the regulation of 
Gfi1 by the ubiquitin proteasome system 
during myelopoiesis is described. Gfi1 is a 
transcriptional repressor, essential during 
myeloid differentiation. Gfi1-/- mice exhibit 
a block in myeloid differentiation resulting 
in the accumulation of an immature myelo-
monocytic cell population and the complete 
absence of mature neutrophils. Even though 
mRNA levels of Gfi1 appear to be very low 
in monocytes, Gfi1 might play a role in the 
monocytic lineage as Gfi1-/- mice exhibit 
diminished monocyte-derived dendritic 
cells and disturbed cytokine production 
by macrophages in response to LPS. We 
show in chapter 6 that Gfi1 protein levels 
are mainly regulated by the ubiquitin-
proteasome system. Upon forced monocytic 
differentiation of U937 cells Gfi1 mRNA 
levels dropped but protein levels increased 
due to diminished proteasomal turnover. 
Similarly, Gfi1 mRNA levels are low in 
primary monocytes while the protein is 
clearly detectable. Conversely, Gfi1 mRNA 
levels are high in granulocytes but the protein 
is swiftly degraded by the proteasome in 
these cells. Chromatin immunoprecipitation 
experiments showed that Gfi1 binds to the 
promoter of several granulocyte specific 
genes in primary monocytes, including C/
EBPα, neutrophil elastase and Gfi1 itself. 
The binding of the repressor Gfi1 to these 
promoters correlated with low expression 
of these genes in monocytes compared to 
granulocytes. Our data fit a model in which 
Gfi1 protein levels are induced in primary 
monocytes, due to diminished proteasomal 
degradation, to repress genes that play a role 
in granulocytic differentiation. 
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The TRIAD domain 
TRIAD proteins form a novel class of E3 
ubiquitin ligase RING finger proteins, 
characterized by a TRIAD domain. This 
domain containing three cysteine rich 
structures: two RING finger and a DRIL/IBR 
domain. It remains unclear why this specific 
domain has been conserved during evolution. 
The TRIAD domain is highly conserved 
in both sequence and spacing of the RING 
fingers and DRIL/IBR domain. Furthermore, 
the RING2 sequence and DRIL/IBR domain 
are only found in combination with the 
classical RING1. Together this suggests that 
these domains require each other to function 
1,2,3. At this moment 13 different mammalian 
TRIAD proteins have been identified (table 
1). For most of them E3 ubiquitin ligase 
activity and interactions with E2 conjugating 
enzymes has been reported. Most of the 
TRIAD proteins interact with the E2 
conjugating enzyme UbcH7 via RING1. Both 
for Parkin 4,5 as well as for Triad1 (chapter 
3) it was shown that RING2 interacts with 
Ubc13. If these interactions, as well as the 
dual ligase activity (K48 and K63) of Parkin 
and Triad1, are indeed common phenomena 
for all TRIAD proteins this might explain the 
function of the conserved TRIAD domain. 
The exact function of the DRIL/IBR domain 
remains unknown, however its conservation 
suggest that also its function is directly 
linked with the E3 ubiquitin ligase function. 
In this thesis we could not find an effect of 
the deletion of DRIL/IBR in E2 interaction 
or biological function of Triad1. 
An interesting question concerning the dual 
ligase function remains; are different subsets 
of substrates ubiquitinated by different types 
of ubiquitin chains, are the same substrates 
modified with different types of ubiquitin 
chains, or do they mediate the conjugation 
of mixed ubiquitin chains 6. For the TRIAD 
protein Parkin it was shown that it could 
ubiquitinate the same protein (synphillin) 
with both K48 as well as K63 linked poly-
ubiquitin chains 4,5. It will be interesting to 
study what determines the activity of the 
different E3 ligase activities of TRIAD E3 
ligases. Future research should clarify the 
different functions of the K48 and K63 ligase 
activities of the dual ubiquitin ligase Triad1 
and their role during myelopoiesis. The 
identification of substrate proteins of Triad1 
will give more insight into these questions. 
RING2 has a different topology compared to 
a classical RING finger structure like RING1. 
The different topologies might explain 
the specificity for the two RING fingers 
to interact with different E2 conjugating 
enzymes. The fact that RING2, with its 
different three dimensional structure, is only 
found in TRIAD domains might imply that it 
can only function in this structure. This might 
explain that RING2, despite its aberrant 
structure, is capable to interact with Ubc13. 
The fact that Parkin mutations in juvenile 
forms of Parkinson are found throughout 
the complete TRIAD domain of Parkin 7 
strengthens the hypothesis that the TRIAD 
domain functions as  one complete domain, 
rather than a collection of three independent 
structures with independent functions.
Concluding remarks and perspectives
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Synonyms UbcH6 UbcH7 UbcH8 Ubc13
Interactions
1 Triad1 ARI2/ARIH2  RING1 RING2
2 Triad3 ZIN/UIP83  + +  
3 Triad4 RNF31/PAUL/ZIBRA    
4 Parc  +  
5 Parkin PARK2  RING1 RING2 RING2
6 HHARI Ariadne-1/ARIH1/UbcH7BP  RING1/IBR  
7 ARA54 RNF14/HFB30 +   
8 RNF144 KAA0161/UbcM4-interacting protein 4  +  
9 Dorfin NKLAM/RNF19  + +  
10 P53RFP IBRDC2  + +  
11 Hoil-1 RNF54/XAP3/C20Orf18/UIP28  +  
12 ANKIB1 Kiaa1386    
13 DJ1174N9.1 IBRDC3     
Table 1, mammalian TRIAD proteins and their interactions with E2 conjugating enzymes
The function of Triad1
Retroviral expression of Triad1 resulted in 
a strong reduction of the clonogenic growth 
of both primary murine bone marrow cells 
(CFU-GM) as well as U937 cells. This effect 
of Triad1 could be explained by increased 
apoptosis and accumulation of cells in G1/
G0 phase of the cell cycle. No effect of 
Triad1 was found on differentiation, which 
suggests that Triad1 inhibits proliferation. 
The studies in primary bone marrow cells 
showed that RING1 of Triad1 and the 
proteasomal activity were essential for the 
inhibition of clonogenic growth. Additional 
studies in U937 cells showed that besides 
RING1 also RING2 was essential. Whether 
both K48 and K63 linked ubiquitination are 
needed for the observed Triad1 phenotype is 
currently unknown. The deletion of RING2 
suggests that also K63 linked ubiquitination 
mediated by Triad1 plays a role during 
hematopoiesis. However, we cannot rule out 
the possibility that the deletion of RING2 
also affects K48 linked ubiquitination 
mediated by the UbcH7 interaction with 
RING1. In vitro ubiquitination experiments 
with Triad1 lacking RING1 or RING2 should 
clarify whether RING1 or RING2 deletions 
effect K48 and/or K63 ubiquitination. The 
inhibition of the Triad1 phenotype after the 
addition of proteasome inhibitors indicates 
that at least the K48 linked ubiquitination 
resulting in protein degradation plays an 
important role.
The effect of Triad1 expression was also 
studied at the hematopoietic stem cell level 
in competitive bone marrow transplantation 
assays. Empty vector and Triad1 transduced 
bone marrow cells were mixed and injected 
in lethally irradiated mice. Analysis of the 
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bone marrow after 4 or 12 weeks showed 
that the empty vector transduced cells had 
completely overgrown the Triad1 transduced 
cells in all lineages, indicating that Triad1 
also inhibits the growth of these immature 
cells (unpublished data). Studies with the 
Triad1 C161A mutant, which can no longer 
interact with UbcH7, showed that this mutant 
had lost its complete activity in clonogenic 
assays. However this Triad1 C161A mutant 
still had some activity in the liquid assays. 
In competitive bone marrow assays these 
cells were outcompeted by empty vector 
transduced cells, however to a lesser extent 
compared to wild type Triad1 transduced 
cells. This indicates that Triad1 also has a 
UbcH7 independent effect, which is different 
than the effect observed in the clonogenic 
assays. Future experiment should point out 
whether this activity is Ubc13/K63 linked 
ubiquitination  dependent.  
Additional studies on the function of 
Triad1 during hematopoiesis could be 
performed by a stable Triad1 knockdown 
using retroviral introduced siRNAs. In 
combination with competitive bone marrow 
transplantations this could give insight in 
which hematopoietic compartments Triad1 
plays an essential role. Furthermore, the 
introduction of Triad1 deletion constructs 
lacking the interaction with either UbcH7 
or Ubc13 in this knockdown background 
could give more insight in the role of these 
interactions and the dual ligase function of 
Triad1 during hematopoiesis. 
Triad1 is predominately localized in the 
nucleus, however a small part is present in the 
cytoplasm. Therefore, we originally assumed 
that Triad1 mainly functions in the nucleus. 
Strikingly, the CC2 and CC1+2 deletion 
mutants are equally active as full length 
Triad1 in a clonogenic assay but are localized 
mainly in the cytoplasm. This may suggest 
that Triad1 can also carry out its function in 
the cytoplasm. While in monocytes Triad1 
is diffusely expressed in the whole nucleus, 
in mature granulocytes Triad1 is localized 
to specific sub-nuclear structures. This 
specific localization seems to overlap with 
the DAPI dull regions of the nucleus. DAPI 
dull regions in the nucleus are normally the 
transcriptional active sites (euchromatin). It 
remains unknown why Triad1 is present in 
this specific compartment. 
Triad1 and Gfi1
In this thesis we describe the identification 
of Gfi1 and Gfi1B as interaction partners 
of Triad1. Gfi1 was originally identified 
as a proviral insertion site resulting in IL2 
independent growth of T-cells 8. Overexpressed 
Gfi1 acts as a dominant oncogene and Gfi1 
cooperates with known oncoproteins like 
Myc and Pim-1 in lymphoma development 
9,10. In normal hematopoiesis, Gfi1 is 
essential for T-cell development and for 
self-renewal and long term reconstituting 
potential of HSC 11,12,13. Recently, Gfi1 was 
also shown to be important for dendritic 
cell (DC) development 14. The transcription 
factor Gfi1 has also been shown to play an 
essential role during myelopoiesis. Gfi1-/- 
knockout mice are severely neutropenic and 
exhibit a block in myeloid differentiation 
resulting in the accumulation of an atypical 
immature myeloid cell population 11,15. This 
is in line with reported heterozygous GFI1 
missense mutations in patients suffering 
from hereditary neutropenia 16. Gfi1 may 
function as a transcriptional repressor 
and regulates genes that play a role in cell 
cycle regulation like E2F5 and cMyc and in 
granulopoiesis like C/EBPα, C/EBPε and 
neutrophil elastase 17. Furthermore, Gfi1 can 
repress its own promoter and the promoter of 
its paralogue Gfi1B 18,19. 
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Triad1 was found to inhibit the ubiquitination 
of Gfi1, thereby stabilizing the Gfi1 protein. 
Whether this stabilization of Gfi1 by Triad1 
could completely explain the observed 
phenotype of Triad1 is unlikely, since the 
Triad1 effect in murine bone marrow cells 
could be overcome by proteasome inhibition 
(chapter 2), while proteasome inhibition had 
no effect on the Triad1 induced inhibition of 
Gfi1 ubiquitination (chapter 5). Furthermore, 
the Triad1 H158A mutant that did not affect 
clonogenic growth in CFU-GM assays still 
inhibited Gfi1 ubiquitination. Together, 
these data suggest that other binding 
partners of Triad1, which are probably 
ubiquitinated and subsequently degraded, 
are responsible for the observed inhibition 
of clonogenic growth. The identification of 
Triad1 substrates, whose degradation cause 
the clonogenic inhibition, would give more 
information about the mechanism how 
Triad1 functions. Yeast-two-hybrid studies 
can be useful to identify putative substrates 
(chapter 4 and 5), however since substrate-
E3 ligase interactions can be very short lived, 
other approaches are preferred. For example 
by selection of ubiquitinated proteins in 
the presence or absence of Triad1 followed 
by Mass spectrometry identification of the 
proteins. Especially in combination with 
stable isotope labeling with amino acids 
in cell culture (SILAC) this seems a very 
promising technique to identify Triad1 
substrates 20. 
It is also unclear whether Triad1 is (partly) 
regulating the Gfi1 stability during 
myeloid differentiation. During monocytic 
differentiation of for example U937 cells 
Gfi1 proteasomal degradation is diminished 
resulting in an increase of protein levels, 
while mRNA levels decreased (chapter 6). 
Triad1 is also induced during differentiation 
of U937 which might suggest that the 
diminished Gfi1 degradation is linked to 
Triad1 activity. In monocytes where Gfi1 is 
stable Triad1 is highly expressed, however 
also in granulocytes Triad1 proteins levels 
are high which seems to be contradictory 
with unstable Gfi1 in granulocytes. A 
possible explanation for the rapid turnover 
of Gfi1, in the presence of Triad1, could be 
that Triad1 is localized is a specific nuclear 
compartment in granulocytes where it cannot 
interact with Gfi1. The paralogue of Gfi, 
Gfi1B, was recently found to localize to the 
heterochromatin 21. When Gfi1 is localized in 
a similar structures as Gfi1B, this indicates 
that Triad1 and Gfi1 do not co-localize. 
Overexpression or knockdown studies with 
Triad1 in differentiation models like for 
example U937 or CD34+ cells should clarify 
this issue.
A recent large yeast-two-hybrid study 
showed that Triad4 might interact with Gfi1 
22. Triad1 was also capable of interacting with 
Triad4 (chapter 4) which might suggest that 
Triad1 functions as heterodimer with Triad4 
in regulating Gfi1 protein levels. Another 
possibility is that Triad4 might be the E3 
ligase of Gfi1. In this case Triad1 could 
compete for Gfi1 interaction with Triad4, 
thereby protecting Gfi1 form proteasomal 
degradation by Triad4.
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Samenvatting
Samenvatting voor de niet ingewijden
Hematopoïese en Leukemie
Ons bloed bestaat uit verschillende soorten 
cellen, die ieder een specifieke en essentiële 
functie in het lichaam hebben. Zo zijn de rode 
bloedcellen verantwoordelijk voor zuurstof 
transport van onze longen naar alle weefsels, 
terwijl bijvoorbeeld de bloedplaatjes er onder 
andere voor zorgen dat onze bloedvaten 
hersteld worden na een verwonding. Een 
andere groep cellen, de witte bloedcellen, 
spelen een belangrijke rol bij de afweer 
tegen verschillende ziekteverwekkers zoals 
bacteriën en virussen. De levensduur van 
onze bloedcellen is betrekkelijk kort en 
deze moeten daarom continue opnieuw 
worden aangemaakt. Er wordt geschat dat 
er per seconde 2.5 miljoen rode bloedcellen, 
1.5 miljoen bloedplaatjes en 250.000 
witte bloedcellen worden aangemaakt. De 
vorming van deze bloedcellen kan heel 
nauwkeurig geregeld worden. Er kunnen 
tijdelijk meer bloedcellen worden verbruikt 
of verloren gaan, bijvoorbeeld bij een 
infectie of een bloeding. Het lichaam vormt 
dan direct meer bloedcellen van het type 
dat is verminderd. De ontwikkeling van alle 
De titel van dit proefschrift is: “Triad1 en de rol tijdens myelopoïese”. In deze 
samenvatting wordt uitgelegd wat dit betekent. Wij als mensen bestaan uit veel 
verschillende soorten cellen. Deze cellen bestaan onder andere uit eiwitten. Eiwitten 
zijn het gereedschap van de cel; eiwitten regelen veel van de verschillende processen die 
in de cel plaatsvinden. Ieder eiwit heeft één of meerdere specifieke taken. Daarom heeft 
ieder soort cel, afhankelijk van zijn functie, dus ook een andere eiwit samenstelling. 
Er wordt geschat dat de mens ongeveer 30.000 verschillende soorten eiwit heeft, het in 
dit proefschrift beschreven Triad1 eiwit is er daar een van. De hier beschreven studies 
laten zien dat het Triad1 eiwit een rol speelt bij twee belangrijke biologische processen; 
de hematopoïese en de ubiquitine proteasome route. Deze processen worden hieronder 
uitgelegd. 
bloedcellen is een gecompliceerd proces dat 
voornamelijk plaats vindt in het beenmerg. In 
het beenmerg bevinden zich voorlopercellen 
die de mogelijkheid hebben om zich 
voortdurend te vernieuwen en zich tot alle 
soorten bloedcellen kunnen ontwikkelen 
(differentiëren/uitrijpen). Dit proces 
heet hematopoïese (Figuur 1, rechts). De 
vernieuwing van deze cellen is noodzakelijk 
om er voor te zorgen dat de ontwikkeling van 
de vele bloedcellen plaats kan blijven vinden 
gedurende het hele leven. 
De ontwikkeling van deze onrijpe cellen, 
hematopoietische stamcellen genaamd, 
tot  rijpe functionele bloedcellen wordt 
gekenmerkt door verschillende celdelingen 
en differentiatie stadia. Indien deze 
processen verstoord zijn kan dit leiden tot 
leukemie (bloedkanker). De oorzaak hiervan 
is een reeks veranderingen in het erfelijk 
materiaal (DNA) van de voorloper cellen, 
waardoor deze cellen niet meer correct tot 
rijpe bloedcellen kunnen differentiëren 
(Figuur 1, links). Deze kwaadaardige onrijpe 
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Figuur 1, hematopoiese en leukemie
Aan de rechterkant een schematische weergave van de hematopoietische stamcel die door celdeling 
zich zelf kan blijven vernieuwen (in het beenmerg), maar ook kan differentiëren (uitrijpen) in 
functionele bloedcellen welke we terug vinden in het bloed. Indien door DNA schade dit differentiatie 
proces verstoord wordt, hopen de leukemische cellen op in het beenmerg waar ze de gezonde 
stamcellen verdringen. Hierdoor wordt de aanmaak van nieuwe bloedcellen verstoord, wat resulteert 
in vermoeidheid, infecties en spontane bloedingen bij patienten met leukemie. 
cellen reageren bovendien niet meer op 
signalen om de aanmaak te remmen als er 
voldoende cellen zijn geproduceerd. Deze 
kwaadaardige cellen vermeerderen zich snel 
en verdringen daardoor de gezonde cellen in 
het beenmerg. Hierdoor komt de productie 
van de normale bloedcellen in het gedrang. 
Dit vertaalt zich dan ook in de klachten van de 
leukemie patiënt; vermoeidheid (tekort rode 
bloedcellen), terugkerende infecties (tekort 
witte bloedcellen) en spontane bloedingen 
(tekort bloedplaatjes). Aanvankelijk is er 
alleen in het beenmerg een overmaat aan 
abnormale bloedcellen. Na verloop van tijd 
komen die cellen in de bloedbaan en dus ook 
in de organen terecht. Om betere therapieën 
te kunnen ontwikkelen voor patiënten die 
lijden aan dit soort ziektes is het van groot 
belang om te begrijpen hoe de normale 
ontwikkeling van bloedcellen gereguleerd is. 
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Figuur 2, Ubiquitinering, een 3 staps proces
A, De ubiquitinering van eiwitten gebeurt door 3 
verschillende soorten eiwitten. Het vrije ubiquitine 
wordt geactiveerd door het E1 ubiquitine 
activerend eiwit. Het geactiveerde ubiquitine 
wordt vervolgens aan het E2 conjugerend 
eiwit gebonden. Deze E2 eiwitten binden aan 
E3 ligases, zoals bijvoorbeeld Triad1. Deze 
E3 ligases herkennen specifiek eiwitten welke 
tenslotte worden voorzien van een ubiquitine 
keten. B, De E3 ligases bepalen de specificiteit 
van het ubiquitine proteasome systeem. Daarom 
zijn er van deze eiwitten ook het meest (ca. 00). 
De E2 en E1 eiwitten worden meer algemeen 
gebruikt, waardoor de cel minder verschillende 
eiwitten van dit type nodig heeft.
A
B
De ubiquitine proteasome route
Tijdens de bloedcel differentiatie van onrijpe 
cel naar functionele bloedcel verandert er 
veel in de cel. De verschillende bloedcellen 
hebben verschillende functies en hebben hier 
dan ook verschillende eiwitten voor nodig 
om deze functies uit te voeren. In een cel 
kan de specifieke code van DNA afgelezen 
worden om eiwitten te maken. Hiervoor 
moet in de eerste plaats een afschrift van het 
DNA gemaakt worden tijdens een  proces 
dat transcriptie heet. Dit proces wordt 
gereguleerd door verschillende eiwitten 
genaamd “transcriptiefactoren”. Dit afschrift, 
ook wel RNA genoemd, wordt dan vervolgens 
weer gebruikt om eiwitten te maken. Tijdens 
de differentiatie wordt gereguleerd welke 
eiwitten wel en niet gemaakt mogen worden 
in de cel. Er is heel veel onderzoek gedaan 
naar hoe het gereguleerd wordt welke 
eiwitten aan gemaakt worden. Echter de 
laatste jaren is gebleken dat eiwitten soms 
ook uit de cel verwijderd moeten worden. 
Deze afbraak van eiwitten is erg belangrijk 
bij veel verschillende biologische processen. 
Ook het afbreken van eiwitten is een 
nauwkeurig gereguleerd proces; niet alle 
eiwitten worden afgebroken. Eiwitten 
welke afgebroken dienen te worden, 
worden voorzien van een “vlaggetje”. Door 
dit “vlaggetje” weet de cel dat dit eiwit 
afgebroken moet worden. Dit “vlaggetje” 
wat aan eiwitten wordt bevestigd bestaat 
uit één of meerdere ubiquitine eiwitten. 
Het ubiquitineren (eraan bevestigen van 
ubiquitine eiwitten) van eiwitten is een 
specifiek proces dat plaats vindt in een 
aantal verschillende stappen. Tijdens 
deze stappen spelen verschillende typen 
eiwitten een rol, waardoor uiteindelijk één 
of meerdere ubiquitine eiwitten aan het af 
te breken eiwit wordt gekoppeld. Allereerst 
wordt vrij ubiquitine (een klein eiwit van 
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Figuur 3, Het 26S Proteasoom 
Het 26S Proteasoom herkent eiwitten voorzien van een ubiqiuitine keten. Deze eiwitten worden door 
het proteasoom in kleine stukjes geknipt waardoor ze verdwijnen. Het ubiquitine komt weer vrij en kan 
hergebruikt worden. 
76 aminozuren) geactiveerd door een E1 
ubiquitine activatie enzym. Vervolgens 
wordt het ubiquitine gekoppeld aan een E2 
ubiquitine conjugatie enzym. Dit E2 enzym 
katalyseert samen met een E3 ubiquitine 
ligase enzym de ubiquitinering van substraat 
eiwitten. De ubiquitine E3 ligases vormen 
de belangrijkste klasse van eiwitten tijdens 
de ubiquitinering aangezien deze specifiek 
substraat eiwitten herkennen en daarmee 
bepalen welke eiwitten ge-ubiquitineerd 
worden. De studies in hoofdstuk 2 en 3 laten 
zien dat Triad1 een ubiquitine E3 ligase is 
en dus andere eiwitten kan voorzien van een 
ubiquitine vlaggetje.
Veel verschillende eiwitten kunnen voorzien 
worden van ubiquitine. Daarom bestaan er 
veel verschillende E3 ligases (> 700) die 
specifiek substraat eiwitten herkennen zoals 
in Figuur 2B is weergegeven. De andere 
meer algemene stappen die betrokken zijn 
bij de ubiquitinering worden verzorgd door 
een veel kleiner aantal eiwitten. Op dit 
moment zijn er één E1 en iets meer dan 10 
E2 enzymen bekend.
Eiwitten voorzien van een ubiquitine vlag 
kunnen worden herkend door het 26S 
proteasoom. Dit eiwit complex breekt de ge-
ubiquitineerde eiwitten af in kleine stukjes 
zodat het eiwit wordt geinactiveerd (Figuur 
3). Het ubiquitine komt bij dit proces weer 
vrij en kan weer hergebruikt worden.  
Uit verschillende onderzoeken is gebleken 
dat de ubiquitine-proteasoom route een 
essentiële rol speelt bij de hematopoïese en 
veranderingen in deze route kunnen bijdragen 
aan het ontstaan van hematologische 
afwijkingen (zie  hoofdstuk 1). Uit klinische 
studies blijkt dat de remming van het 
proteasoom een antitumor effect heeft bij 
sommige hematologische maligniteiten. 
Het herkennen van specifieke afwijkingen 
in de ubiquitine-proteasoom route bij 
hematologische maligniteiten kan mogelijk 
voorzien in nieuwe aanknopingspunten voor 
het ontwikkelen van therapieën die mogelijk 
in de toekomst kunnen bijdragen aan het 
genezen van hematologische maligniteiten. 
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Triad1
In dit proefschrift wordt het onderzoek 
naar de rol van het Triad1 eiwit tijdens de 
hematopoïese beschreven. Triad1 is het eerst 
beschreven eiwit van de TRIAD familie van 
ubiquitine E3 ligases. De TRIAD eiwitten 
worden gekenmerkt door een specifiek 
TRIAD domein. Dit domein bestaat uit twee 
RING fingers met daar tussen een nieuw 
geïdentificeerd domein: DRIL of IBR. Dit 
domein wordt alleen in TRIAD eiwitten 
gevonden en geeft samen met de RING fingers 
ook de naam aan deze groep van eiwitten: 
Two RING fingers and DRIL. Naast het 
TRIAD domein bevat het 493 aminozuur 
bevattende Triad1 eiwit ook een zuur domein 
(N-terminaal) en twee coiled-coil domeinen 
(C-terminaal). In Hoofdstuk 2 wordt de 
identificatie van Triad1 beschreven. De 
Triad1 eiwit expressie wordt opgereguleerd 
tijdens de differentiatie van monocyten 
en granulocyten en bindt naast het E2 
conjugerend eiwit UbcH7, ge-ubiquitineerde 
eiwitten. In vitro ubiquitinerings assays 
laten zien dat Triad1 eiwitten ubiquitineert 
met ketens die herkend worden door het 
26S proteasoom. Triad1 expressie in 
muizenbeenmergcellen resulteerde in een 
remming van het aantal en de grootte van de 
gevormde kolonies in myeloïde differentiatie 
assays. Een Triad1 puntmutant die niet 
meer aan UbcH7 kan binden heeft geen 
effect op deze cellen. Het groei remmende 
effect van Triad1 op muizenbeenmergcellen 
kon tegengegaan worden door toevoeging 
van proteasoom inhibitors. Aan de hand 
van de resultaten in dit hoofdstuk  werd 
geconcludeerd dat Triad1 de clonogene groei 
van primaire muizenbeenmergcellen remt 
door andere eiwitten te ubiquitineren waarna 
deze  vervolgens worden afgebroken. 
In hoofdstuk 3 hebben we de functie van 
de verschillende domeinen van Triad1 
bestudeerd. Triad1 heeft 2 RING finger 
domeinen en een DRIL/IBR domein. 
RING fingers zijn in E3 ubiquitine ligases 
verantwoordelijk voor de binding met de 
E2 conjugerende eiwitten. Het is echter 
onbekend waarom Triad1 twee RING fingers 
heeft. Door gebruik te maken van deletie 
mutanten die een van deze domeinen misten 
is de functie van de domeinen in Triad1 
onderzocht. De N-terminale RING fingers 
bleek essentieel voor de interactie met het 
E2 conjugerende enzym UbcH7, terwijl de 
C-terminale RING finger nodig bleek voor 
binding met het E2 conjugerend enzym 
Ubc13. Ubc13 zorgt voor poly-ubiquitinering 
via lysine 63, terwijl UbcH7 zorgt voor poly-
ubiquitinering via lysine 48 van ubiquitine. 
In overeenstemming met deze interacties 
bleek dat Triad1 inderdaad eiwitten kan 
poly-ubiquitineren via zowel lysine 48 
als 63. Functionele studies lieten zien dat 
beide RING fingers van Triad1 belangrijk 
zijn voor de remming van clonogene groei 
van hematopoïetische cellen. Deze data 
suggereren dat zowel de binding van UbcH7 
als Ubc13 belangrijk zijn voor de rol van 
Triad1 tijdens de hematopoïese. 
Veel RING finger E3 ubiquitine ligases 
kunnen hun functie uitoefenen zonder dat 
daar andere eiwitten dan de algemene E1 
and E2 eiwitten voor nodig zijn. RING 
finger eiwitten kunnen ook functioneren 
in grotere eiwitcomplexen die meerdere 
RING finger eiwitten bevatten. In hoofdstuk 
4 hebben we twee andere RING finger 
eiwitten gevonden, Triad4 en Trim62, die 
aan Triad1 binden. Verder is gevonden dat 
Triad1 zichzelf kan binden, waarvoor de C-
terminale RING finger van Triad1 nodig is. 
In hoofdstuk 5 hebben we bestudeerd 
welke eiwitten mogelijk gereguleerd worden 
door Triad1. Met behulp van het gist-twee-
hybriden systeem hebben we gevonden dat 
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Triad1 via de C-terminale RING finger aan 
de zinc-fingers van Gfi1B bindt. Gfi1, een 
homoloog van Gfi1B, bindt ook aan Triad1 
in co-immunoprecipitatie experimenten. Gfi1 
is een transcriptie factor die een belangrijke 
functie heeft bij diverse aspecten van de 
hematopoïese. Ubiquitinerings assays lieten 
zien dat Gfi1 wordt ge-ubiquitineerd. Triad1 
remt de ubiquitinering van Gfi1, waardoor 
de proteosomale afbraak van Gfi1 wordt 
vermindert. Triad1 reguleert op deze manier 
de Gfi1 eiwit levels.  
Tenslotte hebben we in hoofdstuk 6 
onderzocht wat de functie is van de 
ubiquitinering en proteasomale afbraak 
van de transcriptiefactor Gfi1 tijdens de 
myelopoïese. Gfi1 mRNA levels zijn 60 
keer hoger in granulocyten vergeleken met 
monocyten. Echter de hoeveelheden eiwit 
zijn hoger in monocyten dan in granulocyten. 
De proeven in dit hoofdstuk lieten zien 
dat dit veroorzaakt wordt doordat Gfi1 in 
granulocyten snel wordt afgebroken door 
het 26S proteasoom, terwijl het minder snel 
wordt afgebroken in monocyten. Daarnaast 
werd aangetoond dat Gfi1 in monocyten 
promoteren bindt van granulocyt specifieke 
genen. Dit correleert met een lagere expressie 
van deze genen in monocyten vergeleken 
met granulocyten. Een mogelijke functie 
van het hier beschreven mechanisme kan 
zijn dat Gfi1 in monocyten de expressie van 
granulocytaire genen onderdrukt om zo de 
monocytaire differentiatie goed te kunnen 
laten verlopen. 
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Dankwoord
Een woord van dank.....
Het mag duidelijk zijn dat er veel mensen 
betrokken zijn bij het tot stand komen van 
een proefschrift. Voordat ik mensen in het 
bijzonder bedank, wil ik in de eerste plaats 
alle mensen van het CHL bedanken voor 
hun gezelligheid, belangstelling en hun 
hulp tijdens het tot stand komen van dit 
proefschrift. Het hier beschreven onderzoek 
weerspiegelt dan ook de veelzijdigheid 
van de kennis en kwaliteiten van het 
CHL. De combinatie van patiëntenzorg en 
fundamenteel onderzoek leidt niet alleen 
tot een erg inspirerende werkomgeving 
maar zorgt ook voor een mooie mix van 
verschillende mensen binnen het CHL. 
In die fijne werksfeer heb ik me kunnen 
ontwikkelen tot wie ik nu ben. Daarom 
bedankt voor alles en ik neem dan ook met 
pijn in mijn hart afscheid van jullie allemaal! 
Een aantal mensen wil hier in het bijzonder 
bedanken.  
Bert, je eerste AIO gaat promoveren, een 
duidelijker bewijs van het succes van je 
onderzoekslijn is er niet. Ik zou af en toe wat 
meer van je oneindige positivisme willen 
bezitten. Jouw positieve benadering en je 
ontzettende drive hebben me doen besluiten 
om met dit AIO project te starten en hebben 
me door menig moeilijk moment heen 
gesleept.  Het is ook niet voor niets dat de 
laatste dagen van het Triad1 project geteld 
leken toen je wegens ziekte thuis zat. Ik had 
geen betere begeleider kunnen bedenken om 
samen, de voor ons allebei nieuwe wereld 
van ubiquitinering te ontdekken. Ik denk 
dat we op deze manier het hoogst haalbare 
hebben gehaald uit mijn promotie! Keep the 
Triad1 spirit alive!
Joop bedankt voor het op afstand kritisch 
volgen van het Triad1 project. Ik heb veel 
gehad aan onze wetenschappelijke discussies 
en aan je kritische opmerkingen. Jammer 
dat je daar af en toe niet meer tijd voor had. 
Ik heb veel geleerd van je artikel gerichte 
manier van werken. Succes met het verder 
uitbouwen van je groep. 
Theo, het feit dat dit onderzoek soms ver 
van je vakgebied af stond was zeker niet te 
merken aan je interesse en betrokkenheid. 
Bedankt voor het feit dat je, ondanks je volle 
agenda, toch altijd tijd wist te vinden om 
mijn artikelen snel te beoordelen. 
Liesje, Beppie of gewoon Liesbeth; een 
nauwgezette duizendpoot op het lab die alles 
voor je wil en kan regelen. Ik denk dat jij 
het beste bent wat een AIO kan overkomen 
tijdens zijn promotie. Zeker na het myb-
debacle hebben we fantastisch samengewerkt 
en een groot deel van het in dit proefschrift 
beschreven onderzoek komt op jouw conto. 
Ik ben daarom ook trots dat je nu als paranimf 
aan mijn zijde staat. Na bijna 5 jaar samen 
veel meegemaakt te hebben komt er voor 
ons allebei een eind aan onze CHL-tijd. Ik 
wens je heel veel plezier en succes toe met 
je nieuwe baan, zeker in combinatie met het 
mama zijn. 
Laurens, je kwam als laatste het Triad1 clubje 
versterken. Behalve dat je goed tafels kon 
beklimmen was je ook de juiste man op de 
juiste plaats. Samen heel wat gave proeven 
gedaan, biertjes gedronken in de autoclaaf en 
een hoop lol beleefd. Bedankt voor de hulp 
bij de laatste proeven en de hand en span 
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diensten die kwamen kijken bij het voltooien 
van dit proefschrift. Fijn dat je mijn paranimf 
wilt zijn.
Sake, samen begonnen aan het grote AIO 
avontuur, tijdens dit avontuur hebben we 
dan ook lief en vooral veel leed gedeeld. Ik 
kon onze wetenschappelijke discussie over 
onze plannen altijd erg waarderen. Bedankt 
voor de vele onvergetelijke momenten; van 
wetenschapsquiz experimenten uitvoeren, de 
stap avondjes in Nijmegen (bedankt voor het 
gebruik van je bank), de Mayflower in Boston 
tot het golfterrein in Papendal! Ook jij veel 
succes met de rat-race...en veel succes met 
het afronden van je boekje! Ik hoop je nog 
vaak tegen te komen tijdens onze volgende 
stappen in de wetenschappelijke wereld. 
Aswin, de overtreffende trap van sociaal. 
Het was fijn om bij jou af en toe ook  eens 
een niet “Rotterdamse” mening te horen. 
Bedankt voor het opzetten en de hulp met 
al het muizenwerk. We hebben een hoop 
cynische grappen kunnen maken over de 
gedeelde frustraties zoals de rijdende treinen! 
Bedankt voor de kilo’s snoep, gezelligheid, 
en heuglijke momenten buiten (Lunteren/
Vermont) en binnen het lab. Heel veel plezier 
en succes in je nieuwe uitdaging. 
Elke’s, al viel je op het eerste gezicht wel 
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